

Financial news for AZN dated on 2020-06-11: Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July

Financial news for AZN dated on 2020-06-10: NIH Official Says U.S. Plans 3 Large Studies of Experimental Coronavirus Vaccines From Moderna, AstraZeneca Johnson & Johnson Starting in July, August, September

Financial news for AZN dated on 2020-06-10: Potential Covid-19 Vaccine From China BBIBP-CorV Shows Promise in Animal Tests

Financial news for AZN dated on 2020-06-09: Barda Says It Awards \$23.7M To Support Development Of Astrazeneca SARS-CoV-2 Monoclonal Antibody Combination

Financial news for AZN dated on 2020-06-08: 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

Financial news for AZN dated on 2020-06-08: Astrazeneca CEO Soriot Said To Have Called Gilead CEO On May 9; Proposed Exploring Merger On A Call

Financial news for AZN dated on 2020-06-08: PreMarket Prep Stock Of The Day: Gilead Sciences

Financial news for AZN dated on 2020-06-08: Navarro: China Is 'Trying To Steal Our Vaccines, As We Speak'

Financial news for AZN dated on 2020-06-08: 3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor

Financial news for AZN dated on 2020-06-08: 'Gilead, AstraZeneca not in merger talks' CNBC's Faber Reports

Financial news for AZN dated on 2020-06-08: A Peek Into The Markets: US Stock Futures Up; OPEC+ Agrees To Extend Output Cuts

Financial news for AZN dated on 2020-06-08: AstraZeneca Approached Gilead With A Deal That Could Be The Biggest On Record: Report

Financial news for AZN dated on 2020-06-07: AstraZeneca Approaches Gilead Regarding Potential Record Health-Care Merger

Financial news for AZN dated on 2020-06-05: 'AstraZeneca blood cancer drug shows signs of helping COVID-19 patients' -Reuters

Financial news for AZN dated on 2020-06-05: AstraZeneca Presents New Data Across Continuum of Care from its Broad Renal Portfolio at ERA-EDTA 2020 Virtual Congress

Financial news for AZN dated on 2020-06-04: AstraZeneca CEO Says We Have 300M Doses In Spare Capacity As Part Of Total 2B Doses Planned, Additional Parties Could Be Intereted

Financial news for AZN dated on 2020-06-04: AstraZenica CEO Says We Expect To Know By August Whether The Vaccine Works, But We Are Dependent On The Infection Rates In The Vaccinated Groups And In The Control Groups In The Trials

Financial news for AZN dated on 2020-06-04: 'AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine' -Company Release

Financial news for AZN dated on 2020-06-04: AstraZeneca Secured Manufacturing Capacity For 2B Doses Of Vaccine

Financial news for AZN dated on 2020-06-04: AstraZeneca Reports \$750M Deal With CEPI, Gavi, Serum Institute Of India To Bring Vaccine To Low-, Middle-Income Countries

Financial news for AZN dated on 2020-06-04: Ex-FDA Chief On White House's Coronavirus Vaccine Shortlist: 'They Chose Very Novel Platforms'

Financial news for AZN dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for AZN dated on 2020-06-04: AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-modifying Proteins in Oncology Collaboration With Accent Therapeutics

Financial news for AZN dated on 2020-06-03: Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics

Financial news for AZN dated on 2020-06-03: UPDATE: Five Companies Chosen For 'Vaccine Finalist' Are Moderna, Johnson & Johnson, Merck, Pfizer And AstraZeneca

Financial news for AZN dated on 2020-06-02: U.S. Army Planning To Test Vaccines From Moderna, AstraZeneca, Johnson & Johnson And Sanofi; Army Will Test Its Own Vaccine Candidate In Human Trials Later This Summer

Financial news for AZN dated on 2020-06-01: Merck and AstraZeneca's LYNPARZA Receives a Positive Opinion from the European Medicines Agency

Financial news for AZN dated on 2020-06-01: AstraZeneca Announces Brilinta Obtains Additional FDA Approval

Financial news for AZN dated on 2020-06-01: AstraZeneca Announces Lynparza Recommended for Approval in EU by CHMP for BRCA-mutated Metastatic Pancreatic Cancer

Financial news for AZN dated on 2020-05-30: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Financial news for AZN dated on 2020-05-29: AstraZeneca shares are trading higher after the company announced its ENHERTU significantly improved tumor response rate. The Overall survival in HER2 positive metastatic gastric cancer in Phase 2 DESTINY-Gastric01 Trial.

Financial news for AZN dated on 2020-05-29: 10 Biggest Price Target Changes For Friday

Financial news for AZN dated on 2020-05-29: AstraZeneca Reports ENHERTU Significantly Improved Tumor Response Rate, Overall Survival In HER2-Positive Metastatic Gastric Cancer In Phase 2 DESTINY-Gastric01 Trial

Financial news for AZN dated on 2020-05-29: AstraZeneca's Announces IMFINZI (durvalumab) Showed 'Sustained Overall Survival Benefit' In 1st-Line Extensive-Stage Small Cell Lung Cancer In Phase III CASPIAN Trial

Financial news for AZN dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immute gets R&D Grant

Financial news for AZN dated on 2020-05-29: AVEO Oncology Reports Phase 1b/2 DEDUCTIVE Study Of FOTIVDA In Combo With IMFINZI in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

Financial news for AZN dated on 2020-05-29: SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to \$65

Financial news for AZN dated on 2020-05-29: AstraZeneca Announces Tagrisso Unprecedented Adjuvant Lung Cancer Data

Financial news for AZN dated on 2020-05-29: Genestack Signs Multi-Year Agreement With AstraZeneca to Implement Genestack's Omics Data Manager -

Financial news for AZN dated on 2020-05-28: AstraZeneca Says TAGRISSO 'Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer'

Financial news for AZN dated on 2020-05-28: 'I'll have story at 5 pm ET on \$AZN Tagrisso in early-stage lung cancer patients. This is the ADAURA adjuvant study stopped in April for "overwhelming benefit."' -Adam Feuerstein Tweet

Financial news for AZN dated on 2020-05-28: Why AstraZeneca's Stock Is Trading Higher Today

Financial news for AZN dated on 2020-05-28: AstraZeneca shares are trading higher after the company announced a commercial supply deal with Oxford Biomedica for manufacturing of its AZD1222 coronavirus vaccine candidate.

Financial news for AZN dated on 2020-05-28: Oxford Biomedica Reports 1-Year Clinical, Commercial Supply Deal With AstraZeneca For Manufacture Of Adenovirus Vector-Based Coronavirus Vaccine Candidate, AZD1222

Financial news for AZN dated on 2020-05-26: AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials

Financial news for AZN dated on 2020-05-23: Project Leader Adrian Hill Says Oxford University Covid-19 Vaccine Trial Has Only 50% Chance of Success

Financial news for AZN dated on 2020-05-23: China Plans to Start Using Coronavirus Vaccine by End of Year Even if Trials Have Not Been Completed

Financial news for AZN dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for AZN dated on 2020-05-22: Enhertu Granted FDA Orphan Drug Designation for Gastric Cancer

Financial news for AZN dated on 2020-05-22: Oxford COVID-19 Vaccine to Begin Phase II/III Human Trials

Financial news for AZN dated on 2020-05-21: Trump Says He Believes AstraZeneca Vaccine Holds Tremendous Promise, As Do Those From Other Companies

Financial news for AZN dated on 2020-05-21: AstraZeneca Shares Quiet As Trump Welcomes Announcement By Co. On Oxford Vaccine

Financial news for AZN dated on 2020-05-21: A Peek Into AstraZeneca's P/E Ratio

Financial news for AZN dated on 2020-05-21: Stocks That Hit 52-Week Highs On Thursday

Financial news for AZN dated on 2020-05-21: AstraZeneca CEO Says Oxford Vaccine Phase 3 Trial To Start In Jun.

Financial news for AZN dated on 2020-05-21: AstraZeneca Receives Over \$1B In BARDA Funding For Coronavirus Vaccine

Financial news for AZN dated on 2020-05-21: AstraZeneca shares are trading higher after the company announced receipt of commitment of 400 million doses for Oxford's potential coronavirus vaccine.

Financial news for AZN dated on 2020-05-21: AstraZeneca CEO Recently Interviewing On CNBC, Highlights Earlier News Co. Received Commitment For 400M Doses Of Oxford's Potential Coronavirus Vaccine

Financial news for AZN dated on 2020-05-21: AstraZeneca Receives Commitment of 400M Doses for Oxford's Potential Covid-19 Vaccine

Financial news for AZN dated on 2020-05-20: Checkpoint Therapeutics CEO On Tapping Into A \$25 Billion Cancer Treatment Market

Financial news for AZN dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for AZN dated on 2020-05-20: AstraZeneca And Merck Announce LYNPARZA Approved By FDA For Treatment Of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment With Enzalutamide Or Abiraterone

Financial news for AZN dated on 2020-05-20: AstraZeneca Says Lynparza Approved in the U.S. for Prostate Cancer

Financial news for AZN dated on 2020-05-18: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

Financial news for AZN dated on 2020-05-18: AstraZeneca's ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer

Financial news for AZN dated on 2020-05-18: AstraZeneca and Daiichi Sankyo Announce Enhertu Granted Breakthrough Therapy Designation in the US for HER2-mutant Metastatic NSCLC

Financial news for AZN dated on 2020-05-18: AstraZeneca Says Bevespi Aerosphere Approved in China for Patients with COPD

Financial news for AZN dated on 2020-05-14: Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.

Financial news for AZN dated on 2020-05-14: Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand

Financial news for AZN dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for AZN dated on 2020-05-14: Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO Virtual Scientific Program

Financial news for AZN dated on 2020-05-13: AstraZeneca Highlights Data For TAGRISSO, ENHERTU To Be Presented At ASCO

Financial news for AZN dated on 2020-05-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for AZN dated on 2020-05-11: Inovio Q1 Results Miss Estimates, Coronavirus Vaccine Program On Track

Financial news for AZN dated on 2020-05-11: AstraZeneca And Merck Announce LYNPARZA Approved In US As 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer

Financial news for AZN dated on 2020-05-11: AstraZeneca And Daiichi Sankyo ENHERTU Granted Breakthrough Therapy Designation In US For HER2-Positive Metastatic Gastric Cancer

Financial news for AZN dated on 2020-05-11: Myriad Receives FDA Approval Of myChoice CDx As Companion Diagnostic For Lynparza In Patients With Advanced Ovarian Cancer

Financial news for AZN dated on 2020-05-11: A Peek Into The Markets: US Stock Futures Edge Lower; Crude Oil Down Over 3%

Financial news for AZN dated on 2020-05-11: AstraZeneca Announces Lynparza Approved in the U.S, as 1st-line Maintenance Treatment With Bevacizumab for HED-positive Advanced Ovarian Cancer

Financial news for AZN dated on 2020-05-11: AstraZeneca Announces Recovery of Global Rights to Brazikumab from Allergan Completed

Financial news for AZN dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for AZN dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for AZN dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for AZN dated on 2020-05-06: AstraZeneca Option Alert: Oct 16 \$65 Calls at the Ask: 349 @ \$0.7 vs 469 OI; Ref=\$54.22

Financial news for AZN dated on 2020-05-06: Argus Research Maintains Buy on AstraZeneca, Raises Price Target to \$60

Financial news for AZN dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for AZN dated on 2020-05-06: AstraZeneca Reports FARXIGA Approved In US For Treatment Of Heart Failure In Patients With Heart Failure With Reduced Ejection Fraction

Financial news for AZN dated on 2020-05-06: AstraZeneca Announces Farxiga Approved by FDA for the Treatment of Heart Failure n Patients With Heart Failure With Reduced Ejection Fraction

Financial news for AZN dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for AZN dated on 2020-05-01: RedHill's CEO On Biopharma's 'Two Shots On Goal' For Coronavirus Drug

Financial news for AZN dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for AZN dated on 2020-04-30: Stocks That Hit 52-Week Highs On Thursday

Financial news for AZN dated on 2020-04-30: AstraZeneca PLC shares are trading higher after the company announced it entered into an agreement with Oxford University for a coronavirus vaccine.

Financial news for AZN dated on 2020-04-30: Astrazeneca Executive Baselga Says To Start Vaccine Clinical Trials With Oxford University With Healthy Volunteers 'Very Very Soon'

Financial news for AZN dated on 2020-04-30: AstraZeneca and Oxford University

Announce Landmark Agreement for COVID-19 Vaccine; AstraZeneca CEO Says We Should Have a Pretty Good Idea in June or July Whether Its Vaccine Works

Financial news for AZN dated on 2020-04-29: Morning Market Stats in 5 Minutes

Financial news for AZN dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for AZN dated on 2020-04-29: Earnings Scheduled For April 29, 2020

Financial news for AZN dated on 2020-04-28: Stocks That Hit 52-Week Highs On Tuesday

Financial news for AZN dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for AZN dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for AZN dated on 2020-04-27: AstraZeneca' Reports LOKELMA US Label Updated to Include Dosing Guidance for the Treatment of Hyperkalemia in Patients With End-Stage Renal Disease on Hemodialysis

Financial news for AZN dated on 2020-04-27: Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer

Financial news for AZN dated on 2020-04-24: AstraZeneca, Merck Announce Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer

Financial news for AZN dated on 2020-04-23: AstraZeneca and Saint Luke's Mid America Heart Institute initiate Phase III DARE-19 Trial with Farxiga in COVID-19 Patient

Financial news for AZN dated on 2020-04-17: AstraZeneca Shares Unaffected Amid Report Co. Will Be Apart Of The UK's Coronavirus Vaccine Taskforce

Financial news for AZN dated on 2020-04-14: AstraZeneca Says Tagrisso Adjuvant Trial Overwhelmingly Positive

Financial news for AZN dated on 2020-04-14: AstraZeneca Initiates CALAVI Vlinical Trial with Calquence against COVID-19

Financial news for AZN dated on 2020-04-13: Why AstraZeneca's Stock Is Trading Higher Today

Financial news for AZN dated on 2020-04-13: AstraZeneca shares are trading higher after the company and Merck received approval for KOSELUGO for pediatric patients two years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.

Financial news for AZN dated on 2020-04-13: AstraZeneca and Merck Announce Approval of KOSELUGO for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas

Financial news for AZN dated on 2020-04-09: Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca

Financial news for AZN dated on 2020-04-08: Collaboration with AstraZeneca, GSK and University of Cambridge to support UK national effort to increase COVID-19 testing

Financial news for AZN dated on 2020-04-01: 10 Biotech Winners And Losers In Q1

Financial news for AZN dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for AZN dated on 2020-03-31: AstraZeneca Announces Lokelma Recommended for Approval in EU for Patients with Hyperkalaemia on Stable Haemodialysis

Financial news for AZN dated on 2020-03-30: AstraZeneca shares are trading higher amid strength in the healthcare sector. The company also earlier announced US approval for IMFINZI in extensive-stage small cell lung cancer.

Financial news for AZN dated on 2020-03-30: FDA Reports Approved AstraZeneca's Durvalumab In Combo With Etoposide, Either Carboplatin Or Cisplatin

Financial news for AZN dated on 2020-03-30: AstraZeneca Reports Brilinta Reduced Bleeding vs Dual Therapy In High-Risk Coronary Patients In Sub Analyses From Phase 4 TWILIGHT Trial

Financial news for AZN dated on 2020-03-30: AstraZeneca to Conclude its Phase III DAPA-CKD Trial Early Following Early Positive Trial Results

Financial news for AZN dated on 2020-03-30: AstraZeneca Announces that its IMFINZI Has Been Approved in the US for Extensive-Stage Small Cell Lung Cancer

Financial news for AZN dated on 2020-03-30: AstraZeneca Announces Imfinzi Approved in U.S. for Small Cell Lung Cancer

Financial news for AZN dated on 2020-03-30: AstraZeneca Says Farxiga Phase III DAPA-CKD Trial to be Stopped Early Following Overwhelming Efficacy in Patients with Chronic Kidney Disease

Financial news for AZN dated on 2020-03-29: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty

Financial news for AZN dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for AZN dated on 2020-03-26: A Peek Into The Markets: US Stock Futures Down, Jobless Claims Data In Focus

Financial news for AZN dated on 2020-03-25: Silence Therapeutics Announces Collaboration with AstraZeneca to Discover, Develop and Commercialize Small Interfering RNA Therapeutics for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory Diseases

Financial news for AZN dated on 2020-03-23: Schrodinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologics

Financial news for AZN dated on 2020-03-20: Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.

Financial news for AZN dated on 2020-03-19: A Peek Into The Markets: US Stock Futures Down; WTI Crude Oil Rises Over 10%

Financial news for AZN dated on 2020-03-19: AstraZeneca Announces Lynparza Granted Orphan Drug Designation in Japan

Financial news for AZN dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for AZN dated on 2020-03-17: Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.

Financial news for AZN dated on 2020-03-17: AstraZeneca shares are trading higher after the company announced that Imfinzi confirmed the overall survival in the final analysis of its phase 3 CASPIAN trial.

Financial news for AZN dated on 2020-03-17: AstraZeneca Announces Imfinzi Confirmed Overall Survival in CASPIAN

Financial news for AZN dated on 2020-03-16: Insmo Announces AstraZeneca Has Exercised Option To Develop INS1007 In Chronic Obstructive Pulmonary Disease Or Asthma

Financial news for AZN dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for AZN dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for AZN dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for AZN dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for AZN dated on 2020-03-12: AstraZeneca and Merck Announce Phase 3 GY004 for Cediranib and LYNPARZA in Platinum-Sensitive Relapsed Ovarian Cancer Did

Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy

Financial news for AZN dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for AZN dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Financial news for AZN dated on 2020-03-06: AstraZeneca Phase III DANUBE Trial for Imfinzi and Tremelimumab in Unresectable, Stage IV Bladder Cancer Did Not Meet Primary Endpoints

Financial news for AZN dated on 2020-03-04: 36 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for AZN dated on 2020-03-04: Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for AZN dated on 2020-03-02: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for AZN dated on 2020-03-02: Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.

Financial news for AZN dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for AZN dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for AZN dated on 2020-02-25: 18 Medical Stocks To Watch Amid The Coronavirus Outbreak

Financial news for AZN dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for AZN dated on 2020-02-25: RedHill Biopharma Acquires Rights to Movantik from AstraZeneca for \$52.5M Upfront Plus \$15M 18 Months after Closing

Financial news for AZN dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for AZN dated on 2020-02-21: AstraZeneca shares are trading higher. Not seeing any news to justify the price action.

Financial news for AZN dated on 2020-02-18: AstraZeneca shares are trading higher. Not seeing any news to justify the price action.

Financial news for AZN dated on 2020-02-14: AstraZeneca shares are trading lower following Q4 results. The company's Tagrisso and Lynparza sales came in below projections while revenue growth forecasts were below analyst expectations.

Financial news for AZN dated on 2020-02-14: AstraZeneca Earlier Reported Q4 EPS \$0.89, Sales \$6.664B Miss \$6.75B Estimate

Financial news for AZN dated on 2020-02-14: 8 Stocks To Watch For February 14, 2020

Financial news for AZN dated on 2020-02-14: Earnings Scheduled For February 14, 2020

Financial news for AZN dated on 2020-02-11: Myriad Submits sPMA For myChoice CDx With Lynparza In First-Line Maintenance Therapy In Advanced Ovarian Cancer

Financial news for AZN dated on 2020-01-30: Coronavirus-Related Stocks On Watch Ahead Of WHO Discussion On Whether Coronavirus Is Public Health Emergency

Financial news for AZN dated on 2020-01-27: AstraZeneca's Phase 3 THALES Trial in Stroke Met its Primary Endpoint

Financial news for AZN dated on 2020-01-27: AstraZeneca Sells Global Commercial

Rights to Hypertension Medicines to Atriana Pharma for \$350M, Contingency Payments Up to \$40M

Financial news for AZN dated on 2020-01-27: AstraZeneca Says Enhertu Phase II Trial Met Primary Endpoint of Improvement in ORR

Financial news for AZN dated on 2020-01-27: AstraZeneca Says Brilinta Met Primary Endpoint in Stroke Trial

Financial news for AZN dated on 2020-01-27: AstraZeneca to Recover the Global Rights to Brazikumab from Allergan

Financial news for AZN dated on 2020-01-22: Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study

Financial news for AZN dated on 2020-01-21: Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy

Financial news for AZN dated on 2020-01-21: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2020-01-21: Myriad Submits sPMA For BRCA Analysis CDx As A Companion Diagnostic For Lynparza In Metastatic Castration-resistant Prostate Cancer

Financial news for AZN dated on 2020-01-21: FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Merck's LYNPARZA In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer And Grants Priority Review

Financial news for AZN dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for AZN dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for AZN dated on 2020-01-13: Acasti Shares Slump On Failed Late-Stage Trial, Amarin Moves In Sympathy

Financial news for AZN dated on 2020-01-13: AstraZeneca and Merck's Supplemental New Drug Application for LYNPARZA Granted Priority Review by the FDA

Financial news for AZN dated on 2020-01-10: PhaseBio Rallies On Funding Agreement For Early Stage Anticoagulant Reversal Agent

Financial news for AZN dated on 2020-01-08: Veracyte Announces Biopharmaceutical Collaboration With Acerta Pharma

Financial news for AZN dated on 2020-01-06: AstraZeneca's FARXIGA Granted Priority Review by the FDA and a Supplemental New Drug Application is Accepted

Financial news for AZN dated on 2020-01-06: AstraZeneca Announces Lokelma Approved in China for Hyperkalemia

Financial news for AZN dated on 2020-01-06: AstraZeneca Announces Farxiga Granted FDA Heart Failure Priority Review

Financial news for AZN dated on 2020-01-03: 34 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2020-01-02: Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug

Financial news for AZN dated on 2019-12-30: Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer

Financial news for AZN dated on 2019-12-30: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for AZN dated on 2019-12-30: Merck's LYNPARZA Approved By FDA As First-Line Maintenance Treatment Of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Financial news for AZN dated on 2019-12-30: AstraZeneca Says FDA Approved Lynparza for Pancreatic Cancer

Financial news for AZN dated on 2019-12-29: Starpharma Announces AstraZeneca's Commencement of Phase 1 Trial for AZD0466 Utilising DEP Delivery Technology

Financial news for AZN dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for AZN dated on 2019-12-27: 31 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for AZN dated on 2019-12-23: Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca And Cincinnati Children's Hospital Medical Center To Develop Novel Treatment For Select CNS Disorders

Financial news for AZN dated on 2019-12-23: AstraZeneca Announces Enhertu Approved in the US for HER2-positive Unresectable or Metastatic Breast Cancer Following Two or More Prior anti-HER2 Based Regimens

Financial news for AZN dated on 2019-12-23: AstraZeneca's Triple-combination Therapy Approved in China for Patients with COPD

Financial news for AZN dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for AZN dated on 2019-12-20: 28 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for AZN dated on 2019-12-20: AstraZeneca Sells rights to Arimidex and Casodex in Europe and Certain Additional Countries to Juvise Pharmaceuticals for Upfront Payment of \$181M

Financial news for AZN dated on 2019-12-17: FDA Panel Backs AstraZeneca's LYNPARZA For Pancreatic Cancer, Voted LYNPARZA Demonstrated Clinically Meaningful Favorable Risk-Benefit Profile

Financial news for AZN dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for AZN dated on 2019-12-16: Stocks That Hit 52-Week Highs On Monday

Financial news for AZN dated on 2019-12-16: AstraZeneca shares are trading higher after the company announced it reached an agreement with Cheplapharm for the rights to its Seroquel and Seroquel XR in Europe and Russia.

Financial news for AZN dated on 2019-12-16: AstraZeneca Announces Agreement with Cheplapharm for Rights to Seroquel and Seroquel XR in Europe and Russia Completed

Financial news for AZN dated on 2019-12-13: 8 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-12-12: AstraZeneca Option Alert: Dec 20 \$48 Calls Sweep (2) above Ask!: 1130 @ \$0.526 vs 1349 OI; Ref=\$47.91

Financial news for AZN dated on 2019-12-12: AstraZeneca Announces Imfinzi Approved in China for the Treatment of Unresectable, Stage III NSCLC Based on Phase III PACIFIC Trial

Financial news for AZN dated on 2019-12-11: AstraZeneca Highlights Presentation Of Data Showing Trastuzumab Deruxtecan Achieved Tumor Response Of 60.9% In Pivotal Phase II HER2-Positive Metastatic Breast Cancer Trial

Financial news for AZN dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for AZN dated on 2019-12-10: 41 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2019-12-09: DeepMatter Group PLC Announces Collaboration with AstraZeneca to Improve Productivity and Reproducibility of Compound Synthesis

Financial news for AZN dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for AZN dated on 2019-12-07: AstraZeneca Reports Calquence Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukaemia at ASH 2019

Financial news for AZN dated on 2019-12-05: AstraZeneca, Merck Announce Lynparza Approved in China as a 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2019-12-03: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2019-12-02: Cowen & Co. Maintains Outperform on AstraZeneca, Raises Price Target to \$55

Financial news for AZN dated on 2019-11-29: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for AZN dated on 2019-11-29: AstraZeneca Announces Imfinzi Granted FDA Priority Review for SCLC

Financial news for AZN dated on 2019-11-26: AstraZeneca And PCI Biotech Expand Collaboration Agreement

Financial news for AZN dated on 2019-11-26: Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca

Financial news for AZN dated on 2019-11-22: AstraZeneca CEO: Closing In On A Cancer Cure

Financial news for AZN dated on 2019-11-22: SVB Leerink Initiates Coverage On AstraZeneca with Outperform Rating

Financial news for AZN dated on 2019-11-22: 19 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-11-21: AstraZeneca Reports Calquence Approved For Patients With Chronic Lymphocytic Leukemia In US

Financial news for AZN dated on 2019-11-20: Health Canada Says For Past Several Weeks, Apotex, Astrazeneca Canada And Teva Canada Have Reported Tamoxifen Shortages On Drug Shortages Canada Website; Reasons Included Unexpected Manufacturing Disruptions & Increased Demand

Financial news for AZN dated on 2019-11-17: AstraZeneca Announced Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial

Financial news for AZN dated on 2019-11-17: Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy

Financial news for AZN dated on 2019-11-14: AstraZeneca, Merck Report FDA Acceptance Of Regulatory Submission For New Drug Application For Selumetinib In Neurofibromatosis Type 1, Priority Review Granted

Financial news for AZN dated on 2019-11-13: AstraZeneca Defends Analysis Of Roxadustat After A Report Said Key Data Was Excluded

Financial news for AZN dated on 2019-11-12: Aravive, AstraZeneca Report Initiation Of Randomized Phase 1/2 Study Of AVB-500 In Combo With Durvalumab In Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Financial news for AZN dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for AZN dated on 2019-11-12: AstraZeneca Announces Anifrolumab Demonstrated Superiority in TULIP 2

Financial news for AZN dated on 2019-11-11: UPDATE: On Primary Endpoint, Anifrolumab Achieved Statistically Significant & Clinically Meaningful Reduction In Disease Activity At Week 52; 47.8% Of Patients Receiving Anifrolumab Responded Compared With 31.5% Of Patients On Placebo

Financial news for AZN dated on 2019-11-11: Astrazeneca Says Anifrolumab Showed Superiority Across Multiple Efficacy Endpoints In Patients With Systemic Lupus Erythematosus In Phase III Tulip 2 Trial

Financial news for AZN dated on 2019-11-11: These Are The Winners Of The Inaugural WeTrader Paper Trading Competition

Financial news for AZN dated on 2019-11-09: Bulls And Bears Of The Week: Roku, Tesla, Twitter, Uber And More

Financial news for AZN dated on 2019-11-08: AstraZeneca Says Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy And No Increased Cardiovascular Risk In Patients With Anemia From Chronic Kidney Disease Versus Comparators

Financial news for AZN dated on 2019-11-08: AstraZeneca Files For Potential Debt Shelf Offering, Size Not Disclosed

Financial news for AZN dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for AZN dated on 2019-11-08: AstraZeneca Says Roxadustat Significantly Increased Haemoglobin

Financial news for AZN dated on 2019-11-07: Former Google, Pharma Execs Start Ritual-Based Cannabis Company

Financial news for AZN dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for AZN dated on 2019-11-06: AstraZeneca Highlights Will Present First Data From Phase 3 ELEVATE-TN Trial Assessing CALQUENCE In Patients with Previously-Untreated Chronic Lymphocytic Leukemia At ASH Dec. 7-10, 2019

Financial news for AZN dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for AZN dated on 2019-11-06: Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China

Financial news for AZN dated on 2019-11-06: AstraZeneca Announces Three Large-scale Initiatives in China to Advance Global Medicine Research and Development

Financial news for AZN dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for AZN dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for AZN dated on 2019-10-30: AstraZeneca shares are trading higher after the company announced it will sell its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm for \$178 million plus up to \$61 million in future sales-contingent payments.

Financial news for AZN dated on 2019-10-30: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for AZN dated on 2019-10-30: AstraZeneca Divests Rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm for \$178M Plus Up to \$61M in Future Sales-Contingent Payments

Financial news for AZN dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for AZN dated on 2019-10-28: AstraZeneca Issues Press Release Confirmed IMFINZI, IMFINZI Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial

Financial news for AZN dated on 2019-10-28: AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial

Financial news for AZN dated on 2019-10-28: AstraZeneca Shares Resume Trade, Up 1.3% For Session

Financial news for AZN dated on 2019-10-28: CORRECTION On Aggregated Headline From 2 Other Publications: AstraZeneca Reported Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial

Financial news for AZN dated on 2019-10-28: UPDATE: AstraZeneca Says Triple Combo Did Not Result In Increased Discontinuation Of Therapy

Financial news for AZN dated on 2019-10-28: UPDATE: AstraZeneca Says Phase 3 Poseidon Trial Met Primary Endpoint

Financial news for AZN dated on 2019-10-28: Merck Shares Fall 2% Following Report AstraZeneca Trial Of Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 Trial

Financial news for AZN dated on 2019-10-28: UPDATE: AstraZeneca Says Poseidon Trial

Will Continue To Assess Added Primary Endpoint Of Overall Survival

Financial news for AZN dated on 2019-10-28: AstraZeneca Says Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial

Financial news for AZN dated on 2019-10-28: AstraZeneca Shares Halted News Pending

Financial news for AZN dated on 2019-10-28: NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with AstraZeneca's Durvalumab in Solid Tumors

Financial news for AZN dated on 2019-10-25: WeTrader Competition: Round Three Wrap-up

Financial news for AZN dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for AZN dated on 2019-10-24: AstraZeneca shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for AZN dated on 2019-10-24: AstraZeneca Q3 EPS \$0.99 vs \$0.95 Est; Revenue \$6.41B vs \$6.11B Est

Financial news for AZN dated on 2019-10-24: Earnings Scheduled For October 24, 2019

Financial news for AZN dated on 2019-10-23: Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Financial news for AZN dated on 2019-10-21: 3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

Financial news for AZN dated on 2019-10-21: Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition

Financial news for AZN dated on 2019-10-21: AstraZeneca's FARXIGA Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes

Financial news for AZN dated on 2019-10-21: AstraZeneca Announces Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients With Type-2 Diabetes

Financial news for AZN dated on 2019-10-19: Benzinga's Bulls And Bears Of The Week: Beyond Meat, Netflix, Johnson & Johnson And More

Financial news for AZN dated on 2019-10-17: AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review

Financial news for AZN dated on 2019-10-17: AstraZeneca And Daiichi Sankyo's Trastuzumab Deruxtecan Granted FDA Priority Review For Treatment Of Patients With HER2-Positive Metastatic Breast Cancer

Financial news for AZN dated on 2019-10-17: AstraZeneca Says Trastuzumab Deruxtecan Granted FDA Priority Review

Financial news for AZN dated on 2019-10-15: Innate Pharma IPO: What You Need To Know

Financial news for AZN dated on 2019-10-14: IPO Outlook For The Week: Cancer Therapies And Protein Powders

Financial news for AZN dated on 2019-10-14: ImaginAb Signs Multi-party Collaboration Agreement With Pfizer, AstraZeneca, Takeda to Help Further Develop Company's Cd8 Immunopet Technology

Financial news for AZN dated on 2019-10-12: Notable Insider Buys In The Past Week: Assured Guaranty, Red Rock Resorts, TerraForm Power

Financial news for AZN dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for AZN dated on 2019-10-09: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for AZN dated on 2019-10-08: Fitch Affirms Astrazeneca At 'BBB+', Stable Outlook

Financial news for AZN dated on 2019-10-08: Goldman Recommends Selling Puma Biotech,

Clovis Oncology; Cites Company-Specific, Competitive Risks

Financial news for AZN dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for AZN dated on 2019-10-04: Hearing Wellington Mgmt. Co. Filing On AstraZeneca Shows 5.88% Stake; BZ NOTE: Wellington Mgmt. Group Had Shown ~66M Share Stake As Of End Of Last Qtr.

Financial news for AZN dated on 2019-10-04: AstraZeneca Reports FASENRA Approved In US For Self Administration Via FASENRA Pen

Financial news for AZN dated on 2019-10-04: Fasenra Approved in the US for Self-administration in a New Pre-filled Auto-injector, the Fasenra Pen

Financial news for AZN dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for AZN dated on 2019-10-01: AstraZeneca Divests Rights for Losec to Cheplapharm; Cheplapharm to Pay AstraZeneca ~\$243M on Completion of the Agreement, Plus Sales-contingent Milestones of up to \$33M in 2021, 2022

Financial news for AZN dated on 2019-09-30: Movers And Shakers At ESMO 2019: Immunomedics, GI Therapeutics, Seattle Genetics And More

Financial news for AZN dated on 2019-09-30: TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years

Financial news for AZN dated on 2019-09-30: Merck, AstraZeneca Highlight Data LYNPARZA More Than Doubled Median Radiographic Progression-Free Survival In BRCA1/2, ATM Metastatic Castration-Resistant Prostate Cancer

Financial news for AZN dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for AZN dated on 2019-09-28: AstraZeneca , Merck Announced LYNPARZA Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer at ESMO 2019

Financial news for AZN dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for AZN dated on 2019-09-26: AstraZeneca Reports BRILINTA Monotherapy In High-bleeding Risk Patients Who Underwent Pci Had Reduced Risk Of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy In The Twilight Trial; Says Achieved Secondary Endpoint Of Non-Inferiority

Financial news for AZN dated on 2019-09-26: Innate Pharma Announces AstraZeneca to Advance Monalizumab to Phase III in Head and Neck Cancer

Financial news for AZN dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for AZN dated on 2019-09-24: 14 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2019-09-23: Astrazeneca Says Qtrilmet Recommended for Approval in EU by CHMP-

Financial news for AZN dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for AZN dated on 2019-09-20: 15 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-09-20: CHMP Recommends Granting Marketing Authorisation for Astrazeneca's Qtrilmet for Treatment of Type 2 Diabetes Mellitus

Financial news for AZN dated on 2019-09-20: CHMP Recommends Granting Marketing Authorization For Astrazeneca's Qtrilmet, Rhokiinsa And Xospata

Financial news for AZN dated on 2019-09-19: AstraZeneca PLC shares are trading higher on seemingly no company-specific news.

Financial news for AZN dated on 2019-09-19: 18 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AZN dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for AZN dated on 2019-09-18: Ironwood Pharmaceuticals, AstraZeneca Amend LINZESS Collaboration in China

Financial news for AZN dated on 2019-09-17: Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline

Financial news for AZN dated on 2019-09-17: 9 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2019-09-16: AstraZeneca Reports FDA Granted Fast Track Designation For FARXIGA In Heart Failure

Financial news for AZN dated on 2019-09-16: A Peek Into The Markets: US Stock Futures Down; Crude Oil Jumps Following Saudi Attack

Financial news for AZN dated on 2019-09-16: AstraZeneca Announces FDA Grants Fast Track Designation for Farxiga in Heart Failure

Financial news for AZN dated on 2019-09-10: Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.

Financial news for AZN dated on 2019-09-10: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AZN dated on 2019-09-10: AstraZeneca shares trading lower on continued momentum despite yesterday's news that the company's Imfinzi improved durable responses in extensive-stage small cell lung cancer.

Financial news for AZN dated on 2019-09-09: AstraZeneca shares trading lower despite earlier news the company's Imfinzi improved durable responses in extensive-stage small cell lung cancer.

Financial news for AZN dated on 2019-09-09: AstraZeneca's Imfinzi Shows Both Significant Survival Benefit and Improved, Durable Responses in Extensive-stage Small Cell Lung Cancer

Financial news for AZN dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for AZN dated on 2019-09-05: Theragnostics Signs IP Agreement with AstraZeneca

Financial news for AZN dated on 2019-09-04: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

Financial news for AZN dated on 2019-09-02: The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

Financial news for AZN dated on 2019-09-01: AstraZeneca Announces BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial

Financial news for AZN dated on 2019-09-01: AstraZeneca Announces Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure

Financial news for AZN dated on 2019-08-30: AstraZeneca Spin-Off Viela Bio Files For IPO

Financial news for AZN dated on 2019-08-28: AstraZeneca Announces Phase III ETHOS Trial Met Its Primary Endpoint In Chronic Obstructive Pulmonary Disease

Financial news for AZN dated on 2019-08-27: Grants Fast Track Designation To AstraZeneca For FARXIGA In Chronic Kidney Disease

Financial news for AZN dated on 2019-08-24: Bulls And Bears Of The Week: Chevron, Disney, Target And More

Financial news for AZN dated on 2019-08-24: 10 Biopharmaceutical Companies Trying To

Cure Cancer

Financial news for AZN dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for AZN dated on 2019-08-22: AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi for \$95M in Cash

Financial news for AZN dated on 2019-08-22: AstraZeneca Announces Roxadustat Approved in China for the Treatment of Anaemia in Non-dialysis-dependent Patients With Chronic Kidney Disease

Financial news for AZN dated on 2019-08-21: AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study

Financial news for AZN dated on 2019-08-20: AstraZeneca Announces FARXIGA Met Primary Endpoint In Landmark Phase III DAPA-HF Trial For The Treatment Of Patients With Heart Failure

Financial news for AZN dated on 2019-08-20: AstraZeneca Says Farxiga Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure

Financial news for AZN dated on 2019-08-14: AstraZeneca 's CALQUENCE Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia

Financial news for AZN dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for AZN dated on 2019-08-14: AstraZeneca And Merck Announce LYNPARZA) Phase 3 PAOLA-1 Trial Met Primary Endpoint In Ovarian Cancer Patients

Financial news for AZN dated on 2019-08-14: AstraZeneca Says Calquence Granted US Breakthrough Therapy Designation from FDA for Chronic Lymphocytic Leukaemia

Financial news for AZN dated on 2019-08-14: Lynparza Phase Iii Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Financial news for AZN dated on 2019-08-14: AstraZeneca, Merck Announce Lynparza Phase III PAOLA-1 Trial Met Primary Endpoint

Financial news for AZN dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for AZN dated on 2019-08-13: AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

Financial news for AZN dated on 2019-08-12: No-deal Brexit Could Worsen Europe's Medicine Shortage

Financial news for AZN dated on 2019-08-09: AstraZeneca PLC shares are trading higher after the company announced its Phase 3 FLAURA trial of Tagrisso significantly improved overall survival in patients with NSCLC.

Financial news for AZN dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for AZN dated on 2019-08-09: AstraZeneca Reports TAGRISSO Significantly Improved Overall Survival In Phase III FLAURA Trial For 1st-Line EGFR-Mutated Non-Small Lung Cancer

Financial news for AZN dated on 2019-08-09: AstraZeneca Announces Tagrisso Significantly Improves Overall Survival in NSCLC

Financial news for AZN dated on 2019-08-07: Aevi Genomic Medicine Enters Into License Agreement With AstraZeneca For Anti-IL-18 Antibody

Financial news for AZN dated on 2019-08-07: AstraZeneca, Merck Announce Lynparza Phase III PROfound Trial in HRR Mutation-selected Metastatic Castration-resistant Prostate Cancer Met Primary Endpoint

Financial news for AZN dated on 2019-08-06: Inovalon Reports Will Implement Comprehensive Value Platform Initiative For AstraZeneca, No Terms Disclosed

Financial news for AZN dated on 2019-08-05: AstraZeneca Announces Forxiga Label Updated in the EU in Type-2 Diabetes

Financial news for AZN dated on 2019-07-29: New Equities that Broke Through 52-Week Highs Monday Morning

Financial news for AZN dated on 2019-07-26: Companies That Achieved 52-Week Highs Friday

Financial news for AZN dated on 2019-07-26: 64 Biggest Movers From Yesterday

Financial news for AZN dated on 2019-07-25: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for AZN dated on 2019-07-25: AstraZeneca shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also extended its 2017 development agreement with BioCardia.

Financial news for AZN dated on 2019-07-25: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for AZN dated on 2019-07-25: AstraZeneca Q2 EPS \$0.73 Beats \$0.29 Estimate, Sales \$5.823B Beat \$5.51B Estimate

Financial news for AZN dated on 2019-07-25: BioCardia and AstraZeneca Extend Their 2017 Development Agreement

Financial news for AZN dated on 2019-07-25: AstraZeneca Shares Rise 6% in London on Strong Sales, Demand for Cancer Drugs

Financial news for AZN dated on 2019-07-22: FDA Approves Inclusion Of Overall Survival Data On Phase III PACIFIC Trial Of AstraZeneca's IMFINZI

Financial news for AZN dated on 2019-07-15: AstraZeneca Announces FDA Issues CRL for Farxiga

Financial news for AZN dated on 2019-07-12: Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Financial news for AZN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for AZN dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for AZN dated on 2019-07-01: AstraZeneca Announces Forxiga Receives Positive EU CHMP Opinion for DECLARE-TIMI 58 Cardiovascular Outcomes Data

Financial news for AZN dated on 2019-06-27: AstraZeneca Announces Imfinzi Improves Overall Survival at Interim Analysis in Phase III CASPIAN Trial in 1st-line Extensive-stage Small Cell Lung Cancer

Financial news for AZN dated on 2019-06-19: AstraZeneca, Merck Announce Lynparza Approved in Japan for 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2019-06-19: AstraZeneca Announces Breztri Aerosphere Approved in Japan for Patients with COPD

Financial news for AZN dated on 2019-06-18: AstraZeneca shares trading higher following news of Lynparza approval in the European Union.

Financial news for AZN dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for AZN dated on 2019-06-18: AstraZeneca, Merck Report LYNPARZA Approved In EU For Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2019-06-18: AstraZeneca, Merck Announce Lynparza Approved in the EU for 1st-line Maintenance Treatment Of BRCA-mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2019-06-17: AstraZeneca Announces Calquence Significantly Prolonged Time Patients Lived Without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

Financial news for AZN dated on 2019-06-14: Astrazeneca Says Lokelma Showed Efficacy

Treating Hyperkalaemia Patients

Financial news for AZN dated on 2019-06-10: AstraZeneca Reports FARXIGA Study Showed Reduced Progression Of Kidney Disease, Renal Death In Patients with Type-2 Diabetes: 'showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death'

Financial news for AZN dated on 2019-06-07: Sanofi's Leadership Transition: What You Need To Know

Financial news for AZN dated on 2019-06-06: AstraZeneca Announces Calquence Phase III ELEVATE-TN Trial Met Primary Endpoint

Financial news for AZN dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for AZN dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for AZN dated on 2019-06-03: AstraZeneca Board Is At Early Stages Of Planning To Seek Eventual Replacement For Leif Johansson, Who Has Chaired Co For 7 Years

Financial news for AZN dated on 2019-06-02: Myriad Genetics Announces BRACAnalysis CDx Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza at #ASCO19

Financial news for AZN dated on 2019-06-02: AstraZeneca IMFINZI Demonstrates Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer at #ASCO19

Financial news for AZN dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for AZN dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for AZN dated on 2019-05-28: Inovio Pharmaceuticals Receives Notification From AstraZeneca Subsidiary MedImmune That AstraZeneca Intends To Discontinue Activities With Respect To Most Research Collaboration Programs

Financial news for AZN dated on 2019-05-28: AstraZeneca to Invest \$220M in Vietnam from 2020-2024

Financial news for AZN dated on 2019-05-20: AstraZeneca Highlights Phase III Data For FASENRA Showed Patients With Severe Eosinophilic Asthma Treated For Up To 2 Years 'reduced their use of oral corticosteroids'

Financial news for AZN dated on 2019-05-20: AstraZeneca Announces New Data Show Symbicort Reduces Attacks in Mild Asthma When Used as Anti-inflammatory Reliever

Financial news for AZN dated on 2019-05-16: Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.

Financial news for AZN dated on 2019-05-16: AstraZeneca Reports New Data on Symbicort as Potential Anti-inflammatory Reliever in Mild Asthma to be Presented at ATS 2019

Financial news for AZN dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for AZN dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for AZN dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for AZN dated on 2019-05-10: AstraZeneca Announces Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety

Financial news for AZN dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for AZN dated on 2019-05-08: AstraZeneca Announces Trastuzumab Deruxtecan Demonstrated Clinically-meaningful Response in Patients With Refractory Her2-positive Metastatic Breast Cancer

Financial news for AZN dated on 2019-05-07: AstraZeneca Reports Calquence Phase III ASCEND Trial Met Primary Endpoint At Interim Analysis in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Will Stop Early

Financial news for AZN dated on 2019-05-06: AstraZeneca Says Safety And Tolerability Of Calquence Was Consistent With Known Profile; Says Study Results Showed Statistically-Significant & Clinically-Meaningful Improvement In Progression-Free Survival With Calquence Monotherapy

Financial news for AZN dated on 2019-05-03: AstraZeneca Announces Qternmet XR Approved in US for Type-2 Diabetes

Financial news for AZN dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for AZN dated on 2019-05-02: Transgene, Astrazeneca Enter Collaboration, Exclusive License Option Agreement for Innovative InVio™ Based Armed Oncolytic Immunotherapies

Financial news for AZN dated on 2019-04-30: Shares of several pharmaceutical companies are trading higher in sympathy with Pfizer and Merck after the companies reported strong Q1 earnings.

Financial news for AZN dated on 2019-04-30: Astrazeneca Starts Artificial Intelligence Collaboration with BenevolentAI to Accelerate Drug Discovery

Financial news for AZN dated on 2019-04-29: AstraZeneca, Merck Announce Lynparza Receives Positive EU CHMP Opinion for 1st-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2019-04-26: AstraZeneca shares trading lower despite better-than-expected Q1 earnings and sales and reaffirmed FY19 guidance.

Financial news for AZN dated on 2019-04-26: AstraZeneca PLC Q1 EPS \$0.47 Beats \$0.42 Est.; Revenue \$5.49B Beats \$5.42B Est

Financial news for AZN dated on 2019-04-24: AstraZeneca Option Alert: May 17 \$40 Calls Sweep (23) near the Ask: 500 @ \$0.549 vs 3443 OI; Earnings 5/17 Before Open [est] Ref=\$38.8

Financial news for AZN dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for AZN dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for AZN dated on 2019-04-17: FDA Approves AstraZeneca's Duaklir Pressair For Patients With Chronic Obstructive Pulmonary Disease (COPD)

Financial news for AZN dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for AZN dated on 2019-04-10: AstraZeneca, Merck Announce Lynparza Approved in EU for the treatment of Germline BRCA-mutated HER2-negative Advanced Breast Cancer

Financial news for AZN dated on 2019-04-09: Mid-Afternoon Market Update: Dow Down Over 200 Points; Precipio Shares Spike Higher

Financial news for AZN dated on 2019-04-09: Mid-Day Market Update: Command Center Surges Following Merger Deal With Hire Quest; Hollysys Automation Shares Slide

Financial news for AZN dated on 2019-04-09: Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452

Financial news for AZN dated on 2019-04-09: The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Financial news for AZN dated on 2019-04-08: Inovio Pharma Reports Achieved Third

Indication Milestone From AstraZeneca Related To Dosing Of Patient In Phase 2 Combo Trial Evaluating MEDI0457

Financial news for AZN dated on 2019-04-04: Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership

Financial news for AZN dated on 2019-04-02: Benzinga's Top Upgrades, Downgrades For April 2, 2019

Financial news for AZN dated on 2019-04-02: UBS Downgrades AstraZeneca to Sell

Financial news for AZN dated on 2019-04-01: AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation

Financial news for AZN dated on 2019-04-01: 10 Biggest Price Target Changes For Monday

Financial news for AZN dated on 2019-04-01: Benzinga's Top Upgrades, Downgrades For April 1, 2019

Financial news for AZN dated on 2019-04-01: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for AZN dated on 2019-04-01: AstraZeneca shares are trading higher after the FDA granted Breakthrough Therapy Designation for the company's Zelumetinib and the stock was upgraded from Market Perform to Outperform by Cowen.

Financial news for AZN dated on 2019-04-01: Merck and AstraZeneca's Selumetinib is Granted Breakthrough Therapy Designation in Neurofibromatosis Type 1

Financial news for AZN dated on 2019-04-01: Cowen & Co. Upgrades AstraZeneca to Outperform, Raises Price Target to \$48

Financial news for AZN dated on 2019-04-01: 62 Biggest Movers From Friday

Financial news for AZN dated on 2019-04-01: AstraZeneca, Merck Announce Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

Financial news for AZN dated on 2019-03-29: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for AZN dated on 2019-03-29: Japan's Daiichi Strikes Cancer Therapy Deal With AstraZeneca Worth Up To \$6.9B

Financial news for AZN dated on 2019-03-29: FDA Approves Astrazeneca's Duaklir Pressair For Maintenance Treatment Of Patients With Chronic Obstructive Pulmonary Disease

Financial news for AZN dated on 2019-03-29: AstraZeneca PLC shares are trading lower after the company announced it would need to make a public offering for \$3.5 billion to fund a \$6.9 billion cancer drug deal with the Japanese company Daiichi Sankyo.

Financial news for AZN dated on 2019-03-29: AstraZeneca Announced A \$3.5B Equity Placement To Fund Deal With Daiichi Sankyo For Collaboration On Novel HER2-Targeting Antibody-Drug Conjugate

Financial news for AZN dated on 2019-03-29: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2019-03-29: The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Financial news for AZN dated on 2019-03-29: Daiichi Sankyo, AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201); Total Payments by AstraZeneca to Daiichi Could Reach \$6.9B

Financial news for AZN dated on 2019-03-28: UK's NHS to Pay for AstraZeneca's Cancer Drug Imfinzi

Financial news for AZN dated on 2019-03-27: UPDATE: Seeking Alpha Post On AstraZeneca For Aveo Shows Price In \$800M-\$1.2B Range; BZ NOTE: Author Of Post Has 5 Followers, Has Posted On SA Only 2 Times Previously, Disclosed Is Long Aveo

Financial news for AZN dated on 2019-03-27: 'According to representatives from several large investment banks, it is their firm belief that Astrazeneca will acquire Aveo Oncology...' -Seeking Alpha Blog Post From TheBlueLion

Financial news for AZN dated on 2019-03-27: Astrazeneca Announces Forxiga Approved In

Japan For Type-1 Diabetes

Financial news for AZN dated on 2019-03-26: Ichor Medical Reports Entered Collab, Research License Deal With AstraZeneca For Development, Clinical Assessment Of Plasmid DNA Constructs

Financial news for AZN dated on 2019-03-25: AstraZeneca Announces Forxiga Approved in Europe for Type-1 Diabetes

Financial news for AZN dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for AZN dated on 2019-03-20: The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

Financial news for AZN dated on 2019-03-19: The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

Financial news for AZN dated on 2019-03-18: AstraZeneca Says First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes

Financial news for AZN dated on 2019-03-18: AstraZeneca is Mounting a Big Push into Digital Technologies

Financial news for AZN dated on 2019-03-18: AstraZeneca Announces FDA Grants Saracatinib Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Financial news for AZN dated on 2019-03-16: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for AZN dated on 2019-03-11: UPDATE: Seres Will Receive \$20M, Financial Support For Research Activities

Financial news for AZN dated on 2019-03-11: Seres Therapeutics Reports Microbiome Immuno-Oncology Focused Collaboration With AstraZeneca

Financial news for AZN dated on 2019-03-11: AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019

Financial news for AZN dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for AZN dated on 2019-03-01: Merck Reports Positive CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Financial news for AZN dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for AZN dated on 2019-02-27: The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

Financial news for AZN dated on 2019-02-27: AstraZeneca Announces FDA Approval Of Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment

Financial news for AZN dated on 2019-02-26: UPDATE: Merck, AstraZeneca Report Phase III POLO Trial Met Primary Endpoint

Financial news for AZN dated on 2019-02-26: Merck, AstraZeneca Report LYNPARZA Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

Financial news for AZN dated on 2019-02-26: AstraZeneca, Merck Announce Phase III POLO Trial Met its Primary Endpoint of Progression-free Survival

Financial news for AZN dated on 2019-02-25: AstraZeneca's Brilinta Found To Alleviate Cardiovascular Risk In Late-Stage Study

Financial news for AZN dated on 2019-02-25: AstrazZeneca's Brilinta's Phase 3 Trial Met its Primary Endpoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes

Financial news for AZN dated on 2019-02-25: AstraZeneca Announces Brilinta's PhIII THEMIS Trial Met Primary Endpoint

Financial news for AZN dated on 2019-02-15: 71 Biggest Movers From Yesterday

Financial news for AZN dated on 2019-02-14: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for AZN dated on 2019-02-14: AstraZeneca shares are trading higher after the company reported Q4 revenue of \$6.42B versus the \$6.27B estimate and announced better than expected 2019 guidance.

Financial news for AZN dated on 2019-02-14: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for AZN dated on 2019-02-14: Earnings Scheduled For February 14, 2019

Financial news for AZN dated on 2019-02-14: AstraZeneca Q4 Adj EPS \$1.58; Revenue \$6.42B vs \$6.27B Est

Financial news for AZN dated on 2019-02-05: AstraZeneca FDA Breakthrough Therapy Designation for Potential Next-generation RSV Medicine MEDI8897

Financial news for AZN dated on 2019-02-05: AstraZeneca Announces EMA Grants PRIME Eligibility for MEDI8897

Financial news for AZN dated on 2019-02-01: Astrazeneca's FORXIGA Receives Positive EU Opinion

Financial news for AZN dated on 2019-01-23: The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study

Financial news for AZN dated on 2019-01-17: Astellas Pharma Announces Sale And Distribution Of Symbicort Turbuhaler Conducted By Astellas In Japan To Be Transferred To Astrazeneca

Financial news for AZN dated on 2019-01-16: Luye Pharma Grants AstraZeneca China Exclusive Rights To Promote Co's Xuezhikang Capsules In Mainland China

Financial news for AZN dated on 2019-01-07: Sosei Heptares to Receive \$15M Milestone Payment in Q1 From AstraZeneca

Financial news for AZN dated on 2019-01-04: Ironwood Pharmaceuticals Picks AstraZeneca Executive To Be Next CEO

Financial news for AZN dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for AZN dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for AZN dated on 2018-12-21: When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?

Financial news for AZN dated on 2018-12-20: AstraZeneca's Bevespi Aerosphere Approved In EU For COPD

Financial news for AZN dated on 2018-12-20: AstraZeneca shares are trading higher after announcing Phase III Olympus And Rockies Trials For Roxadustat Met Primary Endpoints In Chronic Kidney Disease Patients With Anaemia.

Financial news for AZN dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for AZN dated on 2018-12-20: AstraZeneca Reports Phase III OLYMPUS, ROCKIES Trials For Roxadustat Each Met Primary Endpoint

Financial news for AZN dated on 2018-12-20: AstraZeneca, Merck Report LYNPARZA Met Primary Endpoint In Phase 3 SOLO-3 Trial For Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2018-12-20: AstraZeneca Reports Phase III Olympus And Rockies Trials For Roxadustat Met Primary Endpoints In Chronic Kidney Disease Patients With Anaemia

Financial news for AZN dated on 2018-12-19: AstraZeneca, Merck Report FDA Approval For LYNPARZA For First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for AZN dated on 2018-12-19: Myriad Genetics Announces FDA Approval Of BRACAnalysis CDxAs A Companion Diagnostic For AstraZeneca's Lynparza For Ovarian Cancer

Financial news for AZN dated on 2018-12-14: Benzinga's Top Upgrades, Downgrades For December 14, 2018

Financial news for AZN dated on 2018-12-14: SunTrust Robinson Humphrey Initiates Coverage On AstraZeneca with Buy Rating, Announces \$48 Price Target

Financial news for AZN dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for AZN dated on 2018-12-11: Jefferies Assumes AstraZeneca at Hold, Announces Price Target \$42

Financial news for AZN dated on 2018-12-11: Circassia Pharmaceuticals Issued Notice Of Option Exercise To AstraZeneca To Acquire Full US Commercial Rights To Tudorza

Financial news for AZN dated on 2018-12-10: AstraZeneca, Cancer Research UK Launch Functional Genomics Centre To Accelerate The Discovery Of New Medicines

Financial news for AZN dated on 2018-12-07: AstraZeneca's Head and Neck Cancer Treatment Fails to Meet Primary Endpoint

Financial news for AZN dated on 2018-12-06: AstraZeneca Says Divestment of Rights to Alvosco, Omnisar and Zetonna to Covis for \$350M has been Completed

Financial news for AZN dated on 2018-12-03: AstraZeneca Announces Grunenthal Agreement for Nexium, Vimovo Completed; AstraZeneca has Received Upfront Payments Totaling \$815M

Financial news for AZN dated on 2018-11-29: Dynavax Technologies Informed By Collaborator AstraZeneca That Initial High-Level Results From Phase 2a Study Indicate AZD1419 Did Not Meet Primary Endpoint; AstraZeneca To Review Will Data Before Deciding Next Steps

Financial news for AZN dated on 2018-11-29: Merck Is Up 40% In 2018: What's Driving The Rally?

Financial news for AZN dated on 2018-11-29: Biocartis, AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results

Financial news for AZN dated on 2018-11-26: AstraZeneca Announces FDA grants Fasenra Orphan Drug Designation for Eosinophilic Granulomatosis with Polyangiitis

Financial news for AZN dated on 2018-11-19: Benzinga's Top Upgrades, Downgrades For November 19, 2018

Financial news for AZN dated on 2018-11-19: Investec Downgrades AstraZeneca to Hold

Financial news for AZN dated on 2018-11-16: AstraZeneca shares are trading down 2.5% after the company's Imfinzi failed to meet primary endpoints in study of lung cancer.

Financial news for AZN dated on 2018-11-16: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2018-11-16: AstraZeneca Reports Combination Of Imfinzi Plus Tremelimumab Did Not Meet The Primary Endpoints Of Improving OS Compared To Soc Chemotherapy in Stage IV NSCLC

Financial news for AZN dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for AZN dated on 2018-11-13: Sobi to Acquire Synagis US Rights from AstraZeneca for \$1.5B in Cash, Sobi Stock

Financial news for AZN dated on 2018-11-12: AstraZeneca, Merck Announce FDA Accepts Regulatory Submission for Lynparza Maintenance Therapy in Newly-diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review

Financial news for AZN dated on 2018-11-10: AstraZeneca Reports FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

Financial news for AZN dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for AZN dated on 2018-11-08: AstraZeneca Shares are up 4.3% after the company beat Q3 EPS estimates but missed on sales.

Financial news for AZN dated on 2018-11-08: Astrazeneca PLC Earlier Reported Q3 EPS \$0.71 Beat \$0.40 Estimate, Sales \$5.34B Missed \$5.49B Estimate

Financial news for AZN dated on 2018-11-08: Earnings Scheduled For November 8, 2018

Financial news for AZN dated on 2018-11-07: Immunomedics Expands Clinical Collaboration With AstraZeneca to Include Metastatic Non-Small Cell Lung Cancer

Financial news for AZN dated on 2018-11-07: AstraZeneca Q3 Earnings Preview

Financial news for AZN dated on 2018-11-06: AstraZeneca Announces Agreement to Sell Rights to Alvesco, Ommaris and Zetonna to Covis Pharma for \$350M at Closing, Plus up to \$21M in Sales Milestones

Financial news for AZN dated on 2018-10-30: UPDATE: AstraZeneca to Receive \$815M Upfront; Up to \$107M in Milestones

Financial news for AZN dated on 2018-10-30: AstraZeneca Announces Agreement to Sell Rights to Grunenthal for Nexium in Europe, Vimovo Worldwide

Financial news for AZN dated on 2018-10-29: UPDATE: AstraZeneca Stake In PhaseBio Pharmaceuticals Was Acquired Before PhaseBio IPO

Financial news for AZN dated on 2018-10-29: PhaseBio Pharmaceuticals 13D Shows AstraZeneca Holds 12.6% Stake In Co.

Financial news for AZN dated on 2018-10-26: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for AZN dated on 2018-10-26: 'A New Way To Treat The Brain': Stanford University Scientists Launch Cannabis Pharma Company

Financial news for AZN dated on 2018-10-25: AstraZeneca Says Phase III Harmonize Global Trial Of LOKELMA Confirms Efficacy In Maintaining Normal Potassium Levels In Patients With Hyperkalemia

Financial news for AZN dated on 2018-10-23: Innate Pharma Expands its Oncology Development Collaboration with AstraZeneca; AstraZeneca to Purchase Newly-issued 9.8% Equity Stake in Innate Pharma

Financial news for AZN dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for AZN dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for AZN dated on 2018-10-21: AstraZeneca, Merck Announce Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer at ESMO

Financial news for AZN dated on 2018-10-17: PhaseBio's IPO: What You Need To Know

Financial news for AZN dated on 2018-10-16: AstraZeneca shares are up 3.8% after the company and Merck received Orphan Drug Designation for Lynparza in pancreatic cancer.

Financial news for AZN dated on 2018-10-16: U.S. FDA Grants Merck And AstraZeneca's LYNPARZA Orphan Drug Designation For Pancreatic Cancer

Financial news for AZN dated on 2018-10-16: AstraZeneca, Merck Receive FDA Orphan Drug for Lynparza in Pancreatic Cancer

Financial news for AZN dated on 2018-10-15: GMB Issues Jobs Warning As AstraZeneca Halts UK Investment Over Brexit Uncertainty

Financial news for AZN dated on 2018-10-15: AstraZeneca Has Suspended Investments In UK Due To Lack Of Clarity Over Brexit

Financial news for AZN dated on 2018-10-04: Stocks Which Set New 52-Week High Yesterday, October 3rd

Financial news for AZN dated on 2018-10-04: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Financial news for AZN dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for AZN dated on 2018-10-02: The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

Financial news for AZN dated on 2018-10-01: AstraZeneca Announces Completion of Agreement with Cheplapharm for Rights to Atacand in 28 European Countries for \$200M

Financial news for AZN dated on 2018-09-25: AstraZeneca And MedImmune Announce Publication Of Data From Phase III Trial Of IMFINZI (durvalumab) Showing Reduced Risk Of Death By Nearly One-Third

Financial news for AZN dated on 2018-09-25: AstraZeneca Announces Bydureon Receives Positive EU CHMP Opinion for EXSCEL Cardiovascular Outcomes Data

Financial news for AZN dated on 2018-09-24: AstraZeneca Gets EU Marking Authorization for Imfinzi

Financial news for AZN dated on 2018-09-24: A Peek Into The Markets: US Stock Futures Edge Lower; Crude Oil Surges

Financial news for AZN dated on 2018-09-24: AstraZeneca Announces its Phase III DECLARE-TIMI 58 Trial Met its Primary Safety Endpoint, Met 1 Efficacy Endpoint and Missed 1 Efficacy Endpoint

Financial news for AZN dated on 2018-09-24: AstraZeneca Reports Farxiga Gets Positive Result in DECLARE-TIMI 58, a Large Cardiovascular Outcomes Trial in 17K Patients with Type-2 Diabetes

Financial news for AZN dated on 2018-09-22: The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

Financial news for AZN dated on 2018-09-18: AstraZeneca's FASENRA Showed 'Consistent' Safety And Sustained Efficacy In Long Term Phase III BORA Trial In Severe Eosinophilic Asthma

Financial news for AZN dated on 2018-09-16: AstraZeneca Announces The Lancet Respiratory Medicine Published First Phase III Trial for PT010 Triple Combination Therapy in Moderate to Very Severe COPD

Financial news for AZN dated on 2018-09-13: PR Confirms FDA Approves AstraZeneca's LUXOMITI In Hairy Cell Leukemia

Financial news for AZN dated on 2018-09-13: FDA Says Granted Approval Of Lumoxiti To AstraZeneca

Financial news for AZN dated on 2018-09-13: AstraZeneca to present Fasenra Long-term Safety and Efficacy data at European Respiratory Society International Congress 2018

Financial news for AZN dated on 2018-09-07: The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

Financial news for AZN dated on 2018-09-07: Amgen, AstraZeneca Announce Tezepelumab Granted Breakthrough Therapy Designation By FDA for Treatment of Patients With Severe Asthma Without an Eosinophilic Phenotype

Financial news for AZN dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for AZN dated on 2018-09-05: Biohaven Licenses Novel Myeloperoxidase Inhibitor from AstraZeneca; Financial Terms Not Disclosed

Financial news for AZN dated on 2018-08-31: AstraZeneca Reports TULIP 1 Phase III Trial for Anifrolumab in SLE Did Not Meet Primary Endpoint

Financial news for AZN dated on 2018-08-30: AstraZeneca, Voluntis Extend In Digital Therapeutics for Oncology With A New Phase Of Clinical Evaluation Of Digital Therapeutic Designed To Support Platinum Resistant Ovarian Cancer Patients

Financial news for AZN dated on 2018-08-30: AstraZeneca Announces EC Approves Bydureon BCise Device for T2 Diabetes

Financial news for AZN dated on 2018-08-27: AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval

Financial news for AZN dated on 2018-08-23: AstraZeneca Says Lynparza Becomes The First PARP Inhibitor To Win Approval In China

Financial news for AZN dated on 2018-08-23: AstraZeneca Says Data from AERISTO Phase IIIb trial for Bevespi Aerosphere in Chronic Obstructive Pulmonary Disease is Inconsistent with Previous Data

Financial news for AZN dated on 2018-08-16: Jefferies Downgrades AstraZeneca, Sees Limited Additional Upside

Financial news for AZN dated on 2018-08-16: Benzinga's Top Upgrades, Downgrades For August 16, 2018

Financial news for AZN dated on 2018-08-16: A Peek Into The Markets: US Stock Futures Surge Ahead Of Earnings

Financial news for AZN dated on 2018-08-16: Jefferies Downgrades AstraZeneca to Hold

Financial news for AZN dated on 2018-08-13: Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

Financial news for AZN dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for AZN dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for AZN dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for AZN dated on 2018-08-09: Stocks Trading Ex Dividend For Thurs., Aug. 9, 2018

Financial news for AZN dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for AZN dated on 2018-08-08: Stocks Which Will Trade Ex Dividend On Thurs., Aug. 9, 2018

Financial news for AZN dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for AZN dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for AZN dated on 2018-08-06: Earlier Ironwood Pharma Announced Termination of Its Licensing Agreement With AstraZeneca for U.S. Lesinurad Franchise

Financial news for AZN dated on 2018-08-03: Merck Reports Co., AstraZeneca's Selumetinib Granted Orphan Designation In Europe For Nerve Fibromatosis Type 1

Financial news for AZN dated on 2018-08-01: Stocks Which Set New 52-Week High Yesterday, July 31

Financial news for AZN dated on 2018-08-01: Price Action In Several Major Healthcare Names Mixed, Stocks Appear Largely Unaffected Following Late-Tues. NY Times Article 'Justice Dept. Investigating Claims That Drug Companies Funded Terrorism in Iraq'

Financial news for AZN dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for AZN dated on 2018-07-27: Stocks Which Set New 52-Week High Yesterday, July 26th:

Financial news for AZN dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for AZN dated on 2018-07-26: Earnings Scheduled For July 26, 2018

Financial news for AZN dated on 2018-07-25: A Preview Of AstraZeneca's Q2 Earnings

Financial news for AZN dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for AZN dated on 2018-07-25: Dr. Reddy's Labs Confirms AstraZeneca Filed Suit Against Co. Related To Infringement Of 3 Patents On Generic Version Of Brilinta

Financial news for AZN dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for AZN dated on 2018-07-24: AstraZeneca Agrees to Sell Commercial Rights to Atacand to Cheplapharm in Europe for \$200M, \$10M in Milestones

Financial news for AZN dated on 2018-07-23: Immunomedics Reports Clinical Partnership With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers

Financial news for AZN dated on 2018-07-23: Immunomedics to Collaborate with AstraZeneca to Evaluate the Combination of Imfinzi and Sacituzumab Govitecan

Financial news for AZN dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for AZN dated on 2018-07-12: AstraZeneca Option Alert: Aug 17 \$37.5 Calls Sweep (33) near the Ask: 3000 @ \$0.551 vs 1274 OI; Earnings 7/26 Before Open Ref=\$36.35

Financial news for AZN dated on 2018-07-12: Health Canada Has Approved AstraZeneca's Tagrisso As First-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer

Financial news for AZN dated on 2018-07-10: Revon Systems Digital Therapeutics Enters Partnership With AstraZeneca In Respiratory Medicine

Financial news for AZN dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for AZN dated on 2018-07-02: AstraZeneca, Merck Announce LYNPARZA Approved in Japan for BRCA-Mutated Metastatic Breast Cancer

Financial news for AZN dated on 2018-06-27: AstraZeneca Reports LYNPARZA Phase III Trial First-Line SOLO-1 Trial For Ovarian Cancer Met Primary Endpoint

Financial news for AZN dated on 2018-06-27: AstraZeneca, Merck Announce LYNPARZA S Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials

Financial news for AZN dated on 2018-06-25: AstraZeneca Says FARXIGA in Combination with ONGLYZA Has Similar Glycemic Control with Additional Benefits as Insulin for Type 2 Diabetes Patients

Financial news for AZN dated on 2018-06-24: Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control

Financial news for AZN dated on 2018-06-19: AstraZeneca Will Report Latest Data From Cardiovascular, Renal, Metabolism Therapy Area At American Diabetes Association Sessions Jun. 22-26

Financial news for AZN dated on 2018-06-15: AstraZeneca Option Alert: Jul 20 \$37.5 Calls Sweep (3) near the Ask: 2444 @ \$0.367 vs 4868 OI; Earnings 7/26 Before Open [est] Ref=\$36.33

Financial news for AZN dated on 2018-06-12: Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat

Financial news for AZN dated on 2018-06-08: EU Has Approved AstraZeneca's Tagrisso For First-Line Treatment Of EGFR-Mutated Non-Small Cell Lung Cancer

Financial news for AZN dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for AZN dated on 2018-06-04: Merck and Astrazeneca Pres Release Announces LYNPARZA In Combo With Abiraterone Delayed Metastatic Prostate Cancer Disease Progression

Financial news for AZN dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for AZN dated on 2018-05-25: UPDATE: AstraZeneca, MedImmune Report IMFINZI Phase III Trial Met Second Primary Endpoint Of Overall Survival

Financial news for AZN dated on 2018-05-25: AstraZeneca, MedImmune Report IMFINZI Significantly Improved Overall Survival In Phase III Pacific Trial For Unresectable Stage III N-Small Cell Lung Cancer

Financial news for AZN dated on 2018-05-23: Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Financial news for AZN dated on 2018-05-22: Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

Financial news for AZN dated on 2018-05-18: Hearing AstraZeneca NDA for Lokelma Gets FDA Approvla

Financial news for AZN dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for AZN dated on 2018-05-18: 7 Stocks To Watch For May 18, 2018

Financial news for AZN dated on 2018-05-18: AstraZeneca Q1 Core EPS \$0.48 vs \$0.60 Est; Revenue \$5.178B vs \$5.283B Est

Financial news for AZN dated on 2018-05-18: Earnings Scheduled For May 18, 2018

Financial news for AZN dated on 2018-05-15: AstraZeneca's Asthma Drug Fasenra Fails In COPD Study

Financial news for AZN dated on 2018-05-14: The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season

Financial news for AZN dated on 2018-05-13: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for AZN dated on 2018-05-08: AstraZeneca and Merck Announce LYNPARZA Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer

Financial news for AZN dated on 2018-05-07: Bactiguard's Licensing Partner Smartwise Enters Collaboration with AstraZeneca

Financial news for AZN dated on 2018-05-01: AstraZeneca Shares Make Near-Term Parabolic Move, Spike To High Over \$36; Traders Circulating Takeover Chatter

Financial news for AZN dated on 2018-04-27: AstraZeneca Reports Tagrisso Received Positive CHMP Opinion For First-Line Treatment Of EGFR-Mutated NSCLC

Financial news for AZN dated on 2018-04-24: AstraZeneca to Raise Stake in Circassia to up to 19.9%

Financial news for AZN dated on 2018-04-20: AstraZeneca Shares Are Looking Very Weak Right Now

Financial news for AZN dated on 2018-04-18: AstraZeneca Says Approves Tagrisso as 1st-line Treatment for EGFR-mutated Non-small Cell Lung Cancer

Financial news for AZN dated on 2018-04-16: UPDATE: AstraZeneca at AACR: Phase Ib Study Showed Clinical Activity In PD-L1 Greater Than Or Equal To 25%, Greater Than 25% Groups In Second Line NSCLC

Financial news for AZN dated on 2018-04-16: AstraZeneca Presents Imfinzi Plus tremelimumab Combination Data at AACR Annual Meeting

Financial news for AZN dated on 2018-04-16: Merck Sunday Announced Updated Overall Survival Data for LYNPARZA(r) (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at #AACR18

Financial news for AZN dated on 2018-04-13: BMO's Bearish Stance On Eli Lilly Comes To An End

Financial news for AZN dated on 2018-04-09: Ionis Licenses IONIS-AZ6-2.5-LRx to AstraZeneca for \$30M

Financial news for AZN dated on 2018-04-03: Astrazeneca Reports The FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control

Financial news for AZN dated on 2018-04-03: AstraZeneca And MedImmune Report US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

Financial news for AZN dated on 2018-04-03: AstraZeneca, Merck Announces EMA Accepts Regulatory Submission for LYNPARZA in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

Financial news for AZN dated on 2018-03-22: AstraZeneca Reports Lokelma Approved For Treatment Of Adults With Hyperkalaemia In EU

Financial news for AZN dated on 2018-03-19: AstraZeneca Announced Results Of DERIVE, Says Study Met Its Primary And Secondary Efficacy Endpoints

Financial news for AZN dated on 2018-03-19: Benzinga's Top Upgrades, Downgrades For March 19, 2018

Financial news for AZN dated on 2018-03-19: Jefferies Upgrades Astrazeneca PLC Common Stock to Buy

Financial news for AZN dated on 2018-03-07: Height Casts 65% Odds That Congress Rolls

Back Pharma Discounts

Financial news for AZN dated on 2018-03-07: AstraZeneca's Forxiga Label Expansion Filing Accepted In EU

Financial news for AZN dated on 2018-02-23: Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More

Financial news for AZN dated on 2018-02-23: Merck, AstraZeneca Reports LYNPARZA Received Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

Financial news for AZN dated on 2018-02-21: AstraZeneca Reports Renewed Recommendation, Availability Of FLUMIST QUADRIVALENT Vaccine In US

Financial news for AZN dated on 2018-02-20: Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca, Earns \$30M License Fee And May Receive Up To \$300M In Additional Milestone Payments

Financial news for AZN dated on 2018-02-17: FDA Approves Imfinz for Unresectable Stage III Non-Small Cell Lung Cancer

Financial news for AZN dated on 2018-02-15: Merck Reports Co., AstraZeneca Won Orphan Drug Designation By FDA For Selumetinib For Treatment Of NF1

Financial news for AZN dated on 2018-02-15: AstraZeneca Says Selumetinib Granted Orphan Drug Designation by FDA for Neurofibromatosis Type 1

Financial news for AZN dated on 2018-02-13: AHNS, ASTRO, ASCO Issue Press Release Highlighting Phase II Trial Of AstraZeneca's Durvalumab Showed Activity In Patients With Recurrent, Metastatic Head And Neck Cancer

Financial news for AZN dated on 2018-02-12: CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise

Financial news for AZN dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for AZN dated on 2018-02-02: Earnings Scheduled For February 2, 2018

Financial news for AZN dated on 2018-02-01: Syndax Pharma Reports Immuno-Oncology Trial Collab With AstraZeneca

Financial news for AZN dated on 2018-01-19: Here's Why Nektar Stock Skyrocketed Almost 500% In A Year

Financial news for AZN dated on 2018-01-17: Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says

Financial news for AZN dated on 2018-01-16: Watching Shares Of AstraZeneca and Merck As White House Doctor Says Pres. Trump Takes Crestor For Cholesterol and Propecia For Hair Loss

Financial news for AZN dated on 2018-01-12: FDA Approves AstraZeneca and Merck's Lynparza, For Breast Cancer With A Certain Inherited Genetic Mutation

Financial news for AZN dated on 2018-01-10: AstraZeneca Reports Fasenra Approved In EU

Financial news for AZN dated on 2018-01-08: Horizon Pharma Earlier Announced Licensing Global Rights To MEDI4945 From AstraZeneca, Will Provide Upfront Cash Payment And Future Milestone Payments

Financial news for AZN dated on 2018-01-03: Myriad Genetics Announces AstraZeneca to Use the Company's myChoice HRD Plus in an Exploratory Cancer Analysis

Financial news for AZN dated on 2018-01-02: AstraZeneca Option Alert: Jan 19 \$36 Calls Sweep (24) at the Ask: 1750 @ \$0.3 vs 8 OI; Ref=\$35.18

Financial news for AZN dated on 2017-12-29: The Market In 5 Minutes: Apple Issues Apology, Softbank & Uber, The Year In Cryptos

Financial news for AZN dated on 2017-12-29: UPDATE: ANI Pharma Says 4 Products Purchased From AstraZeneca Generated ~\$19M In US Market Sales During Trailing 12 Mos. Through Oct.

Financial news for AZN dated on 2017-12-29: UPDATE: ANI Pharma Will Buy NDAs, US Rights To Market ATACAND, ATACAND HCT, ARIMIDEX, CASODEX

Financial news for AZN dated on 2017-12-29: ANI Pharma Reports Purchase Of 4 NDAs

From AstraZeneca For \$46.5M

Financial news for AZN dated on 2017-12-29: Benzinga's Top Upgrades, Downgrades For December 29, 2017

Financial news for AZN dated on 2017-12-29: A Peek Into The Markets: U.S. Stock Futures Surge On Last Trading Day Of 2017

Financial news for AZN dated on 2017-12-29: JP Morgan Upgrades AstraZeneca to Overweight

Financial news for AZN dated on 2017-12-21: AstraZeneca Announces FDA Updates SYMBICORT Label With LABA Safety Revisions, Removes Boxed Warning For Serious Asthma-Related Outcomes

Financial news for AZN dated on 2017-12-20: UPDATE: Pieris Says First Dosing Triggers \$12.5M Milestone Payment From AstraZeneca

Financial news for AZN dated on 2017-12-19: Chembio Diagnostics, AstraZeneca Report Collaboration To Develop Point-Of-Care Diagnostic Test; Chembio Will Receive Up To \$2.9M In Funding

Financial news for AZN dated on 2017-12-18: FDA Accepts AstraZeneca's Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

Financial news for AZN dated on 2017-12-18: AstraZeneca Announces FDA Accepts Regulatory Submission for TAGRISSO in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer And Granted Priority Review

Financial news for AZN dated on 2017-12-09: AstraZeneca Announces CALQUENCE Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial at #ASH2017

Financial news for AZN dated on 2017-12-08: Pfizer Reports Updated Data From Phase III Study On Ibrance

Financial news for AZN dated on 2017-12-04: AstraZeneca Reports Tudorza Reduces Exacerbations; Demonstrates Cardiovascular Safety in COPD Patients

Financial news for AZN dated on 2017-12-01: FDA Decisions In November: The Month In Review

Financial news for AZN dated on 2017-11-28: G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer

Financial news for AZN dated on 2017-11-15: AstraZeneca Tues. Afternoon Reported FDA Approval Of FASENRA For Severe Eosinophilic Asthma

Financial news for AZN dated on 2017-11-15: AstraZeneca Reports FASLODEX Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

Financial news for AZN dated on 2017-11-15: AstraZeneca Announces Faslodex Receives FDA Approval for Treatment of Advanced Breast Cancer in Combination with Abemaciclib

Financial news for AZN dated on 2017-11-09: Adam Feuerstein Tweets: \$TSRO comments (negatively) on \$AZN Lynparza Q3 sales. Interesting. Don't see this often, so publicly. Per Leerink note.

Financial news for AZN dated on 2017-11-09: Earnings Scheduled For November 9, 2017

Financial news for AZN dated on 2017-11-06: AstraZeneca Option Alert: Nov 17 \$33.5 Puts Sweep (30) at the Ask: 2244 @ \$0.45 vs 1704 OI; Ref=\$34.22

Financial news for AZN dated on 2017-11-06: Pharma Stock Roundup: Pfizer, Teva, Novartis, And More

Financial news for AZN dated on 2017-11-01: Here's What Was Intriguing About Incyte's Q3 Report

Financial news for AZN dated on 2017-11-01: AstraZeneca Completes Commercialization Agreement with Aspen

Financial news for AZN dated on 2017-11-01: AstraZeneca Says Tralokinumab Phase III Programme in Severe, Uncontrolled Asthma did Not Achieve Primary Endpoint

Financial news for AZN dated on 2017-10-31: Incyte, AstraZeneca Announce Clinical Trial Collaboration in Early Lung Cancer

Financial news for AZN dated on 2017-10-23: US FDA Approves AstraZeneca's Once-Weekly BYDUREON BCise Injectable Medicine for Patients with Type-2 Diabetes

Financial news for AZN dated on 2017-10-23: AstraZeneca, Merck Rapidly Advance LYNPARZA in Japan With a NDA To Japan's Pharmaceuticals and Medical Devices Agency

Financial news for AZN dated on 2017-10-18: AstraZeneca Reports New Data Showing Us Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change

Financial news for AZN dated on 2017-10-18: Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

Financial news for AZN dated on 2017-10-18: AstraZeneca Issues Release Highlighting FDA Acceptance Of Regulatory Submission For LYNPARZA, Has Granted Priority Review

Financial news for AZN dated on 2017-10-17: AstraZeneca's Supplemental Biologics License Application for IMFINZI in Locally Advanced, Unresectable Non-Small Cell Lung Cancer is Accepted by the FDA

Financial news for AZN dated on 2017-10-10: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for AZN dated on 2017-10-09: Benzinga's Option Alert Recap From October 9

Financial news for AZN dated on 2017-10-09: AstraZeneca Option Alert: Apr 20 \$35 Calls at the Ask: 5000 @ \$1.801 vs 671 OI; Ref=\$34.465

Financial news for AZN dated on 2017-09-25: Hearing BNP Paribas Upgraded AstraZeneca From Neutral To Outperform

Financial news for AZN dated on 2017-09-22: 15 Biggest Mid-Day Gainers For Friday

Financial news for AZN dated on 2017-09-22: Benzinga's Top Upgrades, Downgrades For September 22, 2017

Financial news for AZN dated on 2017-09-22: 4 Reasons To Buy, 2 Controversies Surrounding AstraZeneca

Financial news for AZN dated on 2017-09-22: The Market In 5 Minutes

Financial news for AZN dated on 2017-09-22: Bernstein Upgrades Astrazeneca PLC Common Stock to Outperform

Financial news for AZN dated on 2017-09-14: Astrazeneca Reports BYDUREON EXSCEL Trial Demonstrates Favorable Safety Profile, Fewer CV Patients With ?Type-2 Diabetes At Wide Range Of CV Risk

Financial news for AZN dated on 2017-09-14: The Market In 5 Minutes

Financial news for AZN dated on 2017-09-14: Liberum Downgrades Astrazeneca PLC Common Stock to Hold

Financial news for AZN dated on 2017-09-14: Aspen to Acquire Residual Rights to Anesthetic Medicines from AstraZeneca

Financial news for AZN dated on 2017-09-13: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AZN dated on 2017-09-08: ACADIA Pharma Shares Indicated Up 0.5% Premarket As Traders Circulate Article From UK Paper, 'Market report: AstraZeneca in spotlight as traders revive chatter over bid for US firm Acadia'

Financial news for AZN dated on 2017-09-08: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for AZN dated on 2017-09-07: Benzinga's Option Alert Recap From September 7

Financial news for AZN dated on 2017-09-07: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AZN dated on 2017-09-07: AZN Option Alert: Sep 15 \$31.5 Calls at the Bid: 1276 @ \$0.451 vs 30 OI; Ref=\$31.29

Financial news for AZN dated on 2017-09-07: Benzinga's Top Upgrades, Downgrades For September 7, 2017

Financial news for AZN dated on 2017-09-07: BMO Capital Initiates Coverage On AstraZeneca PLC Common Stock with Outperform Rating, Announces \$38.00 Price Target

Financial news for AZN dated on 2017-09-07: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Fed Speakers

Financial news for AZN dated on 2017-09-07: AstraZeneca Phase III AMPLIFY trial for Duaklir Met Primary Endpoint

Financial news for AZN dated on 2017-09-06: Amgen and AstraZeneca's Press Release Announces PATHWAY Trial Of Tezepelumab Achieved Its Primary Efficacy Endpoint, Results Published Today In New England Journal of Medicine

Financial news for AZN dated on 2017-09-01: Wall Street's M&A Chatter From August 31: Barnes & Noble, Constellium, Daiichi Sankyo

Financial news for AZN dated on 2017-09-01: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for AZN dated on 2017-08-31: Benzinga's Option Alert Recap From August 31

Financial news for AZN dated on 2017-08-31: Daiichi Sankyo Denies Nikkei Business Report That Co. Received An Acquisition Offer From AstraZeneca

Financial news for AZN dated on 2017-08-31: AstraZeneca Option Alert: Sep 15 \$29.5 Calls Sweep (22) at the Ask: 3500 @ \$0.6 vs 1081 OI; Ref=\$29.75

Financial news for AZN dated on 2017-08-31: Japan's Daiichi Sankyo Rejected Takeover Bid from AstraZeneca Last Year -Nikkei Business

Financial news for AZN dated on 2017-08-29: AstraZeneca,Takeda to Collaborate to Develop and Commercialize MEDI1341 for Parkinson's Disease; Takeda to Pay AstraZeneca Up to \$400M

Financial news for AZN dated on 2017-08-28: AstraZeneca's FASLODEX Gets FDA Approvals Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer

Financial news for AZN dated on 2017-08-24: AstraZeneca Announces Extended Treatment With Brilinta Reduces Risk Of Cardiovascular Death By 29% In Patients With History Of Heart Attack

Financial news for AZN dated on 2017-08-21: Ethris Announces Five-Year Strategic Collaboration with AstraZeneca, MedImmune to Develop mRNA Therapies for Respiratory Diseases

Financial news for AZN dated on 2017-08-17: AstraZeneca Reports Additional FDA Acceptance For LYNPARZA

Financial news for AZN dated on 2017-08-17: AstraZeneca, Merck Issue Release Confirming Added, Broad Approval Of LYNPARZA In US For Ovarian Cancer

Financial news for AZN dated on 2017-08-17: AstraZeneca Shares Unaffected As Lynparza Receives Added, Broad US Approval For Ovarian Cancer Treatment

Financial news for AZN dated on 2017-08-16: Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

Financial news for AZN dated on 2017-08-09: Investec Upgrades AstraZeneca to Buy from Hold; Lowers PT to 4900P from 5000P

Financial news for AZN dated on 2017-08-08: A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Financial news for AZN dated on 2017-08-01: AstraZeneca Reports FDA Granted Breakthrough Therapy Designation For Acalabrutinib

Financial news for AZN dated on 2017-07-31: AstraZeneca Reports durvalumab Granted Breakthrough Therapy Designation by US FDA

Financial news for AZN dated on 2017-07-28: Morgan Stanley Downgrades AstraZeneca PLC Common Stock to Equal-Weight

Financial news for AZN dated on 2017-07-27: 20 Biggest Mid-Day Losers For Thursday

Financial news for AZN dated on 2017-07-27: Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge

Financial news for AZN dated on 2017-07-27: Leerink Swann Downgrades AstraZeneca PLC

Common Stock to Market Perform

Financial news for AZN dated on 2017-07-27: Mid-Morning Market Update: Markets Open Higher; Facebook Beats Q2 Estimates

Financial news for AZN dated on 2017-07-27: AstraZeneca Shares Down 15% Pre-Market After Announcing Imfinzi Plus Tremelimumab Combination Did Not Meet Primary Endpoint, Despite News Of Strategic Oncology Collab Deal With Merck

Financial news for AZN dated on 2017-07-27: Why Is AstraZeneca Sinking Today?

Financial news for AZN dated on 2017-07-27: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for AZN dated on 2017-07-27: Earnings Scheduled For July 27, 2017

Financial news for AZN dated on 2017-07-27: Astrazeneca Says Imfinzi Plus Tremelimumab Combination Did Not Meet Primary Endpoint of Progression-Free Survival Compared to Chemotherapy; Mystic Trial Continues as Planned to Assess Additional Primary Endpoints of Overall Survival

Financial news for AZN dated on 2017-07-27: AstraZeneca CEO Declines Comment on Reports He is Leaving to Join Teva -Reuters

Financial news for AZN dated on 2017-07-27: AstraZeneca, Merck Announce Strategic Oncology Collaboration; Merck to pay AstraZeneca up to \$8.5B in Total Consideration

Financial news for AZN dated on 2017-07-26: AstraZeneca Faslodex Gets EU Approval For 1L Breast Cancer

Financial news for AZN dated on 2017-07-18: AstraZeneca CEO Rumor Reportedly Ends, Shares Rise

Financial news for AZN dated on 2017-07-17: Fast Money Traders Share Their Picks That Could Make A Strong Move Higher

Financial news for AZN dated on 2017-07-16: Fast Money Traders Share Their Picks For The Week

Financial news for AZN dated on 2017-07-14: AstraZeneca Spokeswoman Declines Comment On Future Of CEO Following Report By Bloomberg Saying He's Not Leaving Company

Financial news for AZN dated on 2017-07-14: AstraZeneca Shares Up ~\$0.30 Over Last 15 Mins Following Report CEO Will Be Staying At Co.

Financial news for AZN dated on 2017-07-14: The Market In 5 Minutes

Financial news for AZN dated on 2017-07-14: AstraZeneca Declines Comment on Report CEO is Leaving Co -Reuters

Financial news for AZN dated on 2017-07-13: Analyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva

Financial news for AZN dated on 2017-07-13: AstraZeneca Shares Down 8% From High Following Word That CEO Will Resign After The Close

Financial news for AZN dated on 2017-07-13: Hearing AstraZeneca CEO Said To Announce He Is Leaving Company After Market Close

Financial news for AZN dated on 2017-07-13: Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher

Financial news for AZN dated on 2017-07-13: Teva Spokesperson Declines Comment Following Calcalist Report Co. Could Hire AstraZeneca CEO Soriot

Financial news for AZN dated on 2017-07-13: Teva Shares Up 2.2% Following News Of The Company Could Hire AstraZeneca CEO Soriot

Financial news for AZN dated on 2017-07-12: Hearing Teva Will Hearing AstraZeneca CEO Soriot

Financial news for AZN dated on 2017-06-29: Chi-Med, AstraZeneca Initiate SAVOIR Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Financial news for AZN dated on 2017-06-28: Watch These 7 Huge Put Purchases In Wednesday Trade

Financial news for AZN dated on 2017-06-27: Benzinga's Option Alert Recap From June 27

Financial news for AZN dated on 2017-06-27: Option Alert: AstraZeneca Jul 32.5 Puts Sweep: 998 @ ASK \$0.80: 1673 traded vs 14k OI: Earnings 7/27 Before Open \$34.64 Ref

Financial news for AZN dated on 2017-06-23: How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'

Financial news for AZN dated on 2017-06-23: AstraZeneca Faslodex CHMP Positive Opinion In 1L Breast Cancer

Financial news for AZN dated on 2017-06-22: Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Financial news for AZN dated on 2017-06-12: AstraZeneca Presents New Data on Safety of Farxiga

Financial news for AZN dated on 2017-06-07: AstraZeneca Entered Agreement with Grunenthal for Global Rights to Zomig Outside Japan; AstraZeneca to Receive \$200M Upon Completion, Up to \$102M in Milestones

Financial news for AZN dated on 2017-06-06: AstraZeneca Reports Data from Trial of Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases: extended the length of time patients with CNS metastases live without disease worsening or death to 11.7 months...

Financial news for AZN dated on 2017-06-04: AstraZeneca Announces LYNPARZA Significantly Reduces the Risk of Disease Worsening or Death in Patients with BRCA-Mutated Metastatic Breast Cancer #ASCO17

Financial news for AZN dated on 2017-06-02: Orexo Receives \$2.5M Milestone Payment from Astrazeneca; OX-CLI Advances into Clinical Trials

Financial news for AZN dated on 2017-05-31: Adam Feuerstein Tweets '\$TSRO "for sale" news good reminder: Plenty 'o PARP data coming. \$AZN Olympiad breast at #ASCO17 (plenary) \$CLVS ARIEL-3 end of June'

Financial news for AZN dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for AZN dated on 2017-05-26: AstraZeneca Reports New Data Related to Expanded Portfolio of Cancer Medicines at ASCO: Highlights Key Trials of Tagrisso Have Shown Effects in Patients with EGFR

Financial news for AZN dated on 2017-05-25: AstraZeneca Initiates Voluntary Nationwide Recall Of One Lot Of BRILINTA 90mg Due To Report Of Another Medicine In One Bottle From That Lot

Financial news for AZN dated on 2017-05-23: AstraZeneca Reports Bydureon EXSCEL Trial Met Primary Endpoint Objective in Type-2 Diabetes Patients with Cardiovascular Risk

Financial news for AZN dated on 2017-05-22: AstraZeneca Announces Phase III ZONDA Trial Achieved Its Primary Endpoint With Statistical Significance

Financial news for AZN dated on 2017-05-22: AstraZeneca Enters Agreement with Recordati for Seloken Commercial Rights in Europe; AstraZeneca to Receive \$300M

Financial news for AZN dated on 2017-05-16: Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns

Financial news for AZN dated on 2017-05-15: Credit Suisse Upgrades Astrazeneca PLC Common Stock to Neutral

Financial news for AZN dated on 2017-05-12: 15 Biggest Mid-Day Gainers For Friday

Financial news for AZN dated on 2017-05-12: AstraZeneca Sharply Higher Off Positive Data For Imfinzi

Financial news for AZN dated on 2017-05-12: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2017-05-12: AstraZeneca +5.73% Premarket @\$32.82, Co Announced Imfinzi Met Primary Endpoint NSCLC

Financial news for AZN dated on 2017-05-06: Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers

Financial news for AZN dated on 2017-05-03: Pieris Pharmaceuticals +58% Premarket @\$3.79; Co, AstraZeneca Collaborate to Develop, Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

Financial news for AZN dated on 2017-05-03: Pieris Pharmaceuticals, AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

Financial news for AZN dated on 2017-05-01: AstraZeneca's IMFINZI Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer

Financial news for AZN dated on 2017-05-01: AstraZeneca Shares at Session Highs, Up 0.7%; Traders Circulating Report FDA Has Approved IMFINZI for Locally-Advanced, Metastatic Urothelial Carcinoma

Financial news for AZN dated on 2017-04-27: Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space

Financial news for AZN dated on 2017-04-27: Astrazeneca Shareholders Vote To Approve Directors' Remuneration Policy

Financial news for AZN dated on 2017-04-27: Companies Holding Shareholder Meetings Today Include: Akorn, AstraZeneca, HCA Holdings, Johnson & Johnson, & Lockheed Martin

Financial news for AZN dated on 2017-04-19: AstraZeneca Shares Volatile Over Last Few Mins as Traders Circulating FDA Confidential Form 483 Doc with Date of Inspection Jan. 18-30

Financial news for AZN dated on 2017-04-10: Cardiovascular Players Could Be Eyeing Esperion

Financial news for AZN dated on 2017-04-06: Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger

Financial news for AZN dated on 2017-03-31: FibroGen Reports China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat

Financial news for AZN dated on 2017-03-31: AstraZeneca Announces FDA Grants Full Approval For TAGRISSO

Financial news for AZN dated on 2017-03-29: AstraZeneca's Inebilizumab for Neuromyelitis Optica Spectrum Disorder Receives Orphan Designation from EMA

Financial news for AZN dated on 2017-03-28: Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April

Financial news for AZN dated on 2017-03-28: AstraZeneca Data Shows RSV Immunoprophylaxis With palivizumab Could Result In Reduced Overall Costs In Infants Born At 29-32 wGA

Financial news for AZN dated on 2017-03-28: How The Market For Tesaro's Niraparib Plays Out Following Early FDA Approval

Financial news for AZN dated on 2017-03-24: 'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market

Financial news for AZN dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for AZN dated on 2017-03-19: AstraZeneca Announces CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death vs Other Type-2 Diabetes Medicines

Financial news for AZN dated on 2017-03-17: Astrazeneca Receives CRL from FDA for ZS-9 for Hyperkalaemia

Financial news for AZN dated on 2017-03-17: AstraZeneca, Circassia Enter Strategic Collaboration in Respiratory Disease; AstraZeneca to Receive \$50M in Ordinary Shares of Circassia, Milestone Payments Up to \$180M

Financial news for AZN dated on 2017-03-15: Lynparza Vs. Niraparib

Financial news for AZN dated on 2017-03-15: Clovis Shares Reiterated As A Sell Following 10% Rally

Financial news for AZN dated on 2017-03-15: Watch These 8 Huge Call Purchases In Wednesday Trade

Financial news for AZN dated on 2017-03-14: Benzinga's Option Alert Recap From March 14

Financial news for AZN dated on 2017-03-14: Option Alert: AstraZeneca Mar 30.0 Calls:

1400 @ ASK \$0.60: 4610 traded vs 8208 OI: Earnings 4/28 Before Open (est) \$30.34
Ref

Financial news for AZN dated on 2017-03-14: AstraZeneca's Lynparza Ovarian Cancer Drug shows Investigator-Assessed Progression-Free Survival Of 19.1 Months, 30.2M Months PFS Based On Independent Central Review

Financial news for AZN dated on 2017-03-14: Adam Feuerstein Tweets: \$AZN Takes PARP Inhibitor Fight to Rival \$TSRO with Strong Ovarian Cancer Study Results --> thestreet.com/story/14043007... \$CLVS, too.

Financial news for AZN dated on 2017-03-14: Adam Feuerstein Tweet \$AZN Lynparza SOLO-2 ovarian cancer maintenance therapy data in 10 minutes. Watch \$TSRO \$CLVS for reaction, as well. Battle of the PARPs.

Financial news for AZN dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for AZN dated on 2017-03-03: Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market

Financial news for AZN dated on 2017-03-03: Sanofi Pasteur, MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV; Sanofi Pasteur to Make Upfront Payment of EUR120M, Pay up to EUR495M upon Achievement of Certain Milestones

Financial news for AZN dated on 2017-03-02: Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable

Financial news for AZN dated on 2017-02-28: AstraZeneca Announces FDA Approves Once-Daily QTERN Tablets for Adults with Type-2 Diabetes

Financial news for AZN dated on 2017-02-24: Carl Icahn's Track Record In Big Pharma

Financial news for AZN dated on 2017-02-24: Eu Medicines Agency Recommends Approval Of AstraZeneca's ZS-9 For High Potassium Levels

Financial news for AZN dated on 2017-02-22: Analyst: Buy AstraZeneca On The Turnaround Story

Financial news for AZN dated on 2017-02-17: AstraZeneca Reports LYNPARZA Met Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer

Financial news for AZN dated on 2017-02-17: AstraZeneca Reports Lynparza Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer

Financial news for AZN dated on 2017-02-16: After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?

Financial news for AZN dated on 2017-02-16: Hearing AstraZeneca Holder Woodford Added to Holding on Recent Share Price Weakness

Financial news for AZN dated on 2017-02-15: Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade

Financial news for AZN dated on 2017-02-14: Chi-Med, AstraZeneca to Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Financial news for AZN dated on 2017-02-06: FDA Watch: February's Notable PDUFA Dates

Financial news for AZN dated on 2017-02-06: The Market In 5 Minutes: One For The Thumb

Financial news for AZN dated on 2017-02-06: Wall Street's M&A Chatter From February 3-6

Financial news for AZN dated on 2017-02-03: ACADIA Spokesperson Tells Benzinga The Company Does Not Comment On Rumors In The Marketplace

Financial news for AZN dated on 2017-02-02: Earnings Scheduled For February 2, 2017

Financial news for AZN dated on 2017-02-01: Q4 2016 Real-Time Call Brief

Financial news for AZN dated on 2017-01-26: How Pharmacy Benefit Managers Add To The Cost Of Your Prescription

Financial news for AZN dated on 2017-01-25: Which Pharma Players Dominate The Lung Cancer Space?

Financial news for AZN dated on 2017-01-12: The Best BioPharma Plays Amid Uncertainty From Trump Comments

Financial news for AZN dated on 2017-01-11: Here's What Merck's Keytruda News Means For Bristol-Myers

Financial news for AZN dated on 2016-12-30: Watch These 5 Huge Call Purchases In Friday Trade

Financial news for AZN dated on 2016-12-29: Option Alert: AZN Jul17 30.0 Calls: 550 @ ASK \$1.65: 10k traded vs 34k OI: Earnings 2/2 Before Open \$27.47 Ref

Financial news for AZN dated on 2016-12-23: 6 Worst Biotech Stocks Of 2016

Financial news for AZN dated on 2016-12-21: Breaking Down The Crowded Novel Ovarian Cancer Treatment Space

Financial news for AZN dated on 2016-12-19: UPDATE: Ionis Says Earns \$25M Milestone Payment, Eligible to Receive Up to \$300M in Added Development, Regulatory Milestones

Financial news for AZN dated on 2016-12-19: Ionis, AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease

Financial news for AZN dated on 2016-12-19: Adam Feuerstein Tweets '\$CLVS Rubraca approval has little bearing on \$TSRO given different ovarian cancer pat pops. Rubraca more competes w/ \$AZN Lynparza.'

Financial news for AZN dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for AZN dated on 2016-12-19: Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell

Financial news for AZN dated on 2016-12-16: Ionis Earns \$28 Million from AstraZeneca for a New Drug to Treat Cancer, AstraZeneca Exercises Option To License IONIS-KRAS-2.5 Rx

Financial news for AZN dated on 2016-12-15: AstraZeneca's Movantik to be Marketed in Canada and Israel by Knight Therapeutics

Financial news for AZN dated on 2016-12-14: Cramer Gives His Opinion On Reynolds American, AstraZeneca And Sony

Financial news for AZN dated on 2016-12-12: Alexion Management Changes Overshadow Potentially Positive Audit Results

Financial news for AZN dated on 2016-12-09: AstraZeneca Higher Off Drug News And Upgrade

Financial news for AZN dated on 2016-12-09: Option Alert: AZN Jan 2018 \$30 Put; 4000 @Bid @\$5.80; Ref=\$27.20

Financial news for AZN dated on 2016-12-09: AstraZeneca Shares Resume Trade, Now Up 4%

Financial news for AZN dated on 2016-12-09: AstraZeneca Shares Indicated in \$27-\$29 Range; Stock Was Halted at \$27.11

Financial news for AZN dated on 2016-12-09: AstraZeneca Shares Trading in London Pull Back from Intraday Highs But Still Up ~5.5% for Session Following News FDA Has Accepted Co.s Durvalumab for BLA, Priority Review

Financial news for AZN dated on 2016-12-09: UPDATE: FDA Has Granted AstraZeneca's Durvalumab for Priority Review Status, Sees PDUFA Date in Q2'17

Financial news for AZN dated on 2016-12-09: AstraZeneca FDA Accepts Durvalumabe For BLA In Bladder Cancer

Financial news for AZN dated on 2016-12-09: AstraZeneca Shares Trading in London Up ~3.3% Since Shares Trading on NYSE Were Halted; Up 5.5% for Session

Financial news for AZN dated on 2016-12-09: Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt

Financial news for AZN dated on 2016-12-09: AstraZeneca Halted News Pending

Financial news for AZN dated on 2016-12-09: Benzinga's Top Upgrades

Financial news for AZN dated on 2016-12-09: AstraZeneca Says Tagrisso Reduced Risk Of Disease Progression By 70%, From AURA3 Phase III Trial On Tagrisso

Financial news for AZN dated on 2016-12-09: Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease

Financial news for AZN dated on 2016-12-09: Leerink Swann Upgrades Astrazeneca PLC Common Stock to Outperform

Financial news for AZN dated on 2016-12-08: UPDATE: AstraZeneca FALCON Trial Met Primary Endpoint, Revealed Median PFS of 16.6 Months vs. ARIMIDEX Arm PFS Of 13.8 Months

Financial news for AZN dated on 2016-12-08: AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX To ARIMIDEX

Financial news for AZN dated on 2016-12-06: AstraZeneca Presents AURA3 Trial Data Which Shows Statistically Significant Improvement In PFS vs. Doublet Chemotherapy

Financial news for AZN dated on 2016-11-25: AstraZeneca +3.3% Premarket @\$27.24; Liberium Upgraded Friday from Hold to Buy

Financial news for AZN dated on 2016-11-23: Stocks Hitting 52-Week Lows

Financial news for AZN dated on 2016-11-22: AstraZeneca Announces FDA Lifted Partial Clinical Hold on Enrollment of New Patients with HNSCC for Clinical Trials of Durvalumab as Monotherapy and in Combination with Tremelimumab

Financial news for AZN dated on 2016-11-11: Novartis Tells Benzinga On Intereconomia Article Suggesting Deal With AstraZeneca 'Novartis Doesn't Comment On Market Rumor Or Speculation'

Financial news for AZN dated on 2016-11-11: BZ NOTE: Watch for Near-Term Profit Taking in AstraZeneca Shares Following Intereconomia Report of Takeover Interest; Traders Often Times Show Skepticism About Rumors Coming from This Publication

Financial news for AZN dated on 2016-11-11: Hearing Intereconomia Reporting Novartis To Acquire AstraZeneca

Financial news for AZN dated on 2016-11-11: AstraZeneca Reports Study Results Show SYMBICORT Improves Lung Function in Pediatric Asthma Patients

Financial news for AZN dated on 2016-11-10: AstraZeneca Reports Q3 EPS \$1.32 vs \$0.74 Est; Revenue \$5.699B vs \$5.95B Est

Financial news for AZN dated on 2016-11-10: Earnings Scheduled For November 10, 2016

Financial news for AZN dated on 2016-11-10: Watch These 4 Huge Put Purchases In Thursday Trade

Financial news for AZN dated on 2016-11-09: Option Alert: AZN Nov16 28.0 Puts Sweep: 3700 @ ASK \$0.45: 3879 traded vs 3564 OI: Earnings tmrrw Before Open \$29.11 Ref

Financial news for AZN dated on 2016-10-28: Amazon's Price Target Reduced To A Measly \$1,000 At Credit Suisse

Financial news for AZN dated on 2016-10-27: Incyte Shares Recently Pulled Back from \$88 Level; Hearing News Astra, FDA Made Deal for Partial Clinical Hold is Negative for Incyte

Financial news for AZN dated on 2016-10-27: Bloomberg Confirms AstraZeneca Spoke To FDA Recently And Agreed To Partial Clinical Halt

Financial news for AZN dated on 2016-10-27: Hearing Astrazeneca Has Stopped Recruitment In Trial Evaluating IO Combination In Head And Neck Cancer

Financial news for AZN dated on 2016-10-26: LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

Financial news for AZN dated on 2016-10-25: 6 Big Pharma Companies Left To Report September Quarterly Figures

Financial news for AZN dated on 2016-10-17: AstraZeneca Spokesperson Declines Comment Following Unconfirmed Report of Roche Interest

Financial news for AZN dated on 2016-10-17: Shares of AstraZeneca Trading Higher Over Past Few Minutes On Rumor Of Potential Roche Acquisition of AstraZeneca

Financial news for AZN dated on 2016-10-05: Insmid Reports Global License Deal with AstraZeneca for Oral DPP1 Inhibitor

Financial news for AZN dated on 2016-10-04: AstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline

Financial news for AZN dated on 2016-10-04: Aralez Pharma Shares Up ~9 Percent in Premarket on News of Beta Blocker Toprol-XL Acquisition from AstraZeneca

Financial news for AZN dated on 2016-10-04: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Crude Oil Drops

Financial news for AZN dated on 2016-10-04: AstraZeneca's Brilinta Didn't Meet Primary Endpoint

Financial news for AZN dated on 2016-10-04: AstraZeneca Announces Agreement with Aralez for Toprol-XL in US; Aralez will Pay AstraZeneca \$175M to Acquire Rights

Financial news for AZN dated on 2016-10-04: AstraZeneca Announces Top-line EUCLID Results in PAD; Brilinta did Not Meet Primary Endpoint

Financial news for AZN dated on 2016-10-03: Allergan Announces Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program

Financial news for AZN dated on 2016-09-30: Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy

Financial news for AZN dated on 2016-09-29: AstraZeneca Gets FDA Approval for Tagrisso

Financial news for AZN dated on 2016-09-26: vTv Therapeutics Shares Initiated With Buy Rating, \$13 Target

Financial news for AZN dated on 2016-09-23: PiperJaffray Initiates Coverage on AstraZeneca at Overweight

Financial news for AZN dated on 2016-09-20: Citi Research Reevaluates Bristol-Myers, Lowers Price Target

Financial news for AZN dated on 2016-09-16: Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes, Met Primary And Secondary Endpoints

Financial news for AZN dated on 2016-09-16: AstraZeneca Says Combination of Diabetes Drugs Bydureon and Forxiga Shows Promise in Study -Bloomberg

Financial news for AZN dated on 2016-09-15: What To Watch For In Autozone's Upcoming Earnings Release

Financial news for AZN dated on 2016-09-15: Option Alert: AZN Fri 10/28 31.5 Calls (Wkly): 500 @ ASK \$2.65: 3117 traded vs 4001 OI: Earnings 11/3 \$33.54 Ref

Financial news for AZN dated on 2016-09-15: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for AZN dated on 2016-09-14: Option Alert: AZN Apr17 32.5 Calls: 500 @ ASK \$2.80: 2000 traded vs 53 OI: Earnings 11/3 \$33.21 Ref

Financial news for AZN dated on 2016-09-14: The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Financial news for AZN dated on 2016-09-14: Benzinga's Top Downgrades

Financial news for AZN dated on 2016-09-14: Exane BNP Paribas Downgrades AstraZeneca to Neutral

Financial news for AZN dated on 2016-09-12: Jefferies Sees Much Larger Market Opportunity For AstraZeneca, Upgrades To Buy

Financial news for AZN dated on 2016-09-12: Benzinga's Top Upgrades

Financial news for AZN dated on 2016-09-12: The Market In 5 Minutes: Hillary Clinton Falls Ill With The Global Stock Markets

Financial news for AZN dated on 2016-09-12: Jefferies Upgrades AstraZeneca to Buy

Financial news for AZN dated on 2016-09-06: Astrazeneca Says Benralizumab Phase III Trials Show Positive Results

Financial news for AZN dated on 2016-09-01: Aspen Pharmacare to Acquire Exclusive Rights to Commercialize Astrazeneca's Anaesthetics Portfolio; Terms Not Disclosed

Financial news for AZN dated on 2016-08-31: UPDATE: AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone

Financial news for AZN dated on 2016-08-31: AstraZeneca Announces Symbicort Demonstrated Comparable Risk Of Serious Asthma-Related Events Compared To Budesonide

Financial news for AZN dated on 2016-08-29: Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential

Financial news for AZN dated on 2016-08-29: The Market In 5 Minutes: Icahn, Netflix And A Quiet Market

Financial news for AZN dated on 2016-08-29: Benzinga's Top Upgrades

Financial news for AZN dated on 2016-08-29: Argus Research Upgrades AstraZeneca to Buy, Announces \$38.00 PT

Financial news for AZN dated on 2016-08-27: Here Are All The Big Biotech Mergers In 2016

Financial news for AZN dated on 2016-08-24: Pfizer's \$1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?

Financial news for AZN dated on 2016-08-24: Option Alert: AZN Sep16 35.0 Calls Sweep: 2158 @ ASK \$0.45: 2212 traded vs 9614 OI: \$34.10 Ref

Financial news for AZN dated on 2016-08-24: The Market In 5 Minutes: Stocks Trading Higher As Earnings Season Quiets Down

Financial news for AZN dated on 2016-08-24: Pfizer to Acquire Small Molecule Anti-Infective Business from AstraZeneca for Up to \$1.575B

Financial news for AZN dated on 2016-08-23: Pfizer Has Had A Busy M&A Year...Or Has It?

Financial news for AZN dated on 2016-08-22: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293

Financial news for AZN dated on 2016-08-10: AstraZeneca Makes \$140M Investment in Moderna; Now has 9% Stake

Financial news for AZN dated on 2016-08-10: AstraZeneca Reports Positive Top-Line Data from Two Phase III SYMBICORT Studies, Achieved Primary Endpoints In Both Studies

Financial news for AZN dated on 2016-08-09: AstraZeneca Announces Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint

Financial news for AZN dated on 2016-08-08: Citi Doesn't See Merck's Lung Cancer Success Lasting Long

Financial news for AZN dated on 2016-08-04: Benzinga's M&A Chatter for Thursday August 4, 2016

Financial news for AZN dated on 2016-08-03: Generics Keeping The Pressure On Big Pharma

Financial news for AZN dated on 2016-07-29: Legg Mason Introduces International High Dividend, Low Vol ETF

Financial news for AZN dated on 2016-07-28: Option Alert: AZN Oct16 35.0 Calls Sweep: 749 @ ASK \$0.75: 1015 traded vs 312 OI: Earnings today Before Open \$33.70 Re

Financial news for AZN dated on 2016-07-28: The Market In 5 Minutes: Facebook Crushes Earnings

Financial news for AZN dated on 2016-07-28: AstraZeneca CEO Declines Comment on Possibility Co Might Become Takeover Target Again -Reuters

Financial news for AZN dated on 2016-07-28: Earnings Scheduled For July 28, 2016

Financial news for AZN dated on 2016-07-18: AstraZeneca Says Phase III Aura3 Trial Met Its Primary Endpoint

Financial news for AZN dated on 2016-07-12: Argus Concerned With Near-Term Challenges At AstraZeneca

Financial news for AZN dated on 2016-07-12: Benzinga's Top Initiations

Financial news for AZN dated on 2016-07-12: Argus Research Initiates Coverage on AstraZeneca at Hold

Financial news for AZN dated on 2016-07-11: Believe It: Brexit Isn't All Bad For U.K. ETFs

Financial news for AZN dated on 2016-07-11: Astra Zeneca's Tagrisso Approved By Heath Canada As Treatment For Lung Cancer Patients

Financial news for AZN dated on 2016-07-08: What's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold?

Financial news for AZN dated on 2016-07-08: FibroGen Receives \$62M License Payment from AstraZeneca

Financial news for AZN dated on 2016-07-07: Medivation Bidders Will Have To Price In Talazoparib; BMO Sees \$68-\$76 Takeout Price

Financial news for AZN dated on 2016-07-07: Here's Why Valeant Is Happy To Relinquish Its European Brodalumab Rights

Financial news for AZN dated on 2016-06-30: Jefferies Downgrades Tesaro Following 108% Stock Move

Financial news for AZN dated on 2016-06-28: AstraZeneca Announces Zavicefta Approved in EU for Patients With Serious Bacterial Infections

Financial news for AZN dated on 2016-06-28: AstraZeneca Announces Zavicefta Approved in EU for Patients With Serious Bacterial Infections

Financial news for AZN dated on 2016-06-27: Chinese Expats Revolutionizing China's Homegrown Biopharma Sector

Financial news for AZN dated on 2016-06-24: Active Premarket Stocks

Financial news for AZN dated on 2016-06-23: Don't Bother Using FluMist; It Just Doesn't Work

Financial news for AZN dated on 2016-06-23: Antares Pharma Reports Settlement of Patent Litigation for Key Alliance Business Product, Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017

Financial news for AZN dated on 2016-06-23: Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta in the United States

Financial news for AZN dated on 2016-06-13: Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Financial news for AZN dated on 2016-06-10: The Market In 5 Minutes: Gotta Get Down On Friday

Financial news for AZN dated on 2016-06-09: Benzinga's M&A Chatter for Thursday June 9, 2016

Financial news for AZN dated on 2016-06-09: StreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus'

Financial news for AZN dated on 2016-06-09: Aspen to Acquire Commercialization Rights to Astrazeneca's Anaesthetic Medicines Portfolio for \$520M Upfront Payment

Financial news for AZN dated on 2016-06-07: Morgan Stanley Downgrades Relypsa, Expects Focus To Return To The Challenged Veltassa Launch & Cash Burn

Financial news for AZN dated on 2016-06-06: Acadia Pharmaceuticals May Be Subject Of A Bidding War

Financial news for AZN dated on 2016-06-06: The Market In 5 Minutes: Float Like A Butterfly, Sting Like A Bee

Financial news for AZN dated on 2016-06-06: Must Watch Stocks for June 6, 2016

Financial news for AZN dated on 2016-06-05: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2016-06-04: Foundation Medicine, AstraZeneca Announce Strategic Collaboration for Lynparza Companion Diagnostic Assay

Financial news for AZN dated on 2016-06-03: AstraZeneca, Teva, Biogen, Allergan Said to be Potential Bidders for Acadia -Daily Mail

Financial news for AZN dated on 2016-06-03: Ironwood Pharmaceuticals Closes Transaction with AstraZeneca for US Rights to Lesinurad

Financial news for AZN dated on 2016-06-02: Grunenthal, AstraZeneca Enter License Agreement for Gout Treatment Zurampic for Europe, Latin America

Financial news for AZN dated on 2016-05-27: 5 Other Times Relypsa Gained 10% In A Day This Year

Financial news for AZN dated on 2016-05-27: Benzinga's Volume Movers

Financial news for AZN dated on 2016-05-27: Mid-Morning Market Update: Markets Edge Higher; Big Lots Beats Q1 Estimates

Financial news for AZN dated on 2016-05-27: 5 Gainers And Losers In The Pre-Market Today

Financial news for AZN dated on 2016-05-27: Overhang For Relypsa Remains, Morgan Stanley Says

Financial news for AZN dated on 2016-05-27: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for AZN dated on 2016-05-27: Relypsa Surges 30% Following Setback From Rival AstraZeneca

Financial news for AZN dated on 2016-05-27: AstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA

Financial news for AZN dated on 2016-05-27: AstraZeneca's ZS-9 Delay Highlights Broader Risk Of Pipeline-Led EPS Growth Outlook

Financial news for AZN dated on 2016-05-27: Relypsa +28% Premarket @\$21.30 as FDA Sends CRL for AstraZeneca's Hyperkalaemia Treatment

Financial news for AZN dated on 2016-05-27: AstraZeneca Reports Positive Phase 3 Falcon Trial Results, Met Primary Endpoint; Trial Showed An Adverse Event Profile Consistent With Current Knowledge Of The Safety Profile Of The Medicines

Financial news for AZN dated on 2016-05-27: AstraZeneca's Fulvestrant Met Its Primary Endpoint

Financial news for AZN dated on 2016-05-27: AstraZeneca Receives CRL from FDA for Sodium Zirconium Cyclosilicate for Oral Suspension for Treatment of Hyperkalaemia

Financial news for AZN dated on 2016-05-27: AstraZeneca's Faslodex Met Primary Endpoint of Extended Progression-free Survival in Advanced Breast Cancer

Financial news for AZN dated on 2016-05-24: The Market In 5 Minutes: Where's The Oil?

Financial news for AZN dated on 2016-05-18: AstraZeneca's Multi-Tumor Opportunity Still Exists

Financial news for AZN dated on 2016-05-17: A Look At All Of Pfizer's Acquisitions Over The Past 2 Years

Financial news for AZN dated on 2016-05-17: As Veltassa Continues To Grow, BTIG Still Buying Relypsa

Financial news for AZN dated on 2016-05-17: AstraZeneca Reports They Met Primary Endpoint In 2 Phase III Trials For SIROCCO and CALIMA Showing Significant Reductions In Asthma Exacerbation Rate vs. Placebo

Financial news for AZN dated on 2016-05-13: UPDATE: AstraZeneca CEO Says Expects Progression-Free Survival Data from Mystic Immuno-Oncology Trial in Early 2017, With Overall Survival Data in Q2/Q3 2017

Financial news for AZN dated on 2016-05-13: AstraZeneca CEO, in Interview Says DDR Drugs Could Treat Up to 40% of Ovarian/Breast Cancers; Also Promising In Lung Cancer -Reuters

Financial news for AZN dated on 2016-05-11: The Market In 5 Minutes: Don't Stop Me Now

Financial news for AZN dated on 2016-05-09: AstraZeneca Launched, Prices EUR2.2B of Bonds; Proceeds to be Used for General Corporate Purposes, Including Repayment of

Debt

Financial news for AZN dated on 2016-05-03: Benzinga's M&A Chatter for Tuesday May 3, 2016

Financial news for AZN dated on 2016-05-01: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2016-04-29: FDA Approves First Generic Crestor-DJ

Financial news for AZN dated on 2016-04-29: Hearing Medivation Seeking Bids of At Least \$65/Share, AstraZeneca, Pfizer Mentioned as Weigh Bids

Financial news for AZN dated on 2016-04-29: Earnings Scheduled For April 29, 2016

Financial news for AZN dated on 2016-04-28: Why Medivation Will Likely Reject Sanofi's \$52.50/Share Buyout Offer

Financial news for AZN dated on 2016-04-28: Why Are Medivation Shares Trading Sharply Above The \$52.50 Offer?

Financial news for AZN dated on 2016-04-26: Astrazeneca Announces US Licensing Agreement With Ironwood; Includes US Rights to Zurampic; Lesinurad/Allopurinol Fixed-Dose Combination in Gout

Financial news for AZN dated on 2016-04-25: Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers

Financial news for AZN dated on 2016-04-18: The Market In 5 Minutes: Brazil, Doha, And Earnings Season

Financial news for AZN dated on 2016-04-18: Medivation Ticks Up 3%, AstraZeneca Said To Be Also Interested In Acquisition

Financial news for AZN dated on 2016-04-18: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for AZN dated on 2016-04-17: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2016-04-15: Morgan Stanley's Berens Highlights Greater Payor Pushback For Relypsa's Veltassa

Financial news for AZN dated on 2016-04-13: SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position

Financial news for AZN dated on 2016-04-12: Cancer Drug Stocks Are The Picture Of Health

Financial news for AZN dated on 2016-04-12: Benzinga's Top Downgrades

Financial news for AZN dated on 2016-04-12: Goldman Sachs Downgrades AstraZeneca To Sell, Cites High Pipeline Expectations

Financial news for AZN dated on 2016-04-11: Goldman Sachs Downgrades AstraZeneca to Sell

Financial news for AZN dated on 2016-04-08: Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data

Financial news for AZN dated on 2016-04-07: Stifel Comments On Relypsa M&A Rumors: 'Timing Could Be Tricky'

Financial news for AZN dated on 2016-04-07: Cantor: Relypsa Sale Makes Sense

Financial news for AZN dated on 2016-04-07: BZ NOTE: Relypsa Has Been Mentioned In Rumors Over Past 7 Months In Possible M&A Talk With Sanofi, Merck, Astra Zeneca

Financial news for AZN dated on 2016-04-06: PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure

Financial news for AZN dated on 2016-04-06: SocGen Picks New Favorites In Big Pharma

Financial news for AZN dated on 2016-04-06: WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP

Financial news for AZN dated on 2016-04-05: Evidence Pfizer Could Revisit GlaxoSmithKline Or AstraZeneca Deals If Allergan Falls Through

Financial news for AZN dated on 2016-04-05: The Market In 5 Minutes: Tuesday, April

5, 2016

Financial news for AZN dated on 2016-03-31: Credit Suisse: Medivation Could Be Worth \$54 To \$75 In Takeout, But Management Won't Sell

Financial news for AZN dated on 2016-03-29: Citi Downgrades Novartis Following SAG Investigation

Financial news for AZN dated on 2016-03-29: Inovio Gives Update On INO-3112 HPV Immunotherapy Development Plan

Financial news for AZN dated on 2016-03-29: AstraZeneca Says Tagrisso Approved in Japan for Cancer Patients

Financial news for AZN dated on 2016-03-22: Medivation Up As Triple M&A Interest Rumor Circulates

Financial news for AZN dated on 2016-03-22: The Market In 5 Minutes: Tuesday, March 22, 2016

Financial news for AZN dated on 2016-03-22: Stocks Hitting 52-Week Lows

Financial news for AZN dated on 2016-03-18: Intercept Shares Move to High; Hearing Unconfirmed Market Chatter of Offer from AstraZeneca

Financial news for AZN dated on 2016-03-17: AstraZeneca Acquires All Rights to Orexo's OX-CLI Project

Financial news for AZN dated on 2016-03-16: Stocks Hitting 52-Week Lows

Financial news for AZN dated on 2016-03-15: Benzinga's Top Downgrades

Financial news for AZN dated on 2016-03-15: Amid Few Catalysts, Jefferies Downgrades AstraZeneca

Financial news for AZN dated on 2016-03-15: Jefferies Downgrades AstraZeneca To Hold, Says FY 2016 Catalysts Are Limited, Sees LT Upside Potential From IO Pipeline But Cautions Driving Catalysts May Not Manifest Until 2017

Financial news for AZN dated on 2016-03-15: Jefferies Downgrades AstraZeneca to Hold

Financial news for AZN dated on 2016-03-14: In The Fight Against Cancer, Roche And AstraZeneca Are Looking At Trillions Of Bacteria That Live In The Body

Financial news for AZN dated on 2016-03-13: AstraZeneca Looks to Link Executive Compensation to \$45B Revenue Target -Bloomberg

Financial news for AZN dated on 2016-03-09: Jim Cramer Advises Viewers On AstraZeneca, Juno Therapeutics, Enbridge Energy Partners, Lockheed Martin And Microsoft

Financial news for AZN dated on 2016-02-29: Watch Pharma Names Following FDA Issuance Of New Mandatory Clinical Study For Bayer's 'Essure', Requires Product Labeling, Including Box Warnings And Patient Decision Checklist

Financial news for AZN dated on 2016-02-29: 6-K Confirms AstraZeneca Failed Trial For Tremelimumab

Financial news for AZN dated on 2016-02-29: Benzinga's Top Initiations

Financial news for AZN dated on 2016-02-29: UPDATE: AZN Says Top-Line Tremelimumab Trial Did Not Meet Primary Endpoint Of Improving Overall Survival In Mesothelioma Patients

Financial news for AZN dated on 2016-02-29: Hearing AstraZeneca Top-Line Results of Tremelimumab Trial Did Not Meet Primary Endpoint

Financial news for AZN dated on 2016-02-29: Tibet Rhodiola Pharmaceutical Says it and Partners Sign Agreement to Acquire Imdur Related Assets from Astrazeneca for \$190M -Reuters

Financial news for AZN dated on 2016-02-29: Drexel Hamilton Initiates Coverage on AstraZeneca at Buy

Financial news for AZN dated on 2016-02-29: AstraZeneca Announces Licensing Agreement with China Medical System Holdings for commercialization Rights in China to Plendil; CMS to pay AstraZeneca \$310M for License to Sell Plendil in China

Financial news for AZN dated on 2016-02-26: Cantor Fitzgerald Initiates Coverage on

AstraZeneca at Buy

Financial news for AZN dated on 2016-02-25: AstraZeneca's Acalabrutinib Receives Orphan Drug Designation in Europe for Treatment of C11/S11, Mantle Cell Lymphoma MCL and Lymphoplasmacytic Lymphoma -Reuters

Financial news for AZN dated on 2016-02-17: UPDATE: AstraZeneca Release Was Posted Earlier To Day

Financial news for AZN dated on 2016-02-17: Durvalumab Granted Breakthrough Therapy Designation By US FDA

Financial news for AZN dated on 2016-02-10: BIND Therapeutics, AstraZeneca Report Publishing of Preclinical Data Showing ACCURINS Ability to Utilize Proprietary Hydrophobic Ion Pairing to Increase Biodistribution to Tumor Sites of Molecularly Targeted Agents

Financial news for AZN dated on 2016-02-09: CentreView Partners Said to be Advising on Sale of Intercept to Astrazeneca

Financial news for AZN dated on 2016-02-08: Benzinga's Top Downgrades

Financial news for AZN dated on 2016-02-08: HBSC Downgrades AstraZeneca to Hold

Financial news for AZN dated on 2016-02-04: AstraZeneca Falls More Than 5% Following Q4 Print

Financial news for AZN dated on 2016-02-04: AstraZeneca Q4Q EPS \$0.94 vs \$0.88 Est; Revenue \$6.39B vs \$6.27B Est

Financial news for AZN dated on 2016-02-04: Earnings Scheduled For February 4, 2016

Financial news for AZN dated on 2016-01-29: Alleran, AstraZeneca Partner To Commercialize ATM-AVI For Gram-Negative Antibiotic Resistant Infections

Financial news for AZN dated on 2016-01-26: Oddo Securities Upgrades AstraZeneca to Top Pick, Says Co Pipeline Well Positioned In Terms Of Newsflow

Financial news for AZN dated on 2016-01-25: Why Shares Of Valeant Pharmaceuticals Spiked

Financial news for AZN dated on 2016-01-19: Dynavax, AstraZeneca Report Amended Deal for Asthma Drug Candidate

Financial news for AZN dated on 2016-01-19: AstraZeneca Shares Higher Following Barclays Upgrade

Financial news for AZN dated on 2016-01-19: Benzinga's Top Upgrades

Financial news for AZN dated on 2016-01-19: Barclays Upgrades AstraZeneca to Equal-weight, Raises PT to \$50.00

Financial news for AZN dated on 2016-01-12: Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside

Financial news for AZN dated on 2016-01-11: Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration

Financial news for AZN dated on 2015-12-28: Must Watch Stocks for Today

Financial news for AZN dated on 2015-12-24: Benzinga's Volume Movers

Financial news for AZN dated on 2015-12-24: Here's What's Been Going On With Relypsa

Financial news for AZN dated on 2015-12-24: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2015-12-24: Report: AstraZeneca Eyes Acquisition Of Relypsa For \$46 Per Share

Financial news for AZN dated on 2015-12-23: AstraZeneca Said to Bid \$46/Share for Relypsa -Daily Mail

Financial news for AZN dated on 2015-12-22: Hearing FDA Has Approved Zurampic for Treatment of High Blood Uric Acid Levels Related to Gout

Financial news for AZN dated on 2015-12-22: Watch Stocks of Co.'s with Flu-Related Solutions; Macquarie Note Earlier Highlighted 'Early Flu Results Lagging

Financial news for AZN dated on 2015-12-20: Jim Cramer Gives His Opinion On

AstraZeneca, Cummins And Dow Chemical

Financial news for AZN dated on 2015-12-18: Regulus Therapeutics Announces Initial Dosing In Phase 1 Clinical Study Of RG-125 By Partner AstraZeneca, Regulus Earns \$10M Milestone Payment

Financial news for AZN dated on 2015-12-18: Hearing AstraZeneca Has Received Positive CHMP Opinions on Lesinurad for Gout, Brilique, Tagrisso

Financial news for AZN dated on 2015-12-18: EMA Grants Conditional Marketing Authorization for Astrazeneca's Lung Cancer Drug Osimertinib

Financial news for AZN dated on 2015-12-18: EMA Recommends Astrazeneca's Gout Drug Lesinurad

Financial news for AZN dated on 2015-12-17: Benzinga's M&A Chatter for Thursday December 17, 2015

Financial news for AZN dated on 2015-12-17: Early Global News: Obama Meets Bloomberg, Microsoft Supplying Chinese Government With Windows 10, And More

Financial news for AZN dated on 2015-12-17: AstraZeneca to Acquire 55% Stake in Acerta for Upfront Payment of \$2.5B

Financial news for AZN dated on 2015-12-16: Benzinga's M&A Chatter for Wednesday December 16, 2015

Financial news for AZN dated on 2015-12-16: AstraZeneca to Acquire Respiratory Portfolio from Takeda for \$575M

Financial news for AZN dated on 2015-12-15: Hearing AstraZeneca Has Reported Closing of Deal with Perrigo, Says Deal Does Not Impact Outlook

Financial news for AZN dated on 2015-12-14: M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down

Financial news for AZN dated on 2015-12-14: AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma

Financial news for AZN dated on 2015-12-14: Must Watch Stocks for December 14, 2015

Financial news for AZN dated on 2015-12-13: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2015-12-11: Several Pharma/Biotech Names Spiking on AstraZeneca Rumor: Baxter, Shire, Baxalta

Financial news for AZN dated on 2015-12-11: UPDATE: Astrazeneca Could Pay \$5B+ for Acerta

Financial news for AZN dated on 2015-12-11: Astrazeneca In Talks To Acquire Acerta Pharma -DJ

Financial news for AZN dated on 2015-12-08: Credit Suisse Desk Lists Best Names To Buy/Sell Today

Financial news for AZN dated on 2015-12-07: These Currency Hedged ETFs Could Enjoy 2016

Financial news for AZN dated on 2015-12-07: UPDATE: Celgene, Astrazeneca Fusion Program Partnership Is To Develop & Commercialize durvalumab Across A Range Of Blood Cancers

Financial news for AZN dated on 2015-12-07: Celgene, Astrazeneca Report Start Of Fusion Clinical Development Program In Immuno-Oncology

Financial news for AZN dated on 2015-12-01: The Rare Double Upgrade: Why Morgan Stanley Loves AstraZeneca After Hating It

Financial news for AZN dated on 2015-12-01: Morgan Stanley Confirms Shares of AstraZeneca Upgraded Mid-Day

Financial news for AZN dated on 2015-12-01: Shares of AstraZeneca Spike Over \$34.20 Level, Up ~1.3% Over Last Few Mins; Some Traders Attributing Move Higher to Mid-Day Upgrade from Morgan Stanley

Financial news for AZN dated on 2015-11-30: 6 Buys And 5 Value Traps Hiding In The European Stock Market

Financial news for AZN dated on 2015-11-23: Early Global News: Alibaba Startup Stake,

Commercial Drones & Under Armour-Lululemon Rumor

Financial news for AZN dated on 2015-11-23: Perrigo Reports Purchase of Entocort Capsules, Authorized Generic Capsules Marketed by Par Pharma from AstraZeneca for \$380M

Financial news for AZN dated on 2015-11-16: Diplomat to Dispense AstraZeneca Drug TAGRISSO(TM) (osimertinib)

Financial news for AZN dated on 2015-11-16: Benzinga's Volume Movers

Financial news for AZN dated on 2015-11-13: AstraZeneca's Targisso Approved By FDA For Patients With EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer-Reuters

Financial news for AZN dated on 2015-11-09: Why These Two Firms Downgraded ZS Pharma Stock

Financial news for AZN dated on 2015-11-09: AstraZeneca Presents Positive Update On Lesinurad Renal Data In Gout Patients; PDUFA Date December 29, 2015

Financial news for AZN dated on 2015-11-09: AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients

Financial news for AZN dated on 2015-11-06: Mid-Afternoon Market Update: Sierra Wireless Drops On Downbeat Earnings; TrueCar Shares Spike Higher

Financial news for AZN dated on 2015-11-06: Mid-Day Market Update: ZS Pharma Jumps On Acquisition News; Men's Wearhouse Shares Slide

Financial news for AZN dated on 2015-11-06: Could Relypsa Be The Next Big Pharma Buyout Target?

Financial news for AZN dated on 2015-11-06: Benzinga's Volume Movers

Financial news for AZN dated on 2015-11-06: Stocks Hitting 52-Week Highs

Financial news for AZN dated on 2015-11-06: Mid-Morning Market Update: Markets Decline; Humana Earnings Beat Estimates

Financial news for AZN dated on 2015-11-06: Morning Market Gainers

Financial news for AZN dated on 2015-11-06: Why ZS Pharma Isn't Game-Changing For AstraZeneca

Financial news for AZN dated on 2015-11-06: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2015-11-06: US Stock Futures Mostly Flat; All Eyes On Jobs Report

Financial news for AZN dated on 2015-11-06: Morgan Stanley Says AstraZeneca Acquisition Of ZS Pharma is 'not game-changing', Deal Fits Well Into AstraZeneca's Portfolio

Financial news for AZN dated on 2015-11-06: AstraZeneca to Acquire ZS Pharma for \$90/Share in Cash

Financial news for AZN dated on 2015-11-05: Inovio's INO-3112 Demonstrates Robust Immune Responses in Patients With Head & Neck Cancer

Financial news for AZN dated on 2015-11-05: AstraZeneca Reports Q3 EPS \$0.61 vs \$0.77 Est; Revenue \$5.945B vs \$5.90B Est

Financial news for AZN dated on 2015-11-05: AstraZeneca CEO Says Nothing Has Changed in Partnership With Valeant on Brodalumab, Despite Issues at Valeant -Reuters

Financial news for AZN dated on 2015-11-05: Earnings Scheduled For November 5, 2015

Financial news for AZN dated on 2015-10-29: How Allergan Could Be Pfizer's Rocket Ship

Financial news for AZN dated on 2015-10-23: FDA Panel Votes Unanimously In Favor Of Clinical Benefit Of Astrazeneca's Gout Drug In Combination With Febuxostat

Financial news for AZN dated on 2015-10-22: 10 Giant M&A Deals That Almost Happened...But Fell Through At The Last Minute

Financial news for AZN dated on 2015-10-20: Benzinga's Top Downgrades

Financial news for AZN dated on 2015-10-20: Credit Suisse Downgrades AstraZeneca to Underperform

Financial news for AZN dated on 2015-10-16: 6-K from AstraZeneca Reports FDA Issues CRL Related to NDA for Investigational Fixed-Dose Combo of Saxagliptin, Dapagliflozin for Treatment of Adults with Type 2 Diabetes

Financial news for AZN dated on 2015-10-15: Peregrine Pharmaceuticals +20% Premarket Following Announcement of Collaboration With AstraZeneca

Financial news for AZN dated on 2015-10-13: Savolitinib, AstraZeneca Complete Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma

Financial news for AZN dated on 2015-10-09: AstraZeneca Halts 2 Lung Cancer Drug Combo Trials

Financial news for AZN dated on 2015-10-08: Option Alert: \$AZN Jan \$35 Call; 4000 Contracts above Ask @\$0.65; Now \$32/15

Financial news for AZN dated on 2015-10-08: AstraZeneca Presents Respiratory Syncytial Virus (RSV) Study Results at IDWeek 2015

Financial news for AZN dated on 2015-09-22: AstraZeneca to Present Data Demonstrating Diversity of Its Portfolio of Innovative Formulations and Devices at the European Respiratory Society International Congress 2015

Financial news for AZN dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for AZN dated on 2015-09-14: Benzinga's Top Upgrades

Financial news for AZN dated on 2015-09-14: Deutsche Bank Upgrades AstraZeneca to Buy

Financial news for AZN dated on 2015-09-11: US Stock Futures Decline Ahead Of Economic Data

Financial news for AZN dated on 2015-09-11: AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline

Financial news for AZN dated on 2015-09-11: AstraZeneca Buys Boulder, CO Manufacturing Facility from Amgen -Reuters

Financial news for AZN dated on 2015-09-07: Starpharma Signs Drug Delivery License with AstraZeneca

Financial news for AZN dated on 2015-09-04: AstraZeneca to Update on Leading Lung Cancer Portfolio at WCLC 2015

Financial news for AZN dated on 2015-09-01: US Stock Futures Tumble Ahead Of Economic Data

Financial news for AZN dated on 2015-09-01: Valeant, AstraZeneca to Partner on Brodalumab; Valeant to Make Upfront Payment to AstraZeneca of \$100M; Up to \$345M in Milestone Payments

Financial news for AZN dated on 2015-08-24: US Stock Futures Tumble, China's Shanghai Plunges 8.5%

Financial news for AZN dated on 2015-08-24: AstraZeneca Names Sean Bohen as Chief Medical Officer

Financial news for AZN dated on 2015-08-24: AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

Financial news for AZN dated on 2015-08-19: O'Leary's O'Shares Triples The Size Of Its ETF Stable

Financial news for AZN dated on 2015-08-18: Juno Therapeutics Could Nearly Double On Data, Multiple Catalysts, Say FBR Analysts

Financial news for AZN dated on 2015-08-10: Diplomat To Dispense AstraZeneca Drug IRESSA

Financial news for AZN dated on 2015-08-10: Mid-Day Market Update: Dow Surges Over 200 Points; Dean Foods Shares Decline On Downbeat Sales

Financial news for AZN dated on 2015-08-10: Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More

Financial news for AZN dated on 2015-08-10: Mid-Morning Market Update: Markets Open Higher; Berkshire Hathaway To Acquire Precision Castparts For \$37.2B

Financial news for AZN dated on 2015-08-10: Morning Market Gainers

Financial news for AZN dated on 2015-08-10: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2015-08-10: Inovoio +9% Premarket on Light Trading, Following Announcement of Licensing Deal With AstraZeneca Unit; Inovio to Receive Up to \$700M in Payments

Financial news for AZN dated on 2015-08-10: Inovio Pharmaceuticals Announces Strategic Cancer Vaccine Collaboration and License Agreement With AstraZeneca's MedImmune Unit

Financial news for AZN dated on 2015-08-06: Sosei Subsidiary Heptares, AstraZeneca Announce Agreement to Develop Novel Immuno-Oncology Treatments for Range of Cancers

Financial news for AZN dated on 2015-08-05: AstraZeneca's MedImmune, Mirati Therapeutics Partner on Immuno-oncology Combination in Lung Cancer

Financial news for AZN dated on 2015-08-03: Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOR Cardiovascular, Metabolic And Renal Disease

Financial news for AZN dated on 2015-08-03: AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Financial news for AZN dated on 2015-07-30: AstraZeneca CEO Says Looking at M&A Deals But Prices are Pretty Hefty -Reuters

Financial news for AZN dated on 2015-07-30: Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement

Financial news for AZN dated on 2015-07-27: US Stock Futures Signal Lower Start On Wall Street

Financial news for AZN dated on 2015-07-27: AstraZeneca to Sell Caprelsa to Sanofi's Genzyme for Up to \$300M

Financial news for AZN dated on 2015-07-23: Celgene's Q2 Earnings Call: Highlights & Analyst Commentary

Financial news for AZN dated on 2015-07-22: Morning Market Losers

Financial news for AZN dated on 2015-07-22: Benzinga's Top #PreMarket Losers

Financial news for AZN dated on 2015-07-22: US Stock Futures Down; Apple Shares Slide After Weak Sales Forecast

Financial news for AZN dated on 2015-07-22: Array BioPharma Shares Fall 20% Premarket Following AstraZeneca Report of Phase 3 SUMIT Metastatic Uveal Melanoma Study

Financial news for AZN dated on 2015-07-22: AstraZeneca Phase 3 SUMIT Study of Selumetinib in Combination with Dacarbazine Did Not Meet Primary Endpoint

Financial news for AZN dated on 2015-07-20: Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs

Financial news for AZN dated on 2015-07-13: Hearing FDA Has Approved Target Therapies For First-Time Patients Seeking Treatment For Types Of Metastatic Lung Cancer

Financial news for AZN dated on 2015-07-09: New Studies And Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials

Financial news for AZN dated on 2015-07-08: AstraZeneca, Ironwood Announce Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linacotide Approval in China

Financial news for AZN dated on 2015-07-02: Benzinga's Top Upgrades

Financial news for AZN dated on 2015-07-02: Berenberg Upgrades AstraZeneca To Buy

Financial news for AZN dated on 2015-07-02: Berenberg Upgrades AstraZeneca to Buy

Financial news for AZN dated on 2015-06-30: Eolas Therapeutics, AstraZeneca Announce Partnership to Develop Orexin-1 Receptor Antagonist for Multiple Indications

Financial news for AZN dated on 2015-06-26: AstraZeneca Changes Ratio To NYSE-Listed ADS, New Ratio Will Be Two ADS For One Ordinary Share, Prior Ratio Was 1:1

Financial news for AZN dated on 2015-06-19: Biotech Stocks Worth Taking A Look At

Financial news for AZN dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for AZN dated on 2015-06-16: New Report: Abbvie Is Jefferies' Top Global Pharma Stock

Financial news for AZN dated on 2015-06-13: AstraZeneca Presents Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at EULAR 2015

Financial news for AZN dated on 2015-06-11: Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference

Financial news for AZN dated on 2015-06-10: AstraZeneca Shares Spike Lower; May be Attributed to Unconfirmed Market Chatter R&D Chief is Leaving

Financial news for AZN dated on 2015-06-09: Benzinga's M&A Chatter for Tuesday June 9, 2015

Financial news for AZN dated on 2015-06-09: Rumor Receptos Rejected \$200/Share AstraZeneca Bid

Financial news for AZN dated on 2015-06-03: US Stock Futures Surge Ahead Of ADP Report, Beige Book

Financial news for AZN dated on 2015-06-03: Ardelyx Regains Worldwide Development, Commercialization Rights for Tenapanor and Related Portfolio of NHE3 Compounds

Financial news for AZN dated on 2015-06-03: Astrazeneca, Innate Pharma Announce Global Co-Development and Commercialisation Collaboration for IPH2201 in Immuno-Oncology

Financial news for AZN dated on 2015-06-02: Juno Shares Falling; May be Attributed to Bloomberg Correcting Earlier Story of AstraZeneca CEO Saying Would Buy Co Such as Juno

Financial news for AZN dated on 2015-06-02: Report: AstraZeneca Might Bid On Juno Therapeutics

Financial news for AZN dated on 2015-06-02: AstraZeneca CEO Soriot Said CAR T Therapy Candidates Would Need to Be Able to Manage Side Effects Before Co. Would Be Interested in Deal

Financial news for AZN dated on 2015-06-02: Hearing AstraZeneca CEO Pascal Soriot Has Suggested Co. 'Would Consider' Cos. Like Juno, Will Partner for Further Immunotherapy Trials

Financial news for AZN dated on 2015-06-02: Shares of Ziopharm, Juno Moving Higher; Note Being Circulated Says Juno, Ziopharm Potential Targets of AstraZeneca

Financial news for AZN dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for AZN dated on 2015-05-31: AstraZeneca Presents Positive Data on AZD9291 in First-Line EGFR Mutated NSCLC at ASCO

Financial news for AZN dated on 2015-05-30: AstraZeneca, MedImmune Present Positive Immuno-Oncology Combination Data at ASCO

Financial news for AZN dated on 2015-05-29: Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors

Financial news for AZN dated on 2015-05-27: CNBC's Stock Pops & Drops From May 26

Financial news for AZN dated on 2015-05-26: Amgen, AstraZeneca End Development Pact; Shares Sink

Financial news for AZN dated on 2015-05-20: DoJ Says Express Scripts' Medco Health Unit to Pay \$7.9M to Settle Kickback Allegations Involving AstraZeneca -Retuers

Financial news for AZN dated on 2015-05-19: LBBW Upgrades AstraZeneca to Hold

Financial news for AZN dated on 2015-05-18: US Stock Futures Edge Lower Ahead Of Housing Market Index

Financial news for AZN dated on 2015-05-18: AstraZeneca to Invest in New Biological Manufacturing Facility in Sweden; To Create 150-250 Jobs By 2019

Financial news for AZN dated on 2015-05-08: Barclays Hopes Pulmicort Is 'Back For Good' At Actavis

Financial news for AZN dated on 2015-05-07: Actavis Earlier After-Hours Release Announced Co. to Immediately Re-Launch Generic Version of AstraZeneca's Pulmicort RESPULES

Financial news for AZN dated on 2015-05-07: AstraZeneca Has Lost Appeal Related to Pulmicort Respules Being Invalid; BZ NOTE: Actavis Winner Here

Financial news for AZN dated on 2015-05-06: Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology

Financial news for AZN dated on 2015-05-05: Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience

Financial news for AZN dated on 2015-05-03: AstraZeneca, Starpharma Sign Extension to Existing Collaboration; AstraZeneca to Develop Oncology Drug Using Stapharma's DEP Technology -Reuters

Financial news for AZN dated on 2015-05-01: Morgan Stanley On What 'Should Be Rewarded' At Gilead

Financial news for AZN dated on 2015-04-29: US Stock Futures Slip Ahead Of Fed Decision

Financial news for AZN dated on 2015-04-29: AstraZeneca Reports FDA Grants Priority Review for Potential New Indication for BRILINTA

Financial news for AZN dated on 2015-04-27: Oppenheimer Comments On 2 Biotech Stocks

Financial news for AZN dated on 2015-04-24: AstraZeneca CEO Declines Comment on Pfizer, Says Completely Focused on Developing Pipeline -Reuters

Financial news for AZN dated on 2015-04-24: Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno-oncology

Financial news for AZN dated on 2015-04-24: Earnings Scheduled For April 24, 2015

Financial news for AZN dated on 2015-04-15: SunTrust's Latest Comments On Merck

Financial news for AZN dated on 2015-04-15: SocGen Initiates Big Drug/Pharma Names

Financial news for AZN dated on 2015-04-13: PatientsLikeMe, AstraZeneca Announce Global Research Collaboration

Financial news for AZN dated on 2015-04-08: Morning Market Gainers

Financial news for AZN dated on 2015-04-07: Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading

Financial news for AZN dated on 2015-04-07: UPDATE: Regulus Therapeutics Says Expect to Initiate Phase I Study of RG-125 in Humans by End of 2015

Financial news for AZN dated on 2015-04-07: RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Chosen As Clinical Candidate by AstraZeneca

Financial news for AZN dated on 2015-04-01: Myriad, AstraZeneca Expand Research Collaboration on Lynparza

Financial news for AZN dated on 2015-03-31: AstraZeneca Reports Launch of MOVANTI in US

Financial news for AZN dated on 2015-03-30: AstraZeneca Announces FDA Approval For BRILINTA, New Administration Option

Financial news for AZN dated on 2015-03-19: The Marijuana CARERS Act: What You Need To Know

Financial news for AZN dated on 2015-03-19: Nektar Announces Partner AstraZeneca Reported Co-Commercialization Deal with Daiichi Sankyo for MOVANTI in US

Financial news for AZN dated on 2015-03-18: US Stock Futures Down; All Eyes On Fed Decision

Financial news for AZN dated on 2015-03-18: AstraZeneca Announces Positive Phase III Top-line Results for PT003 from PINNACLE 1, PINNACLE 2 Studies in COPD

Financial news for AZN dated on 2015-03-14: AstraZeneca Announces Positive BRILINTA Results in PEGASUS-TIMI 54 Study

Financial news for AZN dated on 2015-03-10: AstraZeneca's MedImmune Reports Co., Joslin Diabetes Center to Offer New Research Collaboration Focused on Advancing Metabolic Disease Research

Financial news for AZN dated on 2015-02-20: Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

Financial news for AZN dated on 2015-02-16: AstraZeneca Says US Court Rules Pulmicort Respules Patent Invalid; Strongly Disagrees With Court Decision; Considering Appeal

Financial news for AZN dated on 2015-02-13: Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4

Financial news for AZN dated on 2015-02-11: Astrazeneca to Pay \$7.9M to Settle Kickback Allegations -Reuters

Financial news for AZN dated on 2015-02-06: After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?

Financial news for AZN dated on 2015-02-06: Amid The Pfizer-Hospira Deal, Are Healthcare ETFs In Play?

Financial news for AZN dated on 2015-02-05: UPDATE: AstraZeneca Board Declared Second Interim Dividend of \$1.90/Share

Financial news for AZN dated on 2015-02-05: US Stock Futures Surge Ahead Of Jobless Claims Data

Financial news for AZN dated on 2015-02-05: AstraZeneca Q4 Profit Misses Estimates

Financial news for AZN dated on 2015-02-05: Earnings Scheduled For February 5, 2015

Financial news for AZN dated on 2015-02-05: AstraZeneca Reports Q4 Adj EPS \$0.76 vs \$0.85 Est; Revenue \$6.68B vs \$6.75B Est

Financial news for AZN dated on 2015-02-03: SEB Equity Research Upgrades AstraZeneca to Buy

Financial news for AZN dated on 2015-02-02: Ardelyx Says Astrazeneca's Phase 2b Clinical Trial Evaluating Tenapanor Met Primary Endpoint

Financial news for AZN dated on 2015-01-27: Benzinga's Volume Movers

Financial news for AZN dated on 2015-01-22: Leerink Raises AstraZeneca Price Target

Financial news for AZN dated on 2015-01-22: AstraZeneca Announces EMA Accepted Marketing Authorization Application for Lesinurad 200mg Tablets

Financial news for AZN dated on 2015-01-16: Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks

Financial news for AZN dated on 2015-01-16: Barclays Downgrades AstraZeneca to Underweight

Financial news for AZN dated on 2015-01-14: AstraZeneca Announces Pegasus Meets Primary Endpoint

Financial news for AZN dated on 2015-01-14: AstraZeneca Announces PEGASUS-TIMI 54 Study of BRILINTA Met Primary Endpoint in 60mg, 90mg Doses

Financial news for AZN dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for AZN dated on 2015-01-12: QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca

Financial news for AZN dated on 2015-01-09: What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts

Financial news for AZN dated on 2014-12-19: FDA Approves Lynparza to Treat Advanced Ovarian Cancer

Financial news for AZN dated on 2014-12-18: AstraZeneca's Lynparza Approved In EU for Ovarian Cancer

Financial news for AZN dated on 2014-12-08: Dynavax, AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma into Phase 2a Clinical Study; AstraZeneca to Fully Fund Trial

Financial news for AZN dated on 2014-12-05: Actavis' Antibiotic Ceftazidime/avibactam Receives Partial FDA Panel Backing

Financial news for AZN dated on 2014-12-05: Jury Verdict in Favor of AstraZeneca in Nexium Patent Litigation -Reuters

Financial news for AZN dated on 2014-12-04: Option Alert: Ariad May \$10 Call; 1,000 Contract Trade at Ask @\$0.70; Currently \$7.44

Financial news for AZN dated on 2014-12-04: Ariad Shares Up 1% Premarket on Rumor of Potential Bids from AstraZeneca, Shire

Financial news for AZN dated on 2014-12-02: Morgan Stanley Pair Trade On Novartis And AstraZeneca

Financial news for AZN dated on 2014-12-02: Morgan Stanley Downgrades Astrazeneca PLC to Underweight

Financial news for AZN dated on 2014-12-02: AstraZeneca Shares Spike Lower; May be Attributed to Morgan Stanley Downgrade

Financial news for AZN dated on 2014-12-02: AstraZeneca NDA for IRESSA Accepted by FDA

Financial news for AZN dated on 2014-12-01: Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH

Financial news for AZN dated on 2014-11-28: AstraZeneca CEO: We Will Achieve Our Targets Through Our Drug Pipeline

Financial news for AZN dated on 2014-11-26: CNBC'S Catherine Boyle Doesn't Think A Pfizer/AstraZeneca Deal Will Happen Soon

Financial news for AZN dated on 2014-11-25: Amgen, AstraZeneca Reports Positive Results from Third, Final Pivotal Phase 3 Study of Brodalumab In Patients with Moderate-to-Severe Plaque Psoriasis

Financial news for AZN dated on 2014-11-24: AstraZeneca's Duaklir Genuair Receives Marketing Authorization from EC

Financial news for AZN dated on 2014-11-21: AstraZeneca Announces Plans For Maryland Manufacturing Center Expansion

Financial news for AZN dated on 2014-11-21: Fitch Downgrades AstraZeneca to 'A+'; Outlook Stable

Financial news for AZN dated on 2014-11-20: ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium

Financial news for AZN dated on 2014-11-18: Astrazeneca PLC Sees FY2023 Sales \$45.0B

Financial news for AZN dated on 2014-11-17: Bank Of America Believes DAPT Adds To Precedent For PEGASUS Success For AstraZeneca

Financial news for AZN dated on 2014-11-16: AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at ACR

Financial news for AZN dated on 2014-11-14: Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca

Financial news for AZN dated on 2014-11-14: AstraZeneca Shares Fall 2% Premarket on Reuters Report Pfizer Unlikely to Bid Again

Financial news for AZN dated on 2014-11-13: AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent

Financial news for AZN dated on 2014-11-13: AstraZeneca, Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

Financial news for AZN dated on 2014-11-11: Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-

Severe Plaque Psoriasis

Financial news for AZN dated on 2014-11-07: #PreMarket Primer: Friday, November 7: Boehner Reveals Intentions To Modify Obamacare

Financial news for AZN dated on 2014-11-06: #PreMarket Primer: Thursday, November 6: Obama, McConnell Prepare For Rocky Road Ahead

Financial news for AZN dated on 2014-11-06: AstraZeneca Raises 2014 Outlook

Financial news for AZN dated on 2014-11-06: Aegerion Acquires Myalept from AstraZeneca for \$325M Upfront Payment

Financial news for AZN dated on 2014-11-06: Astrazeneca PLC Reports Q3 EPS of \$1.05 vs \$1.04 Est; Revenue of \$6.54B vs \$6.28B Est

Financial news for AZN dated on 2014-11-05: Isis Pharmaceuticals Earns \$7.5M Milestone Payment from AstraZeneca for Advancement of ISIS-STAT3Rx

Financial news for AZN dated on 2014-11-04: AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA

Financial news for AZN dated on 2014-11-04: AstraZeneca Says Medimmune to Acquire Definiens for Initial Payment of \$150M, Plus Milestone Payments

Financial news for AZN dated on 2014-10-30: Markets Rally On Better Than Expected GDP; Dow Has Best Close In More Than A Month

Financial news for AZN dated on 2014-10-30: AstraZeneca Announces FDA Approves Once-Daily XIGDUO(tm) XR Tablets

Financial news for AZN dated on 2014-10-09: 8-K from Targacept Shows AstraZeneca Has Ended Collaborative Research Deal

Financial news for AZN dated on 2014-10-06: AstraZeneca Reports BRILINTA Preferred Over Clopidogrel in '14 AHA/ACC Guideline for Mgmt

Financial news for AZN dated on 2014-10-03: What Are The Best-Selling Drugs Of 2014?

Financial news for AZN dated on 2014-09-29: AstraZeneca Expects to File Lung Cancer Pill for US Regulatory Approval in H2 2015 -Reuters

Financial news for AZN dated on 2014-09-26: AstraZeneca Reports CHMP Recommends Constipation Drug Moventig for Approval

Financial news for AZN dated on 2014-09-25: 8-K from IGI Labs Shows Co. Paid ~\$500K for 18 Products from AstraZeneca, Co. Required to Pay Up to \$6M in Added Milestones

Financial news for AZN dated on 2014-09-23: Benzinga's M&A Chatter for Tuesday September 23, 2014

Financial news for AZN dated on 2014-09-23: Pfizer Inc. Is Kicking The Tires At Actavis PLC

Financial news for AZN dated on 2014-09-23: UPDATE: Pfizer Has Weighed Other Options Including an Offer for AstraZeneca

Financial news for AZN dated on 2014-09-23: AstraZeneca Spikes to High

Financial news for AZN dated on 2014-09-23: UPDATE: Pfizer Seeking Friendly Inversion Deal

Financial news for AZN dated on 2014-09-23: Inversion Crackdown Leaves Several Deals In Limbo

Financial news for AZN dated on 2014-09-23: Midday Losers From September 23 - Alco Stores Inc, CarMax, Inc And More

Financial news for AZN dated on 2014-09-23: Markets Mixed; Carnival Profit Tops Street View

Financial news for AZN dated on 2014-09-23: Robert Willens Commenting to Bloomberg: Treasury's New Rules Do Not Strike a Mortal Blow to Inversion Deals, Believes Deals Should Be Completed Without Missing a Beat

Financial news for AZN dated on 2014-09-23: AstraZeneca's Medimmune Has Received Fast Track Designation for MEDI3902 for Prevention of Nosocomial Pneumonia

Financial news for AZN dated on 2014-09-23: Citi Says New Tax Inversion Measures

Should have Little Impact on Pfizer Deal for AstraZeneca

Financial news for AZN dated on 2014-09-23: AstraZeneca, Shire Shares Fall 5% Premarket on Proposed New US Rules Affecting Tax Inversion Deals

Financial news for AZN dated on 2014-09-16: AstraZeneca Confirms FDA Approval of MOVANTIK Tablets

Financial news for AZN dated on 2014-09-16: UPDATE: FDA Posts Approval of 'Movantik for Opioid-Induced Constipation'

Financial news for AZN dated on 2014-09-16: FDA Has Issued Approval for Nektar's Movantik for Opioid-Induced Constipation

Financial news for AZN dated on 2014-09-16: Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to \$500M in Milestones

Financial news for AZN dated on 2014-09-03: Teva Announces Positive Judgment in Company's Patent Case vs AstraZeneca by UK High Court

Financial news for AZN dated on 2014-09-03: Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca

Financial news for AZN dated on 2014-09-02: SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'

Financial news for AZN dated on 2014-09-02: AstraZeneca CEO Says Back to Normal Despite Pfizer Rumors -Reuters

Financial news for AZN dated on 2014-08-29: AstraZeneca Moves MEDI-4736 into Mid-Stage Study in Colorectal Cancer -Reuters

Financial news for AZN dated on 2014-08-27: Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline

Financial news for AZN dated on 2014-08-25: The 4 Companies Teaming Up For A New Tool To Fight Cancer

Financial news for AZN dated on 2014-08-21: Markets Continue To Rally Ahead Of Yellen's Speech At Jackson Hole

Financial news for AZN dated on 2014-08-21: Pfizer Could Revive AstraZeneca Bid As Early As Tuesday

Financial news for AZN dated on 2014-08-21: Illumina Announces Strategic Partnerships with AstraZeneca, Janssen, Sanofi

Financial news for AZN dated on 2014-08-20: Pfizer Could Be Exploring Alternatives to Deal with AstraZeneca, May Consider Other Targets, Including Actavis - Bloomberg

Financial news for AZN dated on 2014-08-19: AstraZeneca Reports DOJ Closes Investigation Into PLATO Clinical Trial for BRILINTA

Financial news for AZN dated on 2014-07-30: Stocks Mixed Despite Better Than Expected GDP

Financial news for AZN dated on 2014-07-29: Citigroup Comments On Potential Pfizer/AstraZeneca Acquisition

Financial news for AZN dated on 2014-07-29: Pfizer CEO Says Best to Remain Silent About AstraZeneca Due to UK Takeover Rules -Reuters

Financial news for AZN dated on 2014-07-29: Pfizer CEO Says Still Interested In Acquisitions

Financial news for AZN dated on 2014-07-28: QIAGEN Announces Collaboration Agreement with AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic

Financial news for AZN dated on 2014-07-26: Benzinga Weekly Preview: FOMC In Focus As Earnings Season Progresses

Financial news for AZN dated on 2014-07-11: 5 British Blue Chips For Your Portfolio

Financial news for AZN dated on 2014-07-11: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for AZN dated on 2014-07-03: Dow Trades Above 17,000 While S&P 500 Inches Closer To 2,000

Financial news for AZN dated on 2014-07-03: JP Morgan Reinstates Underweight on AstraZeneca PLC

Financial news for AZN dated on 2014-06-25: UPDATE: FDA Panel Says Safety, Efficacy Results for AstraZeneca's Olaparib Did Not Support Accelerated Approval - Reuters

Financial news for AZN dated on 2014-06-25: AstraZeneca, Pfizer Shares Volatile Over Last Few Mins as Reuters Reporting FDA Panel Has Voted 11-2 Admin Should Wait for Study Known as Solo-2 Before Granting Approval of Olaparib

Financial news for AZN dated on 2014-06-25: Left Behind In The Rally: Pfizer

Financial news for AZN dated on 2014-06-23: Rumor Of Massive Monsanto-Syngenta Deal Gets Agriculture Sector Moving

Financial news for AZN dated on 2014-06-20: FT Reports AstraZeneca Considering Plan to Sell Some Rights to Future Revenue on Existing Drugs

Financial news for AZN dated on 2014-06-19: UPDATE: AstraZeneca Reports PDUFA Date for Movantik Now Sept. 16th

Financial news for AZN dated on 2014-06-19: AstraZeneca Announces 12.5mg Dose in Kodiak-5 Trial Did Not Meet Statistical Significance

Financial news for AZN dated on 2014-06-16: Dow Jones Reports AstraZeneca Hires Centerview to Advise on Potential Deal,, According to Sources

Financial news for AZN dated on 2014-06-16: AstraZeneca Spikes Higher

Financial news for AZN dated on 2014-06-13: AstraZeneca Issues Clarification on AXA Stake, Says AXA Investment Has 0.93% Voting Rights, AXA SA Has 0.06% Voting Rights, AllianceBernstein 0.08% Voting Rights - Bloomberg

Financial news for AZN dated on 2014-06-11: Amgen Announces Study of Brodalumab Showed Achieving of Primary Endpoint

Financial news for AZN dated on 2014-06-11: Pfizer's D'Amelio Will Not Comment on Whether Co. Will Continue to Engage AstraZeneca

Financial news for AZN dated on 2014-06-11: Pfizer's D'Amelio Said Co. Allowed to Again Approach AstraZeneca Following Regulatory Period

Financial news for AZN dated on 2014-06-11: UPDATE: Pfizer's D'Amelio Speaking at Goldman's Healthcare Conference Disclosed Reason Deal with AstraZeneca Didn't Happen Was Price

Financial news for AZN dated on 2014-06-11: Pfizer CEO Frank D'Amelio Says Strong Hand on AstraZeneca

Financial news for AZN dated on 2014-06-11: AstraZeneca Spikes Higher

Financial news for AZN dated on 2014-06-10: Morning Market Movers

Financial news for AZN dated on 2014-06-10: Isis Pharmaceuticals Gets \$15M From AstraZeneca For Phase 1 Study Initiation

Financial news for AZN dated on 2014-06-09: Cancer Genetics Reports Partnership with AstraZeneca for Providing Biomarker, Molecular Based Testing

Financial news for AZN dated on 2014-06-04: ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy

Financial news for AZN dated on 2014-06-04: ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects

Financial news for AZN dated on 2014-06-03: AstraZeneca Announces Enlarged Recruitment For Tremelimumab Phase II

Financial news for AZN dated on 2014-06-03: AstraZeneca Announces Announces Positive AZD9291 Trial Results

Financial news for AZN dated on 2014-06-02: Cigna Enters Contract with AstraZeneca for CRESTOR

Financial news for AZN dated on 2014-05-27: Pfizer Jilted By AstraZeneca; Analyst Sees Break-Up

Financial news for AZN dated on 2014-05-26: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2014-05-26: UPDATE: Pfizer Won't Bid for for AstraZeneca, Still Believes Final Proposal was Compelling

Financial news for AZN dated on 2014-05-25: Pfizer Reportedly to Abandon Bid for AstraZeneca -BBC

Financial news for AZN dated on 2014-05-22: SkyNews Reporting BlackRock Has Urged AstraZeneca Board to Hold New Talks

Financial news for AZN dated on 2014-05-21: Benzinga's M&A Chatter for Wednesday May 21, 2014

Financial news for AZN dated on 2014-05-21: Market Wrap For May 21: Fed's Minutes Support Wednesday's Bull Run

Financial news for AZN dated on 2014-05-21: AstraZeneca's Board Feeling Pressure From Stockholders Following Pfizer Bid Rejection

Financial news for AZN dated on 2014-05-21: UPDATE: AstraZeneca Says Won't Reopen Talks with Pfizer Before May 26 Deadline -FT

Financial news for AZN dated on 2014-05-21: AstraZeneca Spikes Lower on Volume

Financial news for AZN dated on 2014-05-21: AstraZeneca Shares Spiking on Volume

Financial news for AZN dated on 2014-05-21: Axa Says Astrazeneca Board Should Not Stop Pfizer PS55/Share Bid from Being Presented to Investors -Reuters

Financial news for AZN dated on 2014-05-21: Shareholder Threadneedle Investments Supports Astrazeneca Board Decision Regarding Pfizer Bid -Reuters

Financial news for AZN dated on 2014-05-21: Dow Jones Reports Large AstraZeneca Shareholder Urges Board to Open Talks With Pfizer, According to Sources

Financial news for AZN dated on 2014-05-20: Benzinga's M&A Chatter for Tuesday May 20, 2014

Financial news for AZN dated on 2014-05-20: Market Wrap For May 20: Markets Sharply Lower On Fed Talk, Disappointing Earnings

Financial news for AZN dated on 2014-05-20: Reuters Reports Pfizer Unlikely to Pay Fees to Advisers on Astrazenaca Bid, According to Source

Financial news for AZN dated on 2014-05-20: AstraZeneca Says Shareholders are Strongly Advised to Take No Action

Financial news for AZN dated on 2014-05-20: Astrazeneca Says Pfizer Must Either Announce a Recommended Firm Offer or State It Does Not Intend to Make an Offer for Astrazeneca

Financial news for AZN dated on 2014-05-20: AstraZeneca Notes Announcement Made By Pfizer Dated 19 May 2014 Seeking To Clarify Certain Matters Set Out In Its Announcement

Financial news for AZN dated on 2014-05-20: AstraZeneca Shareholders Have Mixed Feelings On Board's Quick Refusal

Financial news for AZN dated on 2014-05-20: Fidelity Worldwide Investment Says Astrazeneca Was Right to Reject Pfizer Bid -Reuters

Financial news for AZN dated on 2014-05-20: Morning Market Movers

Financial news for AZN dated on 2014-05-20: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2014-05-20: AstraZeneca Shares Gain 2% Premarket on Investor Call for Talks with Pfizer

Financial news for AZN dated on 2014-05-20: AstraZeneca Shareholder Schrodgers Calls on Board to Reopen Talks with Pfizer Regarding Proposal -Reuters

Financial news for AZN dated on 2014-05-19: Benzinga's M&A Chatter for Monday May 19, 2014

Financial news for AZN dated on 2014-05-19: Bloomberg Headlines Suggest Pfizer's New Bid for AstraZeneca Likely to Fail, AstraZeneca Said Does Not Intend to Reevaluate Pfizer's Latest Offer

Financial news for AZN dated on 2014-05-19: Market Wrap for May 19: Markets Finish

Higher On M&A Monday

Financial news for AZN dated on 2014-05-19: Mid-Day Market Movers

Financial news for AZN dated on 2014-05-19: Mid-Afternoon Market Update: Markets Drift Higher Amid A Flurry Of Weekend M&A Activity

Financial news for AZN dated on 2014-05-19: ISI Says AstraZeneca Needs To 'Speak Up For Increased Bid'

Financial news for AZN dated on 2014-05-19: #Premarket Prep Technical Update - Pfizer Inc. Higher

Financial news for AZN dated on 2014-05-19: AT&T, DirecTV, Pfizer And AstraZeneca Dominate M&A Headlines Over The Weekend

Financial news for AZN dated on 2014-05-19: Mid-Day Market Update: Campbell Soup Slides After Weak Forecast; InterMune Shares Spike Higher

Financial news for AZN dated on 2014-05-19: Mid-Morning Market Update: Markets Mixed; AT&T To Buy DirecTV For \$48.5B

Financial news for AZN dated on 2014-05-19: Morning Market Losers

Financial news for AZN dated on 2014-05-19: UPDATE: AstraZeneca's Johansson Sees No Prospect of Pfizer Deal Before May 26 Deadline or Extension of Deadline

Financial news for AZN dated on 2014-05-19: AstraZeneca Chairman Says Spoke on Phone with Pfizer for More than One Hour on Sunday; Says Pfizer Shut Down Discussions -Reuters

Financial news for AZN dated on 2014-05-19: Benzinga's Top #PreMarket Losers

Financial news for AZN dated on 2014-05-19: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2014-05-19: DirecTV Imminent Takeover By AT&T, Pfizer To AstraZeneca: 'Take It Or Leave It'

Financial news for AZN dated on 2014-05-19: UPDATE: AstraZeneca Shares Fall 11% Premarket on Rejection of Final Pfizer Offer

Financial news for AZN dated on 2014-05-19: Jupiter Fund Manager Alastair Gunn Disappointed With Astrazeneca Rejection of Pfizer Proposal -Reuters

Financial news for AZN dated on 2014-05-19: UPDATE: AstraZeneca Board Rejects Pfizer's Final Proposal

Financial news for AZN dated on 2014-05-19: AstraZeneca Rejects Pfizer's Final Offer of PS55/Share

Financial news for AZN dated on 2014-05-19: Stocks To Watch For May 19, 2014

Financial news for AZN dated on 2014-05-18: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2014-05-18: UPDATE: Pfizer Makes Final Proposal to AstraZeneca of PS55/Share

Financial news for AZN dated on 2014-05-18: UPDATE: Pfizer Raises Bid for AstraZeneca to PS55/Share

Financial news for AZN dated on 2014-05-18: Mark Kleinman Sky News Tweet: ' Latest intell on AstraZeneca is that Pfizer may offer up to PS55-a-share but would walk away from the situation if that proposal is rejected'

Financial news for AZN dated on 2014-05-18: DAVID FABER Tweet: 'Looks like a busy afternoon for all you merger fans. Expect we will have a \$T, \$DTV deal later today and Pfizer will raise for \$AZN'

Financial news for AZN dated on 2014-05-18: Pfizer Expected to Raise Bid for AstraZeneca -FT

Financial news for AZN dated on 2014-05-16: Shares of AstraZeneca Down ~1% Over Last 45 Mins, Spiked Down to \$79.65 Right as Pfizer Shares Were Halted

Financial news for AZN dated on 2014-05-15: Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Financial news for AZN dated on 2014-05-15: Ardelyx Recives \$25M Milestone from AstraZeneca For Tenapanor

Financial news for AZN dated on 2014-05-14: UPDATE: Astrazeneca CEO Says Not One Shareholder Said Board Should Have Accepted PS50/Share Offer

Financial news for AZN dated on 2014-05-14: Reuters Reports Astrazeneca CEO Says Would Engage With Pfizer if Offer Reflected Value of Company and Implementation Risks

Financial news for AZN dated on 2014-05-14: UPDATE: Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases

Financial news for AZN dated on 2014-05-14: UK PM Cameron Says Want More Assurances from Pfizer on AstraZeneca Deal

Financial news for AZN dated on 2014-05-14: Ligand Enters into Research and License Agreement with Omthera Pharmaceuticals, a Wholly-owned Subsidiary of AstraZeneca -8-K

Financial news for AZN dated on 2014-05-14: Incyte, MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial

Financial news for AZN dated on 2014-05-13: Market Wrap For May 13: Markets Close Again At Record Highs

Financial news for AZN dated on 2014-05-13: 7 Stocks For Your Retirement Portfolio

Financial news for AZN dated on 2014-05-13: UPDATE: Astrazeneca Issues Statement Regarding Pfizer Announcement

Financial news for AZN dated on 2014-05-13: AstraZeneca Says Pfizer's Announcement Contains No New Proposal

Financial news for AZN dated on 2014-05-12: Market Wrap For May 12: Dow And S&P Close At Record Highs

Financial news for AZN dated on 2014-05-12: Astrazeneca's Mavrilimumab and Sifalimumab Met Primary Endpoints

Financial news for AZN dated on 2014-05-12: FDA Panel for Mu Opioid Atagonists Scheduled for June 11, According to Bloomberg

Financial news for AZN dated on 2014-05-12: Pfizer Submits Statement Supporting AstraZeneca Buy to UK Govt Committ

Financial news for AZN dated on 2014-05-11: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2014-05-09: Amgen, AstraZeneca Offer Positive Results from Phase 3 Study of Brodalumab, Study Met Primary, Secondary Endpoints

Financial news for AZN dated on 2014-05-09: AstraZeneca Shares Now Have Almost Fully Recovered Losses Following 'Blocking' Report, More Recent Headline Suggests UK's Business Department is Neutral on Deal with Pfizer

Financial news for AZN dated on 2014-05-09: Will The U.K.'s Business Department Block Pfizer's Bid?

Financial news for AZN dated on 2014-05-09: Bloomberg Reporting UK Business Department Could Be Looking at Ways to Block Pfizer's Bid

Financial news for AZN dated on 2014-05-08: Benzinga's M&A Chatter for Thursday May 8, 2014

Financial news for AZN dated on 2014-05-08: Pfizer's Heart Races Of AstraZeneca Amidst Rumored Deal & Drug Approval

Financial news for AZN dated on 2014-05-08: Pfizer Holders Could Face Tax Hit in AstraZeneca Deal -DJ

Financial news for AZN dated on 2014-05-08: Reuters Reports Pfizer Could Raise Bid for AstraZeneca to \$89.90/Share

Financial news for AZN dated on 2014-05-08: Astrazeneca Initiates Phase Iii Study for Medi4736

Financial news for AZN dated on 2014-05-07: CEOs at Pfizer, AstraZeneca Will Testify to UK Regulators on May 14th - Bloomberg

Financial news for AZN dated on 2014-05-06: Market Wrap For May 6: Dow Suffers Triple-Digit Point Loss, Nasdaq Underperforms Once Again

Financial news for AZN dated on 2014-05-06: Astrazeneca CEO Says Range of Opinion on

Pfizer Offer from Shareholders, Overall Feedback Supportive -Reuters

Financial news for AZN dated on 2014-05-06: Spokesperson for British PM Cameron Says Significant that Pfizer has Chosen to Engage With Britain Over Potential Takeover of AstraZeneca -Reuters

Financial news for AZN dated on 2014-05-06: British Parliament Science Committee Requests Meeting with Pfizer, Astrazeneca Management to Discuss Potential Takeover

Financial news for AZN dated on 2014-05-06: AstraZeneca Announces FDA Approval of EPANOVA for Treatment of Adults with Severe Hypertriglyceridemia

Financial news for AZN dated on 2014-05-05: Danske Downgrades Astrazeneca PLC to Sell

Financial news for AZN dated on 2014-05-04: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2014-05-02: Market Wrap For May 2: Markets Slip On Ukraine Tensions Despite Positive Jobs Data

Financial news for AZN dated on 2014-05-02: Option Alert: Pfizer Jun \$29 Put; 20,000 Contract Trade Between Bid and Ask @\$0.44 vs 8,453 OI; Currently \$30.67

Financial news for AZN dated on 2014-05-02: Moody's Says Pfizer's New Proposal for Astrazeneca is Credit-Positive

Financial news for AZN dated on 2014-05-02: UPDATE: AstraZeneca CEO Says New Pfizer Offer Underappreciated AstraZeneca Drug Pipeline -DJ

Financial news for AZN dated on 2014-05-02: UK Government Says Letter from Pfizer CEO a Positive Sign, Will Consider Proposals to See if they Offer Sufficient Protection of Priorities

Financial news for AZN dated on 2014-05-02: #PreMarket Primer: Friday, May 2: Nonfarm Payrolls Data Expected To Impress

Financial news for AZN dated on 2014-05-02: UPDATE: AstraZeneca Board Says Terms of Pfizer Proposal are Inadequate, Undervalue Astrazeneca

Financial news for AZN dated on 2014-05-02: UPDATE Astrazeneca Board Rejects Pfizer Proposal

Financial news for AZN dated on 2014-05-02: UPDATE: Pfizer Sends Letter to UK PM Cameron Regarding Commitments If Proposed Combination with AstraZeneca is Completed

Financial news for AZN dated on 2014-05-02: UPDATE: Pfizer Confirms Delivery of Increased Proposal to AstraZeneca, Offer Represents Value of PS50.00 (\$84.47)/Share

Financial news for AZN dated on 2014-05-02: Pfizer Confirms Increased Offer for Astrazeneca, 1.845 Shares, 1,598P Cash/Share

Financial news for AZN dated on 2014-05-01: Benzinga's M&A Chatter for Thursday May 1, 2014

Financial news for AZN dated on 2014-05-01: Market Wrap For May 1: Markets Mixed To Start The New Month

Financial news for AZN dated on 2014-05-01: Pfizer Could Weigh New Bid for AstraZeneca as Earlier as Next Week, May Be Over PS50/Share - Bloomberg

Financial news for AZN dated on 2014-04-30: Option Alert: AstraZenca Oct \$90 Call; 4,072 Contracts Traded vs 33 OI: Currently \$78.99

Financial news for AZN dated on 2014-04-29: Express Scripts Received Subpoena from NJ AG in March Related to Relationship with AstraZeneca

Financial news for AZN dated on 2014-04-29: Option Alert: Pfizer Jun \$33 Call; 25,350 Contracts Traded vs 16,043 OI; Currently \$31.64

Financial news for AZN dated on 2014-04-29: S&P Says Pfizer Ratings Unaffected by Proposd AstraZeneca Merger

Financial news for AZN dated on 2014-04-29: ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

Financial news for AZN dated on 2014-04-29: Fitch Says Pfizer, AstraZeneca Combination Would Achieve Strategic Aims

Financial news for AZN dated on 2014-04-29: Panmure Upgrades Astrazeneca PLC to Buy

Financial news for AZN dated on 2014-04-29: Kepler Cheuvreux Upgrades AstraZeneca PLC to Hold

Financial news for AZN dated on 2014-04-28: Benzinga's M&A Chatter for Monday April 28, 2014

Financial news for AZN dated on 2014-04-28: Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week

Financial news for AZN dated on 2014-04-28: Mid-Afternoon Market Update: Markets Trade in Swing-Prone Session as J.C. Penney Rallies

Financial news for AZN dated on 2014-04-28: Mid-Day Market Update: NASDAQ Drops 0.8%; Susser Shares Surge On Acquisition News

Financial news for AZN dated on 2014-04-28: BBC's Kamal Ahmed Tweet: 'Am told Pfizer has been in touch with Vince Cable & David Willett's office on AstraZeneca. Gov looking for 'jobs and investment' assurances'

Financial news for AZN dated on 2014-04-28: Benzinga's Volume Movers

Financial news for AZN dated on 2014-04-28: Pfizer Courts AstraZeneca (Again) With \$100 Billion Offer

Financial news for AZN dated on 2014-04-28: Mid-Morning Market Update: Markets Open Higher; Forest Labs To Acquire Furiex For \$1.1B In Cash

Financial news for AZN dated on 2014-04-28: Stocks Hitting 52-Week Highs

Financial news for AZN dated on 2014-04-28: Morning Market Movers

Financial news for AZN dated on 2014-04-28: From Pfizer Call to Discuss AstraZeneca Potential Deal: CEO Ian Read Says Co. is Reconsidering Options Related to AstraZeneca

Financial news for AZN dated on 2014-04-28: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2014-04-28: Societe Generale Upgrades AstraZeneca PLC to Hold

Financial news for AZN dated on 2014-04-28: UPDATE: AstraZeneca Shares Rise 16% Premarket Following Rejection of Pfizer's \$76.62/Share Bid

Financial news for AZN dated on 2014-04-28: UPDATE: Pfizer CEO Says Can't Make Firm Commitments on UK Investment, Jobs

Financial news for AZN dated on 2014-04-28: UPDATE: Pfizer CEO Says Will Continue to Invest In US

Financial news for AZN dated on 2014-04-28: UPDATE: AstraZeneca Board Says Not Appropriate to Engage in Discussions with Pfizer, Says Pfizer Proposal Undervalues AstraZeneca

Financial news for AZN dated on 2014-04-28: UPDATE: Pfizer Confirms \$76.62/Share Offer for AstraZeneca

Financial news for AZN dated on 2014-04-28: Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Merger

Financial news for AZN dated on 2014-04-24: Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns

Financial news for AZN dated on 2014-04-24: AstraZeneca PLC Reports Q1 Adjusted EPS of \$1.17 vs \$1.22 Est; Revenue of \$6.42B vs \$6.29B Est

Financial news for AZN dated on 2014-04-22: Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

Financial news for AZN dated on 2014-04-22: AstraZeneca Down 3% Despite Citigroup Upgrade

Financial news for AZN dated on 2014-04-22: Citigroup Upgrades AstraZeneca PLC to Buy

Financial news for AZN dated on 2014-04-21: DAVID FABER Tweet: 'So Ackman can buy \$3b in \$AGN stock, which he will sell to \$VRX for a lot more if it succeeds in an offer Ackman knew was coming'

Financial news for AZN dated on 2014-04-21: Market Wrap For April 21: S&P 500 Extends Winning Streak To Five Days, Dow & Nasdaq Also Positive

Financial news for AZN dated on 2014-04-21: Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research Shares Decline

Financial news for AZN dated on 2014-04-21: Benzinga's Volume Movers

Financial news for AZN dated on 2014-04-21: Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

Financial news for AZN dated on 2014-04-21: Morning Market Movers

Financial news for AZN dated on 2014-04-21: Rumor: Pfizer Planning \$100 Billion Bid For AstraZeneca

Financial news for AZN dated on 2014-04-21: Benzinga's Top #PreMarket Gainers

Financial news for AZN dated on 2014-04-21: UPDATE: AstraZeneca Shares Rise 8% Premarket on Report of Potential Acquisition by Pfizer

Financial news for AZN dated on 2014-04-20: Benzinga's Weekend M&A Chatter

Financial news for AZN dated on 2014-04-20: Sunday Times Reports Pfizer Considering \$100B Offer for AstraZeneca

Financial news for AZN dated on 2014-04-08: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for AZN dated on 2014-04-01: Panmure Upgrades Astrazeneca PLC to Hold

Financial news for AZN dated on 2014-03-17: AstraZeneca, Nektar Therapeutics: FDA Meeting to Review Mu Opioid Antagonists Is Tentatively Scheduled for June 11-12

Financial news for AZN dated on 2014-03-13: Astrazeneca Shares Push Below \$66 Level as JP Morgan Downgrades to Underweight

Financial news for AZN dated on 2014-03-07: Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains

Financial news for AZN dated on 2014-03-04: Adam Feuerstein Tweet: '\$AMRN new strategy -- patent trolling. Sues \$AZN over pending Epanova launch'

Financial news for AZN dated on 2014-03-03: Bank of America Downgrades Astrazeneca PLC to Underperform

Financial news for AZN dated on 2014-03-03: AstraZeneca Announces FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes

Financial news for AZN dated on 2014-02-25: Dow Jones Reports AstraZeneca Proposed \$70.00/Share Bid for Forest Laboratories, According to Sources

Financial news for AZN dated on 2014-02-25: UPDATE: AstraZeneca Announces FDA Approves Orphan Drug Myalept

Financial news for AZN dated on 2014-02-25: AstraZeneca Shares Briefly Spike Higher But Now Unaffected as Bloomberg Now Highlighting Earlier News of FDA Orphan Drug Approval of Myalept

Financial news for AZN dated on 2014-02-21: EMA Isuses New Compassionate-Use Programme

Financial news for AZN dated on 2014-02-14: FDA Site Shows AstraZeneca Receives FDA Orphan Drug Designation for Crestor

Financial news for AZN dated on 2014-02-06: AstraZeneca Announces 2nd Interim Dividend of \$1.90/Share

Financial news for AZN dated on 2014-02-06: Astrazeneca Reports Q4 Adjusted EPS of \$1.23 vs \$1.22 Est; Revenue of \$6.84B vs \$6.91B Est

Financial news for AZN dated on 2014-02-03: Bristol-Myers Squibb Completes Sale of Global Diabetes Business to AstraZeneca

Financial news for AZN dated on 2014-01-22: Market Wrap For January 22: Earnings Season Continues To Come In Mixed

Financial news for AZN dated on 2014-01-15: Danske Bank Upgrades Astrazeneca PLC to Buy

Financial news for AZN dated on 2014-01-14: Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

Financial news for AZN dated on 2014-01-14: Morgan Stanley Upgrades Astrazeneca PLC to Equalweight

Financial news for AZN dated on 2014-01-14: Stocks Hitting 52-Week Highs

Financial news for AZN dated on 2014-01-09: Jefferies Upgrades Astrazeneca PLC to Hold

Financial news for AZN dated on 2014-01-08: AstraZeneca, Bristol-Myers Report FDA Approval of Farxiga

Financial news for AZN dated on 2014-01-07: Maeil Reporting AstraZeneca, Teva, Roche Are Considering Buying a Celltrion Stake

Financial news for AZN dated on 2013-12-20: Benzinga's Top Downgrades

Financial news for AZN dated on 2013-12-20: Bryan Garnier & Cie Downgrades Astrazeneca PLC to Neutral

Financial news for AZN dated on 2013-12-19: Market Wrap For December 18: Markets Flat During Day One Post Fed Taper

Financial news for AZN dated on 2013-12-19: Bristol-Myers, AstraZeneca Shares Higher Following Confirmation AstraZeneca Will Buy JV Diabetes Stake for Up to \$4.3B

Financial news for AZN dated on 2013-12-18: WSJ Reporting Bristol Myers Could Be Near a Deal to Sell Diabetes JV Stake to AstraZeneca in \$3B Deal

Financial news for AZN dated on 2013-12-17: AstraZeneca Issues Response to Launch of Esomeprazole Strontium in US, Says 2013 Views Unch

Financial news for AZN dated on 2013-12-12: Genpact, AstraZeneca Extend Finance and Accounting Services Agreement

Financial news for AZN dated on 2013-12-11: Bloomberg First Word Reporting Bristol Myers, AstraZeneca Have Won FDA Panel Support for Metreleptin in Lipodystrophy

Financial news for AZN dated on 2013-12-09: FDA Posts Staff Review of AstraZeneca/Bristol's Metreleptin on Website

Financial news for AZN dated on 2013-12-03: UPDATE: AstraZeneca Says Awarded Damages Will Have No Effect on 2013 Earnings

Financial news for AZN dated on 2013-12-03: AstraZeneca Announces Awarded \$76M in Damages Related to Prilosec Patent Litigation

Financial news for AZN dated on 2013-12-03: Hearing Unconfirmed Takeover Chatter in Forest Labs, AstraZeneca Rumored Buyer

Financial news for AZN dated on 2013-11-19: Horizon to Acquire US Rights for VIMOVO from Pozen

Financial news for AZN dated on 2013-11-15: Benzinga's Top Upgrades

Financial news for AZN dated on 2013-11-15: Liberum Upgrades Astrazeneca PLC to Buy

Financial news for AZN dated on 2013-11-13: Panmure Downgrades Astrazeneca PLC to Sell

Financial news for AZN dated on 2013-11-04: UBS Downgrades Astrazeneca PLC to Neutral

Financial news for AZN dated on 2013-10-28: UPDATE: Bank of America Upgrades AstraZeneca plc on Slightly Better Outlook

Financial news for AZN dated on 2013-10-28: Benzinga's Top Upgrades

Financial news for AZN dated on 2013-10-28: Bank of America Upgrades Astrazeneca PLC to Neutral

Financial news for AZN dated on 2013-10-27: Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More

Financial news for AZN dated on 2013-10-25: FDA Says AstraZeneca's Drug for Systemic Sclerosis Wins Orphan Drug Designation

Financial news for AZN dated on 2013-10-21: Acacia Subsidiary Enters into Settlement Agreement with AstraZeneca

Financial news for AZN dated on 2013-10-16: AstraZeneca Shares Unch Following FDA's Orphan Drug Designation for Olaparib in Ovarian Cancer

Financial news for AZN dated on 2013-10-14: AstraZeneca Reports New Safety Data for Naloxegol, Says Most Naloxegol-Emergent AES Early in Treatment

Financial news for AZN dated on 2013-10-11: Jefferies Downgrades Astrazeneca PLC to Underperform

Financial news for AZN dated on 2013-10-09: MainFirst Initiates Coverage on Astrazeneca PLC at Underperform

Financial news for AZN dated on 2013-10-03: Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV

Financial news for AZN dated on 2013-09-30: Shares of Clovis Oncology Down 4+% Following Mixed Ariad Data on AP26113, Data on AZD9291 from AstraZeneca

Financial news for AZN dated on 2013-09-24: AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin Data

Financial news for AZN dated on 2013-09-18: US Stock Futures Edge Higher; All Eyes On Fed

Financial news for AZN dated on 2013-09-18: FDA Accepts NDA for AstraZeneca's Epanova

Financial news for AZN dated on 2013-09-16: Form 8-K Filing from Nektar Therapeutics Shows AstraZeneca Filed NDA with FDA, AstraZeneca Will Pay Nektar \$70M Milestone on Acceptance of NDA

Financial news for AZN dated on 2013-09-16: Nordea Upgrades Astrazeneca PLC to Buy

Financial news for AZN dated on 2013-09-11: AstraZeneca Shares Spike Higher

Financial news for AZN dated on 2013-09-11: US Stock Futures Flat; Apple Shares Drop In Pre-Market Trading

Financial news for AZN dated on 2013-09-11: Merck, AstraZeneca Announce License Agreement for MK-1775

Financial news for AZN dated on 2013-09-04: Myriad Genetics, AstraZeneca Expand Collaboration on Olaparib Phase 3 Clinical Trials

Financial news for AZN dated on 2013-08-28: Form 8-K from Nektar Therapeutics Shows AstraZeneca Filed NDS with HC for Naloxegol on Aug. 26th

Financial news for AZN dated on 2013-08-26: Benzinga's M&A Chatter for Monday August 26, 2013

Financial news for AZN dated on 2013-08-26: Amgen and Onyx Finally Ink Deal Two Months In The Making

Financial news for AZN dated on 2013-08-26: AstraZeneca's MedImmune Division to Acquire Amplimmune for up to \$500M

Financial news for AZN dated on 2013-08-15: Morgan Stanley Downgrades Astrazeneca PLC to Underweight

Financial news for AZN dated on 2013-08-14: How Much Does It Cost To Develop A New Drug?

Financial news for AZN dated on 2013-08-08: AstraZeneca Will Pay Nektar \$25M Milestone if MAA Accepted by EMA, \$70M Milestone if NDA Accepted by FDA

Financial news for AZN dated on 2013-08-02: Swedbank Upgrades Astrazeneca PLC to Reduce

Financial news for AZN dated on 2013-08-02: Swedbank Upgrades Astrazeneca PLC to Reduce

Financial news for AZN dated on 2013-08-01: Astrazeneca PLC Reports Q2 EPS of \$1.20 vs \$1.16 Est; Revenue of \$6.23B vs \$6.24B Est

Financial news for AZN dated on 2013-07-28: Earnings Expectations for the Week of July 29

Financial news for AZN dated on 2013-07-26: Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected

Financial news for AZN dated on 2013-07-25: U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application From AstraZeneca

Financial news for AZN dated on 2013-07-22: Benzinga's M&A Chatter for Monday July 22, 2013

Financial news for AZN dated on 2013-07-22: Bloomberg Reporting Pfizer, Novartis, AstraZeneca Said to Be Preparing Onyx Pharma Bids

Financial news for AZN dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for AZN dated on 2013-06-28: Big Pharma's Next Blockbuster is Fish Oil?

Financial news for AZN dated on 2013-06-28: EMA Gives Positive Recommendations For AstraZeneca's Nexium Control, Extension of Onglyza

Financial news for AZN dated on 2013-06-24: ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)

Financial news for AZN dated on 2013-06-22: AstraZeneca, Bristol-Myers Squibb, Announce Results from Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin

Financial news for AZN dated on 2013-06-17: AstraZeneca's MedImmune, and NGM Biopharmaceuticals Announce Agreement to Develop Therapies for Diabetes and Obesity

Financial news for AZN dated on 2013-06-12: Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association

Financial news for AZN dated on 2013-06-10: Benzinga's M&A Chatter for Monday June 10, 2013

Financial news for AZN dated on 2013-06-10: AstraZeneca to Buy Pearl Therapeutics to Gain Lung Medicine

Financial news for AZN dated on 2013-06-10: AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)

Financial news for AZN dated on 2013-06-10: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2013-06-10: AstraZeneca to Acquire Pearl Therapeutics for Up to \$1.15B

Financial news for AZN dated on 2013-06-10: US Stock Futures Signal Higher Start On Wall Street

Financial news for AZN dated on 2013-06-10: Stocks To Watch For June 10, 2013

Financial news for AZN dated on 2013-06-04: Market Wrap for Tuesday, June 4: Stocks Retreat as Uncertainty Rises

Financial news for AZN dated on 2013-06-04: Traders Passing Around Fool Article 'AstraZeneca Writes Off \$140 Million Following Product Trial' Related to Results from Fostamatinib

Financial news for AZN dated on 2013-06-04: Stocks Hitting 52-Week Lows

Financial news for AZN dated on 2013-06-04: Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform, Removes \$10.00 PT

Financial news for AZN dated on 2013-06-04: Morning Market Losers

Financial news for AZN dated on 2013-06-04: U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy

Financial news for AZN dated on 2013-06-04: Benzinga's Top Pre-Market Losers

Financial news for AZN dated on 2013-06-04: Rigel, AstraZeneca Announce Topline Results from OSKIRA-2 and OSKIRA-3 Phase 3 Clinical Trials Investigating Fostamatinib

Financial news for AZN dated on 2013-06-03: Isis Pharma Announces \$10M Milestone Payment from AstraZeneca for ISIS-AR

Financial news for AZN dated on 2013-05-28: Benzinga's M&A Chatter for Tuesday May 28, 2013

Financial news for AZN dated on 2013-05-28: Morning Market Movers

Financial news for AZN dated on 2013-05-28: Benzinga's Top Pre-Market Gainers

Financial news for AZN dated on 2013-05-28: Benzinga Market Primer: Tuesday, May 28

Financial news for AZN dated on 2013-05-28: AstraZeneca To Acquire Omthera Pharmaceuticals For \$12.70/Share

Financial news for AZN dated on 2013-05-28: Stocks To Watch For May 28, 2013

Financial news for AZN dated on 2013-05-21: Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013

Financial news for AZN dated on 2013-05-18: U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying

Financial news for AZN dated on 2013-05-17: Impax Labs Launches Authorized Generic of Zomig in US

Financial news for AZN dated on 2013-05-15: Optimer Spokesperson Declines Comment on Rumor of Cubist Bid

Financial news for AZN dated on 2013-05-15: Benzinga's M&A Chatter for Wednesday May 15, 2013

Financial news for AZN dated on 2013-05-15: UPDATE: Cubist Reportedly Bid \$20/Share for Optimer -Reuters

Financial news for AZN dated on 2013-05-15: Hearing Cubist Bid Near \$1B for Optimer

Financial news for AZN dated on 2013-05-15: Optimer Spikes Higher

Financial news for AZN dated on 2013-05-13: Benzinga's M&A Chatter for Monday May 13, 2013

Financial news for AZN dated on 2013-05-13: Hearing Chatter of Bids for Optimer from AstraZeneca, Cubist

Financial news for AZN dated on 2013-04-25: Astrazeneca PLC Reports Q1 EPS of \$1.41 vs \$1.33 Est; Revenue of \$6.39B vs \$6.53B Est

Financial news for AZN dated on 2013-04-18: Under The Hood: An ETF For International Income

Financial news for AZN dated on 2013-04-10: Bloomberg First Word Reporting AstraZeneca Gets Further Delay in Generic Pulmicort Repsules

Financial news for AZN dated on 2013-04-08: S&P Lowers Outlook on AstraZeneca from Stable to Negative

Financial news for AZN dated on 2013-04-05: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2013-04-05: AstraZeneca Announces Results from OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

Financial news for AZN dated on 2013-04-03: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2013-04-03: Astrazeneca's Medimmune Biologics Unit Acquires Alphacore Pharma

Financial news for AZN dated on 2013-04-03: Actavis Confirms Court Issues TRO Preventing Distribution of Generic Pulmicort RESPULES

Financial news for AZN dated on 2013-04-02: Benzinga's Top Upgrades

Financial news for AZN dated on 2013-04-02: JP Morgan Upgrades Astrazeneca PLC to Neutral

Financial news for AZN dated on 2013-04-01: Actavis Confirms Favorable Court Ruling in Patent Suit Involving Generic Version of AstraZeneca's Pulmicort RESPULES

Financial news for AZN dated on 2013-03-26: EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs

Financial news for AZN dated on 2013-03-22: Natixis Upgrades Astrazeneca PLC to Neutral

Financial news for AZN dated on 2013-03-21: AstraZeneca to Resubmit Dapagliflozin Dossier in Germany

Financial news for AZN dated on 2013-03-21: AstraZeneca to Reduce Global SG&A Workforce by 2,300

Financial news for AZN dated on 2013-03-18: AstraZeneca to Open Strategic R&D Center in Maryland, Sees \$1.4B in One-Time Restructuring Charges

Financial news for AZN dated on 2013-03-08: UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Financial news for AZN dated on 2013-03-08: Swedbank Downgrades Astrazeneca PLC to Sell

Financial news for AZN dated on 2013-03-08: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for AZN dated on 2013-03-05: Targacept, AstraZeneca Amend Pact, Targacept Wins Right to Pursue Any Alpha7 NNR Modulator

Financial news for AZN dated on 2013-02-27: These ETFs Have Moving Average Problems

Financial news for AZN dated on 2013-02-22: Are Global Health Care ETFs Worth Prescribing?

Financial news for AZN dated on 2013-02-14: Mylan Loses Bid to Challenge AstraZeneca Patent on Seroquel XR

Financial news for AZN dated on 2013-01-31: Astrazeneca PLC Reports Q4 EPS of \$1.56 vs \$1.41 Est; Revenue of \$7.28B vs \$7.17B Est

Financial news for AZN dated on 2012-12-17: Astrazeneca Says Got Updated Guidelines on Stemi

Financial news for AZN dated on 2012-12-14: AstraZeneca Wins Appeals Court Ruling on Crestor Payment

Financial news for AZN dated on 2012-12-14: Societe Generale Downgrades Astrazeneca PLC to Sell

Financial news for AZN dated on 2012-12-13: Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint

Financial news for AZN dated on 2012-12-05: Par Pharma Begins Shipping Generic Atacand HCT

Financial news for AZN dated on 2012-12-03: From Earlier: Optimer, AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in LatAm

Financial news for AZN dated on 2012-11-15: AstraZeneca Spokesperson Declines Comment on Rumored Amarin Interest

Financial news for AZN dated on 2012-11-15: Amarin Rises 12% Pre-Market on Takeover Rumor

Financial news for AZN dated on 2012-11-15: Teva, AstraZeneca May Bid for Amarin -Calcalist

Financial news for AZN dated on 2012-11-14: Bristol-Myers, AstraZeneca's Forxiga Wins EU Approval for Treatment of Type 2 Diabetes

Financial news for AZN dated on 2012-11-12: Nektar Therapeutics Plunges on FDA Worries, Downgrade

Financial news for AZN dated on 2012-11-12: AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

Financial news for AZN dated on 2012-10-29: AstraZeneca Begins Phase III Study of FASLODEX Injection in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Financial news for AZN dated on 2012-10-26: UPDATE: Pareto Securities Downgrades AstraZeneca to Sell

Financial news for AZN dated on 2012-10-26: UPDATE: Swedbank Downgrades AstraZeneca to Reduce on Valuation

Financial news for AZN dated on 2012-10-26: Swedbank Downgrades AstraZeneca from Neutral to Reduce

Financial news for AZN dated on 2012-10-26: Pareto Securities Downgrades AstraZeneca from Hold to Sell

Financial news for AZN dated on 2012-10-17: Charles River Laboratories Enters Strategic Partnership with AstraZeneca

Financial news for AZN dated on 2012-10-08: SumTotal Systems Appoints Holly Rollo as CMO

Financial news for AZN dated on 2012-10-03: Benzinga's M&A Chatter for Wednesday October 3, 2012

Financial news for AZN dated on 2012-10-03: Hearing Unconfirmed Takeover Chatter in Forest Labs

Financial news for AZN dated on 2012-10-01: Benzinga's M&A Chatter for Monday October 1, 2012

Financial news for AZN dated on 2012-10-01: AstraZeneca Suspends Share Repurchase Program

Financial news for AZN dated on 2012-09-19: Benzinga's Top Upgrades

Financial news for AZN dated on 2012-09-10: UPDATE: Bank of America Downgrades AstraZeneca to Underperform Following Recent Gain

Financial news for AZN dated on 2012-09-10: Bank of America Downgrades AstraZeneca from Neutral to Underperform

Financial news for AZN dated on 2012-09-07: Benzinga's Top Upgrades

Financial news for AZN dated on 2012-09-07: Morgan Stanley Upgrades AstraZeneca from Underweight to Equal-weight

Financial news for AZN dated on 2012-09-06: Seven Cheap Large-Caps Yielding Over 4%

Financial news for AZN dated on 2012-08-30: Pharma Companies Switch Drugs to OTC Market

Financial news for AZN dated on 2012-08-28: AstraZeneca Appoints Pascal Soriot As New CEO

Financial news for AZN dated on 2012-08-20: JP Morgan Downgrades AstraZeneca from Neutral to Underweight

Financial news for AZN dated on 2012-08-07: Option Alert: AstraZeneca Call Volume at 3,232% of Average Ahead of Wednesday's Ex-Dividend; Currently \$48.25

Financial news for AZN dated on 2012-07-26: AstraZeneca Reports Q2 EPS \$1.53 vs \$1.36 Est; Revenues \$6.66B vs \$6.78B Est

Financial news for AZN dated on 2012-07-17: From Earlier: AstraZeneca to Initiate a New Study of BRILINTA (Ticagrelor) in Patients with PAD

Financial news for AZN dated on 2012-07-16: BRILINTA Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of UA/NSTEMI Patients

Financial news for AZN dated on 2012-07-12: AstraZeneca Acquires Neuroscience Assets From Link Medicine; Terms Not Disclosed

Financial news for AZN dated on 2012-07-05: Hearing dealReporter Saying AstraZeneca Could Have Interest in Amarin

Financial news for AZN dated on 2012-07-02: Bristol-Myers to Acquire Amylin

Financial news for AZN dated on 2012-07-02: AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis

Financial news for AZN dated on 2012-06-30: Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for \$31/Share

Financial news for AZN dated on 2012-06-27: J.P. Morgan Cazenove Reiterates Neutral Rating for AstraZeneca

Financial news for AZN dated on 2012-06-27: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2012-06-27: Merck and AstraZeneca Agree to Amend Partnership

Financial news for AZN dated on 2012-06-26: Benzinga's M&A Chatter for Tuesday June 26, 2012

Financial news for AZN dated on 2012-06-26: Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies

Financial news for AZN dated on 2012-06-26: Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports

Financial news for AZN dated on 2012-06-26: Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters

Financial news for AZN dated on 2012-06-22: EMA: Positive Recommendations On New Generic Medicine Zyclara

Financial news for AZN dated on 2012-06-19: AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma

Financial news for AZN dated on 2012-06-03: Benzinga's M&A Chatter for Friday June 1, 2012

Financial news for AZN dated on 2012-05-25: Amylin Shares Jump as Sanofi, Merck Submit Bids

Financial news for AZN dated on 2012-05-09: GlaxoSmithKline to Get Hostile with Offer for Human Genome

Financial news for AZN dated on 2012-05-01: Benzinga's Top Upgrades with Color for May 1, 2012

Financial news for AZN dated on 2012-05-01: AstraZeneca LUNAR Examines Cholesterol-Lowering Effects of CRESTOR Compared with Atorvastatin in Patients with Acute Coronary Syndrome

Financial news for AZN dated on 2012-05-01: UPDATE: Bank of America Upgrades AstraZeneca

Financial news for AZN dated on 2012-05-01: Financial Breakfast: Morning News Summary for May 1, 2012

Financial news for AZN dated on 2012-05-01: Bank of America Upgrades AstraZeneca from Underperform to Neutral, Maintains PO at \$49.2

Financial news for AZN dated on 2012-04-30: FDA Considering Letting Patients Purchase Drugs Without Prescriptions

Financial news for AZN dated on 2012-04-30: Benzinga's Top Upgrades

Financial news for AZN dated on 2012-04-28: Benzinga's M&A Chatter for Friday April 27, 2012

Financial news for AZN dated on 2012-04-26: AstraZeneca's CEO Quits As Earnings, Revenue Drop - IBD

Financial news for AZN dated on 2012-04-26: Earnings Recap for April 26, 2012

Financial news for AZN dated on 2012-04-26: From Earlier: Astrazeneca's CEO Will Retire June 1

Financial news for AZN dated on 2012-04-26: AstraZeneca Reports Q1 EPS \$1.81 vs \$1.78 Est; Revenues \$7.35B vs \$7.85B Est

Financial news for AZN dated on 2012-04-25: Benzinga's M&A Chatter for Wednesday April 25, 2012

Financial news for AZN dated on 2012-04-25: AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease

Financial news for AZN dated on 2012-04-24: Financial Breakfast: Morning News Summary for April 24, 2012

Financial news for AZN dated on 2012-04-23: Benzinga's M&A Chatter for Monday April

23, 2012

Financial news for AZN dated on 2012-04-23: Ardea Biosciences Surges 51% After Buyout

Financial news for AZN dated on 2012-04-23: Financial Breakfast: Morning News Summary for April 23, 2012

Financial news for AZN dated on 2012-04-23: Benzinga's Top Pre-Market Gainers

Financial news for AZN dated on 2012-04-23: From Earlier: AstraZeneca to Acquire Ardea Biosciences for \$1.26B Including Lead Product Lesinurad in Phase III Development for Gout

Financial news for AZN dated on 2012-04-23: US Stock Futures Signal Lower Start On Wall Street

Financial news for AZN dated on 2012-04-23: AstraZeneca To Acquire Ardea Biosciences For \$32/Share

Financial news for AZN dated on 2012-04-12: Benzinga's M&A Chatter for Thursday April 12, 2012

Financial news for AZN dated on 2012-04-12: AstraZeneca Spokesperson Won't Comment on Earlier UBS Note Saying Mylan Could be a Takeover Target

Financial news for AZN dated on 2012-04-12: Positive Rumors Circulate About Mylan

Financial news for AZN dated on 2012-04-12: AstraZeneca Launches DUTOPROL

Financial news for AZN dated on 2012-04-12: AstraZeneca Launches DUTOPROL

Financial news for AZN dated on 2012-04-02: Amgen

Financial news for AZN dated on 2012-04-02: Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio

Financial news for AZN dated on 2012-04-02: Amylin Shares Active on Monday; Stock Down 4%

Financial news for AZN dated on 2012-03-28: ImmunoCellular's Intellectual Property Steadily Increases

Financial news for AZN dated on 2012-03-28: Trading Ideas: Stocks to Watch for Thursday (AMLN, SABA, ANGI, RHT, LGF, AE)

Financial news for AZN dated on 2012-03-28: Amylin Rejected \$3.5 Billion Offer; Stock Soars

Financial news for AZN dated on 2012-03-27: UPDATE: Pareto Securities Upgrades AstraZeneca; Raises PT

Financial news for AZN dated on 2012-03-27: Benzinga's Top Upgrades

Financial news for AZN dated on 2012-03-27: Pareto Securities Upgrades AstraZeneca from Sell to Hold, Raises PT from \$46 to \$47

Financial news for AZN dated on 2012-03-26: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2012-03-26: Financial Breakfast: Morning News Summary for March 26, 2012

Financial news for AZN dated on 2012-03-26: US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice

Financial news for AZN dated on 2012-03-26: US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice

Financial news for AZN dated on 2012-03-22: AstraZeneca Announces Increased Coverage of BRILINTA Through Plan Preferred Formulary Status on Medco Health Solutions

Financial news for AZN dated on 2012-03-21: St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now

Financial news for AZN dated on 2012-03-20: Morning Market Losers

Financial news for AZN dated on 2012-03-20: Targacept Down 14.3% Pre-Market on Disappointing Phase 3 Study Results

Financial news for AZN dated on 2012-03-20: Benzinga's Top Pre-Market Losers

Financial news for AZN dated on 2012-03-20: From Earlier: AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued

Financial news for AZN dated on 2012-03-13: From Earlier: AstraZeneca Files Lawsuit against the FDA for Decision Regarding Quetiapine Product Labeling and Exclusivity

Financial news for AZN dated on 2012-03-08: Benzinga's M&A Chatter for Thursday March 8, 2012

Financial news for AZN dated on 2012-03-08: Hearing Bernstein Saying Astra Zeneca Could Buy Amylin for \$4.5B

Financial news for AZN dated on 2012-02-28: FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters

Financial news for AZN dated on 2012-02-16: AstraZeneca Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX Tablets to Patients for Only \$40 Per Month

Financial news for AZN dated on 2012-02-14: Notable Call Options Activity in AstraZeneca

Financial news for AZN dated on 2012-02-08: Three Conservative Stocks To Play The Stock Market Rally

Financial news for AZN dated on 2012-02-02: Notable Put Options Activity in AstraZeneca

Financial news for AZN dated on 2012-02-02: AstraZeneca Cuts 7,300 Jobs, Warns of Lower Profits

Financial news for AZN dated on 2012-02-02: AstraZeneca Reports Q4 EPS \$1.61 vs \$1.56 Est; Revenues \$8.66B vs \$8.59B Est

Financial news for AZN dated on 2012-02-02: AstraZeneca To Cut 7,300 Jobs, Projects Drop In Profit

Financial news for AZN dated on 2012-01-19: From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin

Financial news for AZN dated on 2012-01-18: Notable Call Options Activity in AstraZeneca

Financial news for AZN dated on 2012-01-09: Market Roundup

Financial news for AZN dated on 2012-01-09: AstraZeneca Reaffirms 2011 Earnings Forecast

Financial news for AZN dated on 2012-01-09: AstraZeneca Reaffirms 2011 Earnings Forecast

Financial news for AZN dated on 2011-12-30: ETF Showdown: Fun With Pharma

Financial news for AZN dated on 2011-12-28: Notable Put Options Activity on AstraZeneca

Financial news for AZN dated on 2011-12-20: AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder

Financial news for AZN dated on 2011-12-19: Citi Reiterates Neutral On AstraZeneca

Financial news for AZN dated on 2011-12-15: AstraZeneca Announces Share Repurchase Programme

Financial news for AZN dated on 2011-12-12: Is Endo Pharmaceuticals Going to Seize Market Share?

Financial news for AZN dated on 2011-12-08: A Peek Into The Market Before The Trading Start

Financial news for AZN dated on 2011-12-08: Astra, Bristol-Myers Report Phase 3 Dapagliflozin Results

Financial news for AZN dated on 2011-12-07: AstraZeneca to Reduce U.S. Sales Force by 1,150 Positions

Financial news for AZN dated on 2011-12-07: AstraZeneca to Cut 1,150 Leadership Jobs -Bloomberg

Financial news for AZN dated on 2011-12-01: Teva Loses Bid Against Astrazeneca's Crestor; Had Claimed Drug Infringed on Patents

Financial news for AZN dated on 2011-11-29: Citigroup Initiates AstraZeneca at Neutral

Financial news for AZN dated on 2011-11-28: ONGLYZA Approved for Use in Europe as Combination Therapy With Insulin in Adults

Financial news for AZN dated on 2011-11-16: End-of-Day Market Summary for November 16, 2011

Financial news for AZN dated on 2011-11-16: Bristol-Myers Squibb and AstraZeneca Announce Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes

Financial news for AZN dated on 2011-11-16: Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients

Financial news for AZN dated on 2011-11-15: AstraZeneca Announces SATURN Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis

Financial news for AZN dated on 2011-11-08: Financial Breakfast: Morning News Summary for November 8, 2011

Financial news for AZN dated on 2011-11-08: AstraZeneca and Targacept Announce First Top-line Phase 3 Results for TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder

Financial news for AZN dated on 2011-11-07: AstraZeneca Announces BRILINTA Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI

Financial news for AZN dated on 2011-10-27: From Earlier: AstraZeneca Reports Q3 EPS \$1.71 vs \$1.68 Est; Revenues \$8.21B vs \$8.25B Est

Financial news for AZN dated on 2011-10-26: Bristol-Myers Squibb and AstraZeneca Announce U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months

Financial news for AZN dated on 2011-10-24: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for AZN dated on 2011-10-13: Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for AZN dated on 2011-10-06: AstraZeneca to Cut 400 US Jobs

Financial news for AZN dated on 2011-10-03: AstraZeneca's MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer

Financial news for AZN dated on 2011-09-29: AstraZeneca Enters Into a Settlement Agreement with Handa Pharmaceuticals regarding U.S. SEROQUEL XR(r) Patent Litigation

Financial news for AZN dated on 2011-09-27: Notable Put Options Activity in AstraZeneca

Financial news for AZN dated on 2011-09-16: Bristol-Myers Squibb and AstraZeneca Announce ONGLYZA When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels Over 52 Weeks in Investigational Study Extension

Financial news for AZN dated on 2011-08-16: Dentsply Sells \$1B Debt Offer To Fund Astra Tech Deal

Financial news for AZN dated on 2011-08-10: Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval

Financial news for AZN dated on 2011-08-04: Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca

Financial news for AZN dated on 2011-08-04: Jefferies Upgrades AstraZeneca To Hold

Financial news for AZN dated on 2011-08-01: AstraZeneca Announces U.S. Enrollment

Opportunities for KODIAC Study to Investigate an Experimental Drug for Constipation from Opioids

Financial news for AZN dated on 2011-07-28: AstraZeneca Reports Q1 EPS \$1.73 vs \$1.80 Est

Financial news for AZN dated on 2011-07-28: Earnings Scheduled For July 28

Financial news for AZN dated on 2011-07-26: AstraZeneca Subpoenaed by DOJ Over Nexium, Prilosec, Plendil, Toprol; Can Not Predict If there Will be Any Liability

Financial news for AZN dated on 2011-07-25: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Financial news for AZN dated on 2011-07-20: UPDATE: FDA Approves New Medicine BRILINTA For Use in the US

Financial news for AZN dated on 2011-07-20: AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation

Financial news for AZN dated on 2011-07-20: UPDATE: FDA Approves AstraZeneca Anticlotting Drug Brilinta

Financial news for AZN dated on 2011-07-20: AstraZeneca Says BRILINTA Not Yet Approved; Expecting Approval Decision Soon

Financial news for AZN dated on 2011-07-20: Hearing AstraZeneca Receives FDA Approval BRILINTA -Unconfirmed

Financial news for AZN dated on 2011-07-01: News Summary for July 1, 2011

Financial news for AZN dated on 2011-07-01: AstraZeneca Drug Nexium Gets Approved In Japan

Financial news for AZN dated on 2011-06-29: AstraZeneca and PTC Therapeutics Announce Strategic Oncology Drug Discovery Collaboration With Potential Extension to Other Therapeutic Areas

Financial news for AZN dated on 2011-06-27: Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca

Financial news for AZN dated on 2011-06-22: News Summary

Financial news for AZN dated on 2011-06-22: News Summary for June 22, 2011

Financial news for AZN dated on 2011-06-22: US Stock Futures Down, Fed In Focus

Financial news for AZN dated on 2011-06-22: AstraZeneca To Sell Astra Tech Unit To Dentsply For \$1.8B

Financial news for AZN dated on 2011-06-21: News Summary for June 21, 2011

Financial news for AZN dated on 2011-06-01: AstraZeneca Canada: Health Canada Approves BRILINTA Cardiovascular Treatment -Dow Jones

Financial news for AZN dated on 2011-06-01: Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE

Financial news for AZN dated on 2011-05-22: Top Healthcare and Major Drugs stocks to watch- Sector Performance

Financial news for AZN dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for AZN dated on 2011-05-16: Long-Term Study Demonstrates Safety and Efficacy of SYMBICORT(r) in African American Patients with Asthma

Financial news for AZN dated on 2011-05-02: FDA Approves NEXIUM I.V. for the Treatment of Gastroesophageal Reflux Disease with Erosive Esophagitis in Pediatric and Adolescent Patients

Financial news for AZN dated on 2011-04-28: Earnings Roundup For April 28 (XOM, AZN, HST, PEP, POT, PG, IP, DOW, S, AET, BMY, VIA, CL, EQT, CCE, OXY)

Financial news for AZN dated on 2011-04-28: AstraZeneca Reports Q1 Net Income of \$2.91 Billion (AZN)

Financial news for AZN dated on 2011-04-15: CEOWORLD Daily Business Roundup- China, GOOG, ZIP, BAC, MAT, HAS, GPC, KNL, SCHW, JPM, WFC...

Financial news for AZN dated on 2011-04-14: AstraZeneca CEO On CNBC (AZN)

Financial news for AZN dated on 2011-03-28: US Stock Futures Up As Investors Await Economic Data, Crude Oil Drops To \$104.92 a barrel

Financial news for AZN dated on 2011-03-28: AstraZeneca to Pay \$1 Billion+ to Resolve U.S. Tax Dispute (AZN)

Financial news for AZN dated on 2011-03-23: Calls Purchased on AstraZeneca PLC (AZN)

Financial news for AZN dated on 2011-03-15: AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation

Financial news for AZN dated on 2011-03-08: FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Financial news for AZN dated on 2011-02-11: International News Trumps Domestic 02-11-2011

Financial news for AZN dated on 2011-02-07: AstraZeneca and Targacept Initiate Phase 2b Clinical Trial of TC-5214

Financial news for AZN dated on 2011-02-02: AstraZeneca and HealthCore Announce Real-World Evidence Data Collaboration

Financial news for AZN dated on 2011-01-28: AstraZeneca Revenues Disappoint - Analyst Blog

Financial news for AZN dated on 2011-01-28: AstraZeneca Revenues Disappoint - Analyst Blog

Financial news for AZN dated on 2011-01-27: BMY Misses by a Penny in Q4 - Analyst Blog

Financial news for AZN dated on 2011-01-27: BMY Misses by a Penny in Q4 - Analyst Blog

Financial news for AZN dated on 2011-01-27: Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)

Financial news for AZN dated on 2011-01-26: Decent Quarter for Dr. Reddy's - Analyst Blog

Financial news for AZN dated on 2011-01-26: Decent Quarter for Dr. Reddy's - Analyst Blog

Financial news for AZN dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for AZN dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for AZN dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for AZN dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for AZN dated on 2011-01-21: Financials & Tech See-Saw 01-21-2011

Financial news for AZN dated on 2011-01-21: CBST Beats on EPS, Misses on Sales - Analyst Blog

Financial news for AZN dated on 2011-01-21: CBST Beats on EPS, Misses on Sales - Analyst Blog

Financial news for AZN dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for AZN dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for AZN dated on 2011-01-17: Earnings Preview: Cubist Pharma - Analyst Blog

Financial news for AZN dated on 2011-01-17: Earnings Preview: Cubist Pharma - Analyst Blog

Financial news for AZN dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for AZN dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for AZN dated on 2011-01-13: Cubist's Q4 Preliminary Sales Down - Analyst Blog

Financial news for AZN dated on 2011-01-13: Cubist's Q4 Preliminary Sales Down - Analyst Blog

Financial news for AZN dated on 2011-01-12: MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565

Financial news for AZN dated on 2011-01-11: Bristol-Myers Inks Deal - Analyst Blog

Financial news for AZN dated on 2011-01-11: Bristol-Myers Inks Deal - Analyst Blog

Financial news for AZN dated on 2011-01-11: PDLI's Synagis Lawsuit Invalidated - Analyst Blog

Financial news for AZN dated on 2011-01-11: PDLI's Synagis Lawsuit Invalidated - Analyst Blog

Financial news for AZN dated on 2011-01-11: AstraZeneca and Sarah Cannon Research Institute Join Forces

Financial news for AZN dated on 2011-01-10: FDA Delays AZN Drug Approval - Analyst Blog

Financial news for AZN dated on 2011-01-10: FDA Delays AZN Drug Approval - Analyst Blog

Financial news for AZN dated on 2010-12-23: Certriad Development Discontinued - Analyst Blog

Financial news for AZN dated on 2010-12-23: Certriad Development Discontinued - Analyst Blog

Financial news for AZN dated on 2010-12-23: AstraZeneca, Abbott End Certriad Pact

Financial news for AZN dated on 2010-12-23: AstraZeneca, Abbott Kill Co-Development Deal Early

Financial news for AZN dated on 2010-12-23: AstraZeneca, Abbott Kill Co-Development Deal Early

Financial news for AZN dated on 2010-12-22: AstraZeneca and Abbott End License Agreement for CERTRIAD Development

Financial news for AZN dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for AZN dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for AZN dated on 2010-12-21: Martek Biosciences: Premarket Trading

Financial news for AZN dated on 2010-12-21: AstraZeneca Halts Drug, Takes \$445M Charge

Financial news for AZN dated on 2010-12-20: Astrazeneca Off After Further Delay In Drug (AZN)

Financial news for AZN dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for AZN dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for AZN dated on 2010-12-17: Company News for December 17, 2010 - Corporate Summary

Financial news for AZN dated on 2010-12-17: Company News for December 17, 2010 - Corporate Summary

Financial news for AZN dated on 2010-12-17: AstraZeneca Down On FDA Delay (AZN)

Financial news for AZN dated on 2010-12-16: Market Stuck at Resistance 12-16-2010

Financial news for AZN dated on 2010-12-16: Puts Purchased on AstraZeneca PLC (AZN)

Financial news for AZN dated on 2010-12-13: MITI Presents Positive Data at ASH - Analyst Blog

Financial news for AZN dated on 2010-12-13: MITI Presents Positive Data at ASH - Analyst Blog

Financial news for AZN dated on 2010-12-10: Wells Fargo Initiating Coverage On RIGL With An Outperform Rating And A \$10-12 Valuation Range

Financial news for AZN dated on 2010-12-09: Watch Relationships 12-09-2010

Financial news for AZN dated on 2010-12-08: Forest Inks Deal for Pain Drugs - Analyst Blog

Financial news for AZN dated on 2010-12-08: Forest Inks Deal for Pain Drugs - Analyst Blog

Financial news for AZN dated on 2010-12-07: Credit Suisse Downgrades AZN To Underperform

Financial news for AZN dated on 2010-12-06: FDA Panel Reviews AstraZeneca Drug - Analyst Blog

Financial news for AZN dated on 2010-12-06: FDA Panel Reviews AstraZeneca Drug - Analyst Blog

Financial news for AZN dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for AZN dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for AZN dated on 2010-12-03: Enrollment for Medivation Study - Analyst Blog

Financial news for AZN dated on 2010-12-03: Micromet Downgraded to Neutral - Analyst Blog

Financial news for AZN dated on 2010-12-02: Enrollment for Medivation Study - Analyst Blog

Financial news for AZN dated on 2010-12-02: Micromet Downgraded to Neutral - Analyst Blog

Financial news for AZN dated on 2010-11-11: Zacks Analyst Blog Highlights: California Pizza Kitchen, The Allstate, Prudential Financial, Micromet and AstraZeneca - Press Releases

Financial news for AZN dated on 2010-10-27: Zacks Analyst Blog Highlights: United States Steel, Bristol-Myers Squibb, AstraZeneca plc, BHP Billiton and Wyndham Worldwide - Press Releases

Financial news for AZN dated on 2010-10-22: Calls Purchased on AstraZeneca PLC (AZN)

Financial news for AZN dated on 2010-10-18: Strong Cubicin Sales Drive Cubist - Analyst Blog

Financial news for AZN dated on 2010-10-05: Five ETFs With Stealth Yields

Financial news for AZN dated on 2010-09-29: Calls Sold on AstraZeneca (AZN)

Financial news for AZN dated on 2010-09-29: Benzinga's Top Downgrades (AZN, SM, TKC, MFE)

Financial news for AZN dated on 2010-09-29: AstraZeneca Falls On Downgrade In Rating

Financial news for AZN dated on 2010-09-28: Positive EU Opinion for AZN Drug - Analyst Blog

Financial news for AZN dated on 2010-09-22: Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest EPS Estimates (AZN, NVS, ABT, GSK)

Financial news for AZN dated on 2010-09-21: BMJ's Diabetes Candidate Encourages - Analyst Blog

Financial news for AZN dated on 2010-09-17: FDA Pushes Out Brilinta Action Date - Analyst Blog

Financial news for AZN dated on 2010-09-13: Top Domain Names are Owned by Publicly Traded Companies

Financial news for AZN dated on 2010-09-07: Red Signal for AstraZeneca Drug - Analyst Blog

Financial news for AZN dated on 2010-09-07: AstraZeneca Inks Agreement - Analyst Blog

Financial news for AZN dated on 2010-09-03: PDLI Gives Third-Quarter Outlook - Analyst Blog

Financial news for AZN dated on 2010-08-31: Under The Hood: A Look At An Interesting Dividend ETF (CVY)

Financial news for AZN dated on 2010-08-19: There is a rumor out on Wall Street today that AstraZeneca PLC (AZN) is looking to acquireDendreon Corp. (DNDN) At \$55.00 to\$60.00 a share.

Financial news for AZN dated on 2010-08-11: Medivation Narrows Loss - Analyst Blog

Financial news for AZN dated on 2010-08-10: Which 52-Week-High Stock Will Outperform? (SI, MCD, AZN, MO, DE)

Financial news for AZN dated on 2010-08-05: Watson Pharma Beats; Adjusts View - Analyst Blog

Financial news for AZN dated on 2010-08-04: Zacks Analyst Blog Highlights: The Clorox, AstraZeneca, Merck, Dean Foods and Coach - Press Releases

Financial news for AZN dated on 2010-08-03: AstraZeneca EPS Beats & Ups - Analyst Blog

Financial news for AZN dated on 2010-08-02: PDLI Matches Ests - Analyst Blog

Financial news for AZN dated on 2010-07-30: REGN's Loss Narrower than Expected - Analyst Blog

Financial news for AZN dated on 2010-07-29: Standpoint Research Downgrades AstraZeneca (NYSE:AZN)

Financial news for AZN dated on 2010-07-29: A Peek Into The Market Before The Trading Starts

Financial news for AZN dated on 2010-07-29: US Stock Futures Indicate Strong Opening Gains

Financial news for AZN dated on 2010-07-29: Standpoint Downgrades AstraZeneca (AZN) from Buy to Hold

Financial news for AZN dated on 2010-07-14: 10 Firms Expecting Clinical Trial Results

Financial news for AZN dated on 2010-06-30: Q2 Wrap Up Holding Market Steady 06-30-2010

Financial news for AZN dated on 2010-06-30: Pharmaceutical ETFs on the Rise

Financial news for AZN dated on 2010-06-30: Heavy Put Selling on Astrazeneca (AZN)

Financial news for AZN dated on 2010-06-30: Benzinga's Top Upgrades (BTU, AZN, NEE, DDMX)

Financial news for AZN dated on 2010-06-30: JP Morgan Upgrades AZN To Neutral

Financial news for AZN dated on 2010-06-30: Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)

Financial news for AZN dated on 2010-06-07: Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)

Financial news for AZN dated on 2010-05-29: The Unusual Suspects (AIG, AZN, BRK-A, BRK-B, MCO, C, GNMK, IEP, LGF, SI, STP, PHYS, SNF, EWP, TEF)

Financial news for AZN dated on 2010-05-25: Look for Opportunity 05-25-2010

Financial news for AZN dated on 2010-05-24: Citi Raises Forecasts for AstraZeneca

(AZN)

Financial news for AZN dated on 2010-04-30: FDA Approves AstraZeneca (AZN) And Pozen (POZN) Drug

Financial news for AZN dated on 2010-04-28: Afternoon Market Update - Goldman Sachs (NYSE: GS), Merck (NYSE: MRK), AstraZeneca (NYSE: AZN)

Financial news for AZN dated on 2010-04-28: Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)

Financial news for AZN dated on 2010-04-27: AstraZeneca Settles Illegal Marketing Case (AZN)

Financial news for AZN dated on 2010-03-22: US Stock Futures Slip; Focus Shifts To Pharmaceutical Stocks

Financial news for AZN dated on 2010-03-18: AstraZeneca Wins Seroquel Trial (AZN)

Financial news for AZN dated on 2010-03-08: Benzinga's News Roundup (LXRX, MET, AZN, BA)

Financial news for AZN dated on 2010-03-03: Top 5 NYSE Stocks In the Healthcare Sector With The Highest ROA (NVO, ACL, HLF, AZN, VAR)

Financial news for AZN dated on 2010-03-03: Top 5 NYSE Stocks In The Healthcare Sector With The Highest Dividend (ACL, AZN, GSK, NVS, JNJ)

Financial news for AZN dated on 2010-02-23: AstraZeneca (AZN) Settles Tax Dispute, Raises Forecast

Financial news for AZN dated on 2010-02-16: Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL, YHOO)

Financial news for AZN dated on 2010-02-16: Rigel Pharmaceuticals, Inc. (RIGL) Maintains An 1-Overweight Rating

Financial news for AZN dated on 2010-02-16: Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug

Financial news for AZN dated on 2010-02-16: Company News for February 16, 2010 - Corporate Summary

Financial news for AZN dated on 2010-02-09: A Look At How Different Sectors Will Behave In 2010 (PG, KO, WMT, GSK, GILD, AZN, EXC, D, DUK)

Financial news for AZN dated on 2010-01-29: I Had A Dream... (TRV, IBM, CMG, APC, AZN)

Financial news for AZN dated on 2010-01-29: AstraZeneca (AZN) To Cut 8000 Jobs By 2014

Financial news for AZN dated on 2010-01-28: Market Round-up (BAC, JPM, NFLX, CSTR, FRE, AAPL)

Financial news for AZN dated on 2010-01-28: AZN Impresses With Q4 Results, Guidance And Dividend Hike

Financial news for AZN dated on 2010-01-28: AstraZeneca (AZN) To Cut 10,400 Jobs

Financial news for AZN dated on 2010-01-28: AZN Impresses With Q4 Results, 2010 Guidance; Announces Dividend Hike

Financial news for AZN dated on 2010-01-28: Benzinga's Top Pre-Market Losers (FLEX, AZN, POT, QCOM, ABFS, TTEK)

Financial news for AZN dated on 2010-01-28: Earnings Round-up For Companies Reporting Before The Markets Open (MOT, T, AMZN, MMM, MSFT, MO, BDX, AEP, AZN, BMY, CAH, CEL, C, D, EL)

Financial news for AZN dated on 2010-01-25: Great 2009 Prompts Astra Zeneca (AZN) to Eye Share BuyBack

Financial news for AZN dated on 2010-01-21: AstraZeneca Upgraded, Sanofi-Aventis Downgraded

Financial news for AZN dated on 2010-01-14: Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK)

Financial news for AZN dated on 2010-01-08: Teva Pharmaceuticals Surging On High Volume (TEVA)

Financial news for AZN dated on 2010-01-07: Market Round-up (JNS, IIVI, ZIGO, KFT, CBY, BRK.A, BA, AZN, TEVA)

Financial news for AZN dated on 2010-01-07: AstraZeneca (AZN) And Teva Pharmaceuticals (TEVA) Settle Patent Dispute Over Nexium

Financial news for AZN dated on 2009-12-24: Benzinga's News Roundup (BG, AZN, QCOR, BSX, CVX, MOS, PFE)

Financial news for AZN dated on 2009-12-04: Strong Late-Stage Pipeline Products to Push AZN's Growth

Financial news for AZN dated on 2009-12-03: Benzinga's News Roundup (CMCSA, BAC, DDS, TGT, AZN)

Financial news for AZN dated on 2009-12-03: Targacept (TRGT), Astra (AZN) in Blockbuster Deal

Financial news for AZN dated on 2009-12-02: Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS

Financial news for AZN dated on 2009-11-19: AstraZeneca (AZN) Submits US New Drug Application for Ticagrelor (BRILINTA(TM))

Financial news for AZN dated on 2009-10-30: FTSE 100 Daily Analysis 30th October 2009

Financial news for AZN dated on 2009-10-29: AstraZeneca (AZN) Beats Q3 Earnings And Revenue Estimates, Guides Higher

Financial news for AZN dated on 2009-10-28: AstraZeneca (AZN) Pulls Regulatory Submissions For A Lung Cancer Drug

Financial news for AZN dated on 2009-10-23: Is It Tea Time For This U.K. ETF (EWU)?

Financial news for AZN dated on 2009-09-18: AstraZeneca (AZN) Gets Secretary Defense Award

Financial news for AZN dated on 2009-08-31: Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink

Financial news for AZN dated on 2009-08-30: AstraZeneca (AZN) Says Blood Thinner Drug Brilinta Works Better Than Plavix

Financial news for AZN dated on 2009-08-17: Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert